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Introduction
1.1. Leukotrienes and their receptors
Leukotrienes (LTs) are short-lived lipid mediators derived from arachidonic acid (AA) via the 
5-lipoxygenase  (5-LO)  pathway.  LTs  were  first  described  in  the  1930s  by  Feldberg  and 
Kellaway as the material released from guinea pig lung in response to antigen stimulus. This 
material was first called “slow reaction smooth muscle-stimulating substance” after its smooth 
muscle contracting capacity in guinea pig ileum and in other vascular preparations, then later 
renamed “slow-reacting substance of anaphylaxis” (SRS-A). The composition of SRS-A was 
identified in the 1970s [reviewed in Brink 2003].
1.1.1. LT biosynthesis
LTs are produced by certain leukocytes, mainly of myeloid origin: neutrophil, basophil and 
eosinophil  granulocytes,  mast  cells,  monocytes  and  macrophages.  Since  these  cells 
constitutively express the components of the enzyme cascade necessary for LT synthesis and 
contain  considerable  amounts  of  esterified  AA,  they  can  generate  and  secrete  LTs  upon 
stimulation [Peters-Golden 2004]. Regarding their LT production profiles, myeloid cells show 
the following differences: neutrophils produce primarily LTB4, and  mast cells, basophils and 
eosinophils mainly cysteinyl LTs (cysLTs), whereas monocytes and macrophages produce both 
types [Peters-Golden 2004]. Other leukocytes such as tonsillar B lymphocytes and dendritic 
cells (DCs) are also capable of LT synthesis, though in smaller quantities [Jakobsson 1991, 
Spanbroek 2000].
LT synthesis is dependent on 5-LO. This enzyme, in concert with the 5-LO activating protein 
(FLAP), catalyzes the conversion of AA into LTA4, which can be hydrolyzed into LTB4 or 
further processed into cysLTs (Figure 1).
Stimuli that trigger increased intracellular [Ca2+] ([Ca2+]ic) can activate the cytosolic phospho-
lipase A2 (cPLA2), which is considered the most important cytosolic phospholipase providing 
substrate  for  5-LO  [Peters-Golden  2004].  After  moving  to  the  nuclear  envelope,  cPLA2 
liberates AA from membrane phospholipids, which is transferred to 5-LO via FLAP. 5-LO can 
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localize in both the cytoplasm and the nucleus [Brock 2005]. Upon increase in [Ca2+]ic, 5-LO 
moves to the cellular membranes and assembles with complexes of FLAP and LTC4 synthase 
(LTC4S). The membrane association and the catalytic activity of 5-LO may be regulated via 
phosphorylation of the enzyme, ATP binding or by glutathione peroxidases [Rådmark 2000, 
Brock 2005].  In  the  first  step  of  LT synthesis,  AA is  oxygenated  and forms  5-(S)-hydro-
peroxyeicosatetraenoic acid (5-HPETE), which is subsequently dehydrated to LTA4. LTA4 is 
an unstable epoxide, which can react with water to form inactive metabolites, or it can serve as 
substrate for two enzymes. LTA4 can be hydrolyzed into LTB4 by LTA4 hydrolase [Shimizu 
1984,  Rådmark  1984],  or  the  membrane  bound  LTC4S can  conjugate  LTA4 with  reduced 
glutathione,  thus  converting it  into LTC4,  the parent  compound of the cysLTs [Yoshimoto 
1985, Penrose 1992]. LTC4 is exported from the cell via an ATP-dependent step by a multidrug 
resistance-associated protein [Leier 1994]. Extracellularly, LTC4 either binds to the cysteinyl 
LT receptors (cysLT-Rs) or it is further metabolized. γ-Glutamyl transpeptidase and γ-glutamyl 
leukotrienase convert LTC4 into LTD4 [Anderson 1982], which, in turn, can be cleaved by a 
dipeptidase into LTE4 [Lee 1983]. LTD4 and LTE4 also bind to the cysLT-Rs.
A  process  termed  transcellular  biosynthesis or  transcellular  metabolism,  enables  LT 
production  to  proceed  also  in  those  cells  that  do not  express  5-LO and,  therefore,  cannot 
initiate the LT cascade. Thus, LTA4 can be released from inflammatory cells and is then taken 
up by nearby cells or platelets, which metabolize it into LTB4 or LTC4 [McGee 1986, Maclouf 
1988]. Human umbilical vein endothelial cells (HUVECs) were shown to produce LTB4 and 
cysLTs from both exogenously added and granulocyte-derived LTA4 [Claesson 1988].  EC-
derived LTs may act  in  a paracrine fashion on neighboring cells  and also in  an autocrine 
fashion on ECs. This raises the possibility that ECs can exacerbate inflammatory processes by 
synthesizing LTs.
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Figure 1. Enzymatic steps of LT biosynthesis. AA released from membrane phospholipids is converted into 
5-(S)-hydroperoxyeicosatetraenoic acid (5-HPETE) and subsequently into LTA4 by 5-LO. LTA4 can be either 
hydrolyzed into LTB4 by LTA4 hydrolase or converted into LTC4 via  conjugation with glutathione by LTC4 
synthase. Removal of the glutamyl group of LTC4 by γ-glutamyl transferase forms LTD4, which can be further 
cleaved into LTE4 by a dipeptidase.
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1.1.2. Physiological and pathological role of the LTs
LTs are proinflammatory mediators produced by stimulated leukocytes at the site of antigen 
entry or tissue injury. LTs are best known for their vasoactive and smooth muscle contracting 
effects [reviewed in Brink 2003, Kanaoka 2004]. Although their involvement in innate and 
adaptive  immune  responses  is  increasingly  investigated,  there  still  remain  a  lot  of  open 
questions regarding their physiological and pathophysiological role(s). The effector functions 
influenced  by  LTs  during  the  immune  response  might  include  effects  on  leukocytes 
(accumulation,  cytokine  generation,  microbial  killing,  phagocytosis)  and  on  the  micro-
environment  (increased  vascular  permeability,  smooth  muscle  contraction,  broncho-
constriction,  enhanced  mucus  secretion)  [reviewed  in  Funk  2001,  Kanaoka  2004,  Peters-
Golden 2004]. These observations are based primarily on in vitro results. Within the last few 
years, several studies addressed and confirmed the role of LTs in vivo in mouse models, e.g. in 
alveolar clearance and phagocytosis during Klebsiella pneumoniae infection [Bailie 1996], and 
in DC migration [Robbiani 2000].
Altered  LT  generation  has  been  associated  with  several  human  diseases.  Decreased  LT 
producing  capacity  was  reported  in  immunosuppressed  states  due  to  malnutrition  or  drug 
treatment [reviewed in Peters-Golden 2004]. Peripheral blood neutrophils and monocytes from 
HIV  infected  patients  showed  impaired  LTB4 generation,  which  was  reversed  by  in  vivo 
treatment with granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage CSF 
(GM-CSF) [Coffey 1998, Coffey 1999]. Increased levels  of LTs were observed in humans 
during viral and bacterial infections [reviewed in Peters-Golden 2004], and in patients with 
asthma  exacerbations  [reviewed  in  Kanaoka  2004].  Involvement  of  cysLTs  in  airway 
inflammation is supported by studies of mouse models of asthma [reviewed in Kanaoka 2004], 
by effects  of exogenously administered LTs resembling symptoms of airway inflammatory 
diseases [reviewed in Brink 2003], and by reports on beneficial effects of LT modifier drugs in 
respiratory disorders [reviewed in Busse 2005]. Nonetheless, the role they play in disease states 
still remains to be clarified.
1.1.3. LT receptors
LTs  act  through  G protein-coupled  seven  transmembrane  domain  containing  receptors 
(GPCRs). The four known LT receptors (LT-Rs) belong to two main classes: BLT-Rs, which 
bind LTB4 and other eicosanoids, and cysLT-Rs, which bind LTC4, LTD4 and LTE4.
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1.1.3.1. BLT-Rs
BLT1-R was the first LT-R to be identified [Yokomizo 1997]. It is predominantly expressed by 
leukocytes  [Yokomizo 2001],  but  endothelial  and  vascular  smooth  muscle  cells  were  also 
shown to express it [Lötzer 2004]. By contrast, BLT2-R is widely expressed, most strongly in 
the spleen, liver and ovary, and it was also detected in leukocytes and endothelial and vascular 
smooth muscle cells. In contrast to BLT1-R, which binds LTB4 with high affinity, BLT2-R has 
lower  affinity  to  LTB4,  and  eicosanoids  with  LTB4-related  structure  can  also  activate  this 
receptor in a dose-dependent manner [Yokomizo 2001]. According to phylogenetic analyses, 
the BLT-Rs have a closer relationship to chemoattractant receptors, e.g. to the complement 
fragment receptors C5aR and C3aR, and to the formyl peptide receptor 1 (FPR1), than to the 
cysLT-Rs  [Izumi  2002].  Both  BLT-Rs  are  expressed  in  human  atherosclerotic  lesions 
[Spanbroek 2003], but their transcript levels are not higher than in control tissues [Qiu 2006a]. 
The data of Qiu et al. (2006a) suggest elevated LTB4 production within atherosclerotic plaques, 
which  implicates  BLT-Rs  in  atherogenesis,  but  the  cell  types  expressing  BLT-Rs  and the 
effects of BLT-R stimulation in these cells remain to be identified.
1.1.3.2. CysLT-Rs
Pharmacological studies applying various inhibitors and radioligand binding assays indicate 
that there are at least two human cysLT-Rs [reviewed in Evans 2002, Brink 2003, Capra 2004]. 
Both  receptors  were  identified  by  ligand  fishing  approaches  screening  orphan  GPCRs. 
CysLT1-R was cloned by two groups independently [Lynch 1999, Sarau 1999]. This gene is 
localized  on  chromosome  Xq13.2  and  the  encoded  protein  consists  of  337  amino  acids. 
CysLT1-R was shown to be highly expressed in peripheral blood leukocytes and in spleen, and 
at a lower level in several  other tissues, e.g. pancreas, placenta, colon, kidney, liver, small 
intestine, brain and lung [Sarau 1999, Lynch 1999].  In the lung, cysLT1-R expression was 
localized in macrophages and airway smooth muscle cells [Lynch 1999, Figueroa 2001].
The human cysLT2-R was cloned by three groups [Heise 2000,  Takasaki  2000,  Nothacker 
2000]. The CYSLTR2 gene was mapped to the chromosome 13q14.12 and encodes a protein 
of 346 amino acids. Northern blot analysis showed strong expression of the cysLT2-R mRNA 
in the  heart,  adrenal  gland and placenta,  and moderate  levels  were found in  several  other 
tissues,  e.g.  spleen,  lymph  nodes,  peripheral  blood  leukocytes  and  throughout  the  central 
nervous system [Heise 2000, Nothacker 2000, Takasaki 2000]. Heise  et al. (2000) provided 
circumstantial evidence for cysLT2-R expression in lung interstitial macrophages and smooth 
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muscle cells by in situ hybridization. By contrast, Takasaki et al. (2000) could not confirm the 
presence of cysLT2-R mRNA in lung by Northern blotting from tissue lysates.  In partially 
purified  blood  leukocyte  populations,  cysLT2-R  mRNA  was  detected  in  monocytes  and 
eosinophil  granulocytes [Heise 2000]. The distinct expression pattern of the two cysLT-Rs 
suggests different functions.
The cysLT1-R and cysLT2-R proteins show only 38% identity to each other at the amino acid 
level  [Heise  2000].  According  to  phylogenetic  analyses,  they  belong  to  the  rhodopsin 
subfamily of the GPCR superfamily [reviewed in Izumi, 2002; Capra, 2004]. Among others, 
they  are  closely  related  to  purinergic  or  pyrimidinergic  receptors  and  thrombin  receptors 
[Capra 2004]. This close relationship is supported by the fact that cysLT-Rs can be activated 
by uridine diphosphate [Mellor 2002].
The  two  cysLT-Rs  differ  from  each  other  in  their  sensitivity  toward  cysLT1-R  selective 
antagonists  and in ligand binding affinity.  In cysLT1-R transfected cells  cysLTs induced a 
dose-dependent increase in [Ca2+]ic with the rank order LTD4 >> LTC4 > LTE4. The cysLT-
induced  mobilization  of  intracellular  Ca2+ was  inhibited  by  Montelukast,  Zafirlukast, 
Pranlukast,  Pobilukast,  MK571  as  well  as  by  Bay u9773  [Lynch  1999,  Sarau  1999].  The 
cysLT2-R-transfected cells also responded to cysLT-stimulation with an elevated [Ca2+]ic in a 
dose-dependent manner. The affinity of cysLT2-R towards the agonists is LTD4 = LTC4 > LTE4 
[Heise  2000,  Nothacker  2000,  Takasaki  2000].  The  cysLT1-R  inhibitors  were  ineffective 
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cysLT1-R cysLT2-R
ligands LTD4 >> LTC4 > LTE4 LTD4 = LTC4 > LTE4
antagonists Montelukast, Zafirlukast,
Pranlukast, Pobilukast, MK571,
Bay u9773
Bay u9773 (partial agonist)
expression high: PBL and spleen
lower: pancreas, placenta, colon,
kidney, liver, brain, lung
high: heart, adrenal gland,
placenta
lower: spleen, PBL, CNS
inducing cytokines IL-4, IL-13, IFNγ, TGFβ IL-4, IFNγ
G protein-coupling Gi, Gq, Go? Gi, Gq, Go?
Ca2+-response solid peak oscillation
Table 1.  Comparison  of  cysLT1-R  and  cysLT2-R  regarding  their  ligand  affinity,  selected  antagonists, 
expression and G protein utilization. On the basis of Brink  et al. (2003), Espinosa  et al. (2003), Fujii  et al. 
(2005), Heise  et al. (2000), Lynch  et al. (1999), Lötzer  et al. (2003), Thivierge  et al. (2001). PBL: peripheral 
blood leukocytes, CNS: central nervous system
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[Heise 2000, Nothacker 2000, Takasaki 2000], and the dual cysLT1-R / cysLT2-R inhibitor 
Bay u9773  also  acted  as  a  partial  agonist  at  the  cysLT2-R  by  eliciting  a  concentration-
dependent increase in [Ca2+]ic [Nothacker 2000] (Table 1).
Recently, an orphan GPCR, GPR17, has been identified as a third putative cysLT-R [Ciana 
2006].  GPR17  is  characterized  as  a  dual  receptor  for  uracil  nucleotides  and  cysLTs.  In 
transfected cells GPR17 responds to cysLTs in the same concentration range as the two other 
cysLT-Rs, but shows different ligand binding affinity: LTC4>>LTD4. GPR17 is inhibited by 
the cysLT1-R antagonists Montelukast and Pranlukast. Expression of GPR17 was detected by 
semi-quantitative PCR in brain, kidney, heart and HUVECs [Ciana 2006].
Pharmacologic  profiling  studies  of  human  pulmonary  artery  smooth  muscle  provided 
indications that a further cysLT-R or a new subtype may exist. Stimulation with LTC4 or LTD4, 
but not with LTE4, induced contractions in human pulmonary artery preparations. Neither the 
classical cysLT1-R antagonists, nor the cysLT1-R / cysLT2-R dual antagonist could modify the 
contractions. However, cell type-specific expression and activation of the receptors, or effects 
resulting from concomitant stimulation of endothelial and smooth muscle cell cysLT-Rs may 
explain these observations [Walch 2002].
1.1.3.3. Functional studies on cysLT-Rs
CysLT1-R expression and function have been extensively studied in various organ preparations 
and in vitro systems [Espinosa 2003, Mellor 2001, Thivierge 2001 and reviewed in Brink 2003 
and  Capra  2004].  However,  there  is  very  little  information  available  on  the  cysLT2-R. 
Experiments with cord blood-derived mast cells that express both cysLT-Rs indicate distinct 
roles and signaling pathways for the two receptors [Mellor 2001, 2002 and 2003]. In these cells 
cysLT2-R  was  responsible  for  cysLT-induced  interleukin 8  (IL-8)  production,  and  it  was 
partially involved in IL-5 secretion. Since both receptors are present on mast cells, downstream 
synergism between  cysLT1-R  and  cysLT2-R  cannot  be  excluded.  In  transient  transfectants 
cysLT2-R did not couple to Gi,  but induced Ca2+ signals  probably via Gq activation [Heise 
2000].  By contrast,  in  mast  cells  cysLT2-R coupling  to  Gi was  observed,  and  the  cysLT-
triggered Ca2+ responses were entirely dependent on cysLT1-R [Mellor 2003].
12
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Analyses of [Ca2+]ic elevations by the two cysLT-Rs in non-transfectant systems where one of 
the receptors was only marginally present revealed differences in kinetics, amplitude, duration 
and oscillatory patterns [Lötzer  2003,  Sjöström 2003].  LTD4 challenge of  the cysLT1-R in 
MonoMac-6 cells (human monocytic cell line) that express mainly the cysLT1-R induced a 
rapid,  short-lived  response,  whereas  stimulation  of  the  cysLT2-R  on  HUVECs  resulted  in 
oscillations maintained for >60 minutes [Lötzer 2003].
CysLT1-R  mRNA  induction  by  IL-4,  IL-13,  interferon  γ  (IFNγ)  or  transforming  growth 
factor β (TGFβ) was described in various cell types [Thivierge 2001, Mellor 2001, Espinosa 
2003]. On the other hand, augmented cysLT2-R transcription was observed only in response to 
IL-4 [Lötzer 2003, Mellor 2003, Sjöström 2003]. In HUVECs other inflammatory mediators 
such  as  lipopolysaccharide  (LPS),  tumor  necrosis  factor α  (TNFα)  and  IL-1  did  not  alter 
cysLT2-R expression [Lötzer 2003, Sjöström 2003]. Peripheral blood eosinophils express both 
cysLT-Rs,  and in  asthmatic  patients  expression  levels  on the  cell  surface  are  significantly 
enhanced, but their functions were not further characterized [Fujii 2005].
These data indicate that regulation of cysLT-R expression, G protein-coupling and signaling 
depend on cell type and pathophysiological conditions. Table 1 provides a short summary on 
cysLT1-R and cysLT2-R attributes.
1.1.3.4. CysLT-Rs in the cardiovascular system
LTs  have  several  effects  on  the  cardiovascular  system,  e.g.  on  blood  pressure  regulation, 
coronary artery contraction,  oedema formation [reviewed in Lötzer 2005]. Kamohara  et al. 
examined the distribution of  cysLT-Rs in  the heart  by  in  situ hybridization and RT-PCR. 
CysLT1-R  was  expressed  in  the  pericardium  at  a  low  level.  However,  cysLT2-R  was 
abundantly  expressed  in  the  left  and  right  atria  and  the  left  ventricle  and  showed weaker 
expression in the artery, where mRNA was detected only in smooth muscle cells and not in the 
endothelium. In cultured coronary artery smooth muscle cells, LTC4 increased the [Ca2+]ic, and 
this increase was not inhibited by cysLT1-R antagonists. LTC4 also initiated migration of these 
cells  [Kamohara  2001].  CysLT-R  expression  was  also  determined  and  confirmed  in 
atherosclerotic lesions [Spanbroek 2003], but neither receptor showed increased mRNA levels 
compared to iliac artery samples as control [Qiu 2006a]. The presence of cysLT-Rs in the 
diseased vessel wall may implicate them in atherogenesis, but these studies provide data only 
about the mRNA levels of these receptors; their expression pattern and function in the lesion 
remain to be identified.
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The role  of  cysLT2-R  in  the  vascular  system was  investigated  in  vivo in  transgenic  mice 
expressing  the  human cysLT2-R in  endothelial  cells  [Hui  2004].  Both  endogenous cysLTs 
elicited  by  passive  cutaneous  anaphylaxis  and  exogenously  added  LTC4 caused  enhanced 
vascular  permeability  in  the  ear  vasculature  of  transgenic  mice.  The  regulatory  role  of 
cysLT2-R on vascular permeability is supported by data of Beller  et al. (2004), who found 
reduced leakage in cysLT2-R-/- mice. As a systemic effect, the pressor effect induced by LTC4 
administration was abolished in cysLT2-R transgenic mice [Hui 2004]. This may be the result 
of increased NO production after LTC4 injection, though the changes in blood pressure and NO 
levels show divergence in time. The source of NO was not identified either, which leaves the 
possibility of indirect  regulation open. Lung endothelial  cells  prepared from the transgenic 
mice showed stronger response to LTC4 and LTD4 in [Ca2+]ic increase than those from control 
mice,  confirming  the  presence  of  functional  cysLT-Rs.  In  the  ECs  from transgenic  mice, 
however, the LTC4- and LTD4-triggered signals differed both in magnitude and kinetics, which 
contradicts the data obtained in human systems, where LTC4 and LTD4 are equipotent agonists 
of the cysLT2-R [Heise 2000, Evans 2002, Lötzer 2003]. This shows that, though such studies 
are important, their results cannot always be transferred directly and need to be confirmed in 
human systems.
1.1.4. LT effects on the endothelium
The endothelium lining the blood vessels forms a barrier between the blood and the vessel 
wall. Due to this location, ECs can be exposed to LTs derived both from blood leukocytes and 
inflammatory  leukocytes  localized  in  the  altered  vessel  wall.  The  effects  of  LTs  on  the 
endothelium is mostly studied in vitro using HUVECs.
As  a  chemotactic  mediator,  LTB4 enhances  leukocyte  attachment  to  the  endothelium 
[Heimbürger 1995, Yokomizo 1997, Tager 2003]. This effect was considered to be the result of 
BLT-R activation on the leukocytes. It has recently been described that HUVECs express both 
BLT-Rs [Lötzer 2003], and BLT-R expression can be induced by inflammatory mediators such 
as  TNFα,  LPS  and  IL-1β,  and  by  LTB4 itself  [Qiu  2006b].  HUVECs  respond  to  LTB4 
stimulation  with increased [Ca2+]ic,  NO generation and monocyte chemoattractant  protein 1 
(MCP-1) release [Qiu 2006b]. These data show that LTB4 acts on both partners to promote 
leukocyte-EC interaction.
14
Introduction
CysLTs have diverse post-transcriptional effects on HUVECs, including the release of AA and 
its derivatives as well as the expression of adhesion molecules.
LTC4 and LTD4 induce release of AA, prostacyclin (PGI2), prostaglandin F2α [Cramer 1983] as 
well  as  platelet-activating  factor  (PAF)  [McIntyre  1986]  in  a  dose-dependent  manner.  In 
contrast to the transient and rapid PGI2 and PAF release mediated by other vasoactive agonists, 
cysLTs trigger continuous liberation of AA and its derivatives [Cramer 1983, McIntyre 1986]. 
The two major phospholipid-derived products, PGI2 and PAF, have opposite effects on poly-
morphonuclear  cells  (PMNs).  Upon vascular  injury,  PAF synthesized  by  ECs can activate 
platelets and attract PMNs to promote hemostasis. At the same time, PGI2 released by ECs can 
control hemostasis by limiting the number of involved platelets and PMNs and by localizing 
thrombus formation.
In  addition  to  liberation  of  the  phospholipid-derived  mediators,  cysLTs  can  mobilize  the 
secretory granules called Weibel-Palade bodies, thus promoting rapid von Willebrand factor 
(vWF) secretion and P-selectin surface expression [Datta 1995]. The mechanism involved in 
this secretory process is not fully understood. A cysLT-induced [Ca2+]ic increase was shown to 
be  necessary  for  vWF secretion,  but  the  Ca2+-activated  protein  kinase C (PKC) is  not  the 
primary mediator. vWF release could be inhibited with high concentrations (5 and 10 µM) of 
the  cysLT1-R-specific  antagonist  Pobilukast.  By  contrast,  Pedersen  et  al. found  that  three 
structurally  unrelated cysLT1-R antagonists  (Zafirlukast,  Pranlukast  and Pobilukast;  highest 
concentration  1 µM)  did  not  have  any  effects  on  LTC4-  and  LTD4-induced  P-selectin 
expression. At 1 µM and 100 nM concentrations, LTD4 was less effective than LTC4. LTC4 
was similarly effective as histamine, a well-known endothelial P-selectin inducer [Pedersen 
1997].  These  controversial  findings  are  not  necessarily  contradictory.  Datta  et  al. did  not 
investigate the effect of cysLT1-R antagonists on P-selectin expression, and Pedersen et al. did 
not measure vWF secretion or show involvement of Weibel-Palade bodies. Both P-selectin and 
vWF can be expressed and released independently from the Weibel-Palade bodies. Moreover, 
the content of Weibel-Palade bodies was shown to change dynamically depending on micro-
environmental  conditions  and  stimuli,  and  the  existence  of  different  subsets  with  various 
contents was also revealed [reviewed in Rondaij 2006].
It has to be noted that the cysLT-Rs had not yet been cloned and characterized at that time. In 
addition, data on cysLT-R expression on HUVECs are also inconsistent and may depend on 
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cell culture conditions [Sjöström 2001, Lötzer 2003]. For PAF and PGI2 synthesis, it was not 
clarified which receptor(s) are responsible for the effect.
1.2. Thrombin and its receptors
Thrombin, a trypsin-like serine protease, is the main protease in the blood coagulation system. 
Activation of both arms of the coagulation cascade, namely the intrinsic (or contact factor) 
pathway and the extrinsic (or tissue factor) pathway, converge on thrombin. Once generated, 
thrombin catalyzes the final steps to clot formation, i.e. the conversion of fibrinogen to fibrin 
and the activation of factor XIII (FXIII) and platelets (Fig. 2, 3). Besides its direct effector role 
in  clot  formation,  thrombin  initiates  several  positive  and  negative  feedback  mechanisms 
regulating  the  coagulation  process  (Fig. 3).  In  addition,  thrombin  elicits  numerous  cellular 
effects via its receptors, the so called protease-activated receptors (PARs).
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Figure 2. Schematic view of the coagulation cascade leading to thrombin formation. The intrinsic pathway is 
initiated through contact and activation of FXII by abnormal surfaces caused by injury. Tissue damage can trigger 
TF expression in ECs or expose TF-bearing vascular wall cells, which induces the extrinsic pathway. Activated 
factors are marked with “a”. Gray ovals indicate proteinase complexes, where TF, and factors Va and VIIIa do 
not have enzymatic activity. ECM: extracellular matrix. [After Berg 2001]
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1.2.1. Thrombin generation and inactivation
Thrombin is derived from prothrombin, its inactive precursor, which is synthesized in the liver 
and  is  secreted  into  circulation.  Upon  vascular  injury,  activation  of  upstream coagulation 
factors results in formation of the prothrombinase complex consisting of FVa, FXa, Ca2+, and 
anionic phospholipids on the surface of platelets or cells (Fig. 2). Prothrombin is localized to 
membrane surfaces via several domains, which compose the F1+2 fragment after cleavage by 
FXa. Loss of the F1+2 module enables thrombin to freely diffuse and to activate its substrates, 
and exposes functional regions important for thrombin activity and specificity [Crawley 2006, 
Davie 2006].
To prevent  inappropriate  clot  formation  or  bleeding,  thrombin  generation  and activity  are 
tightly  controlled  by  several  mechanisms.  Thrombin itself  regulates  its  own generation  by 
activating factors V, VIII and XI, but also its own termination via the protein C system in the 
case of normal endothelium. Due to the great amount of circulating serine protease inhibitors, 
active  thrombin is  short-lived in  the blood.  The most  important  endogenous inhibitors  are 
antithrombin, heparin cofactor II, protease nexin I, which all inhibit the catalytic activity of 
thrombin. Exogenous thrombin inhibitors such as hirudin, hemadin and rhodniin isolated from 
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Figure 3. The central role of thrombin in hemostasis. Activation of the coagulation cascade leads to thrombin 
formation. Besides its essential role in clot formation, thrombin triggers its own production by activating platelets 
and factors V, VII and XI, and induces cellular responses via its receptors. Thrombin binding to thrombomodulin 
(TM)  activates  the  protein  C  system,  which  negatively  regulates  the  coagulation  cascade.  Serine  protease 
inhibitors and possible degradation lead to inactivation of thrombin. [After Crawley 2006]
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hematophagous animals have similar inhibitory properties [Davie 2006]. In addition, autolytic 
degradation of thrombin was also shown, but based on present knowledge it only takes place 
ex vivo after prolonged standing in solution (Fig. 3) [Davie 2006].
1.2.2. Thrombin receptors
Thrombin signaling is mediated through members of the protease-activated receptor (PAR) 
family. Thrombin can activate three of the four known receptors. PARs are GPCRs expressed 
on a variety of cell types and can be activated by several proteases that are usually generated 
during  inflammation  and  injury  (Table 2).  Thus,  actions  mediated  by  PARs  contribute  to 
hemostasis, inflammation and nociception.
1.2.2.1. Mechanism of PAR activation and signaling
Proteases  activate  PARs  by  a  mechanism  unique  among  GPCRs  but  common  for  PARs. 
Cleaving the receptor unmasks a new N-terminal domain, which serves as a tethered peptide 
ligand and binds irreversibly to the body of the receptor. This intramolecular ligation induces 
conformational changes resulting in G protein activation. Principally, liberating the tethered 
ligand by any protease activates the receptor and triggers cellular effects. The specificity of the 
18
Receptor Activating protease Expression in ECs Expression in other cells
PAR-1
thrombin
trypsin
FXa
APC
HUVECs, HAECs, HCAECs,
HMECs, rat sinusoidal ECs,
porcine CAECs
platelets, fibroblasts,
neurons, T cells, VSMCs, 
rat cardiomyocytes
PAR-2
trypsin
mast cell tryptase
TF/FVIIa/FXa 
complex
APC
HUVECs, HAECs, HMECs
fibroblasts, neurons,
neutrophil granulocytes,
epithelial cells,
bovine VSMCs,
rat cardiomyocytes
PAR-3 thrombintrypsin
human and rat brain MECs,
HUVECs(?) VSMCs, mouse platelets
PAR-4
thrombin
trypsin
neutrophil cathepsin G
rat aortic ECs,
stimulated HCAECs
human platelets, VSMCs,
rat cardiomyocytes
Table 2. Comparison of PARs regarding their activating enzyme and expression in the vasculature. On the 
basis of Bretschneider (1999, 2000 and 2003), Bunnett (2006), Coughlin (2005), Macfarlane (2001), Minami 
(2004b), Ossovskaya (2004) and Sabri (2000 and 2003). HAECs: human aortic ECs, HCEAECs: human coronary 
artery ECs, HMECs: human microvascular ECs, VSMCs: vascular smooth muscle cells
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reaction lies in differences in the proteases, in the receptors (both the ligand and the ligand 
binding site)  and in  the  cell  types  expressing them.  Peptides  corresponding  to  the  protein 
sequence  of  the  activating  site  cause  receptor  activation  without  proteolysis  [reviewed  in 
Ossovskaya 2004, Coughlin 2005, Davie 2006]. PARs couple to several subtypes of G proteins 
and can initiate a signaling network in a cell type-dependent fashion [reviewed in Macfarlane 
2001, Ossovskaya 2004, Coughlin 2005]. Termination of the signaling of irreversibly activated 
receptors is not clearly understood. C-terminal phosphorylation by G protein-coupled receptor 
kinases and PKC, and interaction with β-arrestin and other adaptor(s) lead to desensitization 
and internalization of PAR-1 [reviewed in Macfarlane 2001, Ossovskaya 2004]. In contrast to 
reversibly  activated  GPCRs,  which  recycle  to  the  surface  after  internalization,  a  large 
proportion of PAR-1 is sorted to lysosomes and becomes degraded [Trejo 2003]. Thrombin 
responsiveness is maintained by an intracellular pool of presynthesized, naïve receptors, which, 
upon stimuli, translocate to the plasma membrane in a cell type-dependent manner, and by 
newly synthesized receptors [Macfarlane 2001].
1.2.2.2. PARs in the cardiovascular system
PARs are expressed on many cell types of the vascular system (ECs, vascular smooth muscle 
cells  [VSMCs],  fibroblasts,  neurons,  cardiomyocytes)  and  by  cells  contributing  to  distinct 
pathophysiological  conditions  (platelets,  monocytes,  T  cells,  mast  cells,  neutrophils).  In 
addition to PAR-1, which is present on nearly all of these cells, several cell types express other 
PAR(s) in various combinations (shown at least  in vitro) (Table 2). The receptors differ in 
availability,  affinity,  activating  mechanism,  and  thus,  they  are  activated  under  different 
microenvironmental conditions and mediate distinct effects. Vascular cells that are separated 
from blood flow (VSMCs,  fibroblasts,  cardiomyocytes)  constitutively  express  tissue  factor 
(TF). Those in contact with blood (ECs and monocytes) do not express TF under physiological 
conditions,  but  TF  is  induced  in  response  to  tissue  damage,  inflammation  or  coagulation 
proteases [Mackman 2004, Stenina 2003].
Upon vascular injury, thrombin is generated at high local concentrations on the surface of TF 
expressing cells and can activate these cells via their PARs. Under normal conditions PARs 
contribute to hemostasis and physiological blood clotting in response to injury. In cases of 
imbalanced  hemostasis,  chronic  inflammation  or  sepsis,  generation  of  thrombin  and  other 
proteases is accelerated, which leads to enhanced activation of PAR-expressing cells. These, in 
turn, maintain their thrombogenic and inflammatory phenotype. This can result in thrombus 
formation  and  development  of  vascular  disorders.  PARs are  implicated  in  mechanisms  of 
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several vascular diseases, e.g. atherosclerosis, coronary artery syndromes, cardiac infarction 
and stroke [reviewed in Mackman 2003, Ossovskaya 2004, Coughlin 2005, Bunnett 2006]. As 
the  use  of  thrombin  inhibitors  may cause  to  excessive  bleeding,  PARs represent  potential 
therapeutic targets in these diseases.
1.2.3. Thrombin effects on the endothelium
Thrombin  triggered  signaling  in  cultured  ECs  can  lead  to  shape  change,  NO production, 
increased permeability [reviewed in Minami 2004b]. Similar to cysLTs, thrombin induces PGI2 
release [Weksler 1978], vWF secretion [Mayadas 1989], P-selectin expression [Sugama 1992], 
PAF  synthesis  [Prescott  1984].  Transcriptional  changes  result  in  a  proinflammatory  and 
prothrombotic phenotype via chemokine and growth factor secretion, increased expression of 
adhesion molecules and of TF. Thrombin also induces proliferation and migration of ECs, thus 
exerting angiogenic effects  [reviewed in Coughlin 2000,  Macfarlane 2001, Minami 2004b, 
Coughlin 2005].
In  ECs  PAR-1  is  the  major  thrombin  receptor  [O’Brien  2000,  Coughlin  2005].  ECs  also 
express PAR-2, which was shown to be transactivated by PAR-1 in the presence of PAR-1 
antagonist in vitro [O’Brien 2000]. In human microvascular ECs PAR-1 couples to Gq, Gi/o and 
G12/13 as  demonstrated  by  inhibition  of  thrombin  signaling  with  “minigenes”  encoding  a 
C-terminal peptide of the Gα subunits [Gilchrist 2001, Vanhauwe 2002]. Thrombin activates a 
complex net of signaling pathways, which involve the transactivation of the epidermal growth 
factor receptor (EGFR) and include the mitogen activated protein (MAP) kinase cascade, PI3 
kinase,  Rho kinase,  PKC, other Ca2+-regulated kinases and phosphatases,  and ion channels 
[reviewed in Ossovskaya 2004, Coughlin 2005]. Thrombin-induced gene expression patterns 
and  transcriptional  regulatory  mechanisms  have  been  studied  only  recently  [reviewed  in 
Stenina 2003, Minami 2004b].
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Rationale
Several vascular diseases are associated with inflammation. Leukocytes that accumulate at sites 
of vascular inflammation produce cytokines, growth factors and vasoactive molecules, among 
them LTs. Previously described effects of cysLTs in ECs include PAF release, vWF secretion, 
P-selectin surface expression, and oscillation in [Ca2+]ic, but the transcriptional changes induced 
by  LTs  remain  to  be  determined.  CysLTs  act  through  three  receptors,  namely  cysLT1-R, 
cysLT2-R, both of which are expressed in the vasculature, and a recently described cysLT-R 
called GPR17. Considerable amounts of data have been published on the cysLT1-R, whereas 
the cysLT2-R is less characterized. Since HUVECs selectively and constitutively express the 
cysLT2-R, they are the first  model to characterize cysLT2-R functions in a non-transfectant 
primary cell system.  Thrombin was chosen as positive control because LTD4 and thrombin 
have  several  immediate  post-transcriptional  effects  on  the  endothelium  in  common. 
Furthermore, both agonists act through GPCRs, and thrombin-activated HUVECs are a well 
characterized model in vascular biology and pathobiology.
Aims
The goal of this study was to characterize cysLT-induced gene signatures in endothelial cells. 
To  this  end,  gene  expression  patterns  in  response  to  LTD4 were  analyzed  in  HUVECs at 
various time points.
In  order  to  understand  the  magnitude  of  cysLT-mediated  transcriptional  changes,  LTD4-
triggered gene signatures were compared to those induced by thrombin, a prototype vasoactive 
agonist of ECs.
Selected LTD4-regulated genes, which have been implicated in vascular biology, were further 
studied at the protein level.
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2.1. Materials
All materials used in this work were from Invitrogen (Karlsruhe, Germany) unless otherwise 
noted.
2.1.1. Reagents
Cycloheximide (Sigma-Aldrich, Munich, Germany)
Cyclosporin A
LTD4 (Cayman Chemical, Hamburg, Germany)
Montelukast (a gift from R. N. Young, Merck Frosst, Quebec, Canada)
Thrombin (Sigma-Aldrich)
TNFα (R&D Systems, Wiesbaden, Germany)
Vascular endothelial growth factor (VEGF; Cayman Chemical)
2.1.2. Kits
Actichrome TF Kit (American Diagnostica, Pfungstadt, Germany)
BD OptEIA Human IL-8 ELISA Kit II (BD Biosciences, Heidelberg, Germany)
Cloned AMV First-Strand cDNA Synthesis Kit
MSB Spin PCRapace Purification Kit (Invitek, Berlin, Germany)
Platinum Taq Polymerase Kit
RNeasy MicroKit and RNeasy MiniKit (Qiagen, Hilden, Germany)
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2.1.3. Buffers and solutions
Phosphate buffered saline (PBS; without Ca2+ and Mg2+) and Hank’s balanced salt solution 
(HBSS; with Ca2+ and Mg2+)  were purchased from Invitrogen. For preparing the following 
buffers and solutions all materials were from Sigma-Aldrich unless otherwise noted.
10x stop solution: 0.05w/v% bromphenolblue, 48% glycerine, 0.1% SDS, 0.1 M EDTA
5x Laemmli  buffer  (pH=6.8): 2.5 M Glycerol,  0.3 M Tris,  3 M EDTA, 0.2 M SDS,  0.2 M 
β-mercaptoethanol, 1 mM bromophenol blue
Agarose gel: 2w/v% agarose (Roche Diagnostics, Mannheim, Germany), 50 ng/ml ethidium 
bromide in TAE buffer (see below)
Amidoblack destaining solution: 90v/v% methanol, 2v/v% acetic acid
Amidoblack staining solution: 0.1w/v% amidoblack, 45v/v% methanol, 10v/v% acetic acid
Blocking solution: 4w/v% non fat dry milk, 1w/v% BSA, 0.1v/v% Tween-20 in PBS
Calcium buffer (pH=7.4): 145 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1.5 mM CaCl2, 10 mM 
HEPES, 10 mM glucose, 0.25w/v% human serum albumin
FACS buffer: 2 mM EDTA, 1% fetal calf serum (FCS) in PBS
Ponceau Red staining solution: 0.5w/v% Ponceau S, 1v/v% acetic acid
Resolving  gel  (10%): 33%  Acrylamide/Bis  Solution  (30% T,  2.67% C;  Roth,  Karlsruhe, 
Germany), 375 mM Tris (pH=8.8), 0.1w/v% SDS, 2.7 mM TEMED, 2.2 mM APS
Running buffer (pH=8.3): Rotiphorese (Roth) diluted in 1:10
Stacking gel (4%): 13% Acrylamide/Bis Solution (30% T, 2.67% C), 125 mM Tris (pH=6.8), 
0.1w/v% SDS, 2.7 mM TEMED, 2.2 mM APS
TAE buffer (pH=8.0): 40 mM Tris, 20 mM glacial acetic acid, 1 mM Na2EDTA
TF lysis buffer (pH=7.4): 50 mM Tris, 100 mM NaCl, 0.1% Triton X-100
Transfer buffer (pH=8.3): 25 mM Tris, 192 mM glycine, 20v/v% methanol
Tris buffer (pH=7.5): 10 mM Tris, 10mM MgCl2, protease inhibitor cocktail (Complete; Roche 
Diagnostics)
Tris-Triton  buffer  (pH=7.5): 10 mM Tris,  10 mM MgCl2,  protease  inhibitor  cocktail,  1% 
Triton X-100
Tween-PBS: 0.1v/v% Tween-20 in PBS
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2.2. Methods
2.2.1. Endothelial cell isolation and culture
Endothelial cells (ECs) were isolated from human umbilical cord vein by collagenase digestion 
according to the protocol described by Jaffe et al. (1973), with minor modifications. Umbilical 
cords  not  older  than  24 h  were  used.  Cords  were  rinsed  and  stored  in  cold  PBS  until 
processing. 0.1% collagenase (collagenase type 2; Worthington, Lakewood, NJ) in HBSS was 
freshly prepared and sterile filtered. Collagenase amount was calculated from the cord length: 
~1 ml / 1 cm.  Petri  dishes  were  preincubated  for  30 min  with  endothelial  cell  serum-free 
medium  (EC-SFM)  containing  10 U/ml  penicillin,  10 µg/ml  streptomycin,  20 µg/ml 
fibronectin (FN) and 5% FCS:
cord length [cm] dish [cm2] medium [ml]
20-45 21 5
>45 58 12
The vein was canulated with a blunt needle and perfused with warm HBSS to remove blood. 
The distal end was clamped; the vein was filled with 0.1% collagenase; then this end was also 
clamped shut. The cord suspended by the clamped ends was incubated in water bath for 3 min 
at 37°C. The effluent solution containing the endothelial cells was collected in a 50 ml tube and 
the  vein  was  flushed  with  medium  M199  containing  5%  FCS  (M199-FCS).  Cells  were 
centrifuged at 200 g for 5 min at 20°C, then resuspended and plated in the preincubated dish. 
About 5 h after isolation the dishes were washed with warm HBSS to remove non-adherent 
cells (mainly blood cells) and fresh medium (EC-SFM containing 20 ng/ml basic fibroblast 
growth factor [bFGF] and 10 ng/ml epidermal growth factor [EGF]) was added. Cells were 
cultured in a humidified incubator at 37°C with a 5% CO2 atmosphere. Cells were fed every 2-
3 days by replacing half of the medium with fresh EC-SFM containing 40 ng/ml bFGF and 
20 ng/ml EGF.
After reaching optical confluence, cells were passaged. Medium was removed and the cells 
were  gently  rinsed  with  trypsin-EDTA.  2 ml  trypsin-EDTA  was  added  and  cells  were 
monitored under the microscope. The reaction was stopped with warm M199-FCS and the cells 
were transferred into a 50 ml tube. The dish was rinsed with M199-FCS and the cells were 
centrifuged at 200 g for 5 min at 20°C. The cell pellet was resuspended in EC-SFM and the 
cells were counted using a Coulter Counter. Cells were seeded at a density of 15,000-20,000 
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cells/cm2 in EC-SFM containing 10 µg/ml FN, 20 ng/ml bFGF and 10 ng/ml EGF. HUVECs 
were used in the first two passages.
Cells  were  characterized  as  endothelial  cells  based  on  their  cobblestone  morphology  and 
surface expression of CD31, vWF and endothelial protein C receptor (EPCR) measured by 
flow cytometry (Fig. 4). See below for the protocol of flow cytometry.
2.2.2. Measurement of [Ca2+]ic
Expression  of  functional  cysLT2-R  and  PAR-1  was  verified  before  each  experiment  by 
measuring the [Ca2+]ic increase in response to receptor activation by 100 nM LTD4 or 10 nM 
thrombin, respectively. HUVECs were cultured in an 8.5 cm2 dish. Fluo4-AM (1 mM dissolved 
in  dimethyl  sulphoxid)  was  added to  the  medium at  a  final  concentration  of  2 µM.  After 
homogenizing the dye by gentle shaking, the cells were incubated for 30 min at 37°C. Cells 
were  rinsed  twice  with  warm  calcium buffer  and  kept  in  1 ml  buffer.  Measurement  was 
performed using a Zeiss Axiovert 200 microscope equipped with an LSM 510 laser scanner 
head and a heatable mounting frame. The stimulant was diluted in 1 ml warm buffer and added 
at  the  beginning  of  scanning.  Picture  series  were  recorded  for  180 s. [Ca2+]ic changes  are 
expressed  as  mean  fluorescence  intensities  of  the  scanned  area  over  time.  Representative 
signals are shown in Fig. 5.
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Figure 4. Endothelial cell characterization. A) Cells grow as a monolayer showing cobblestone morphology. 
Original magnification: 400x. B) Surface expression of CD31, vWF and EPCR was measured using monoclonal 
antibodies by flow cytometry. moIgG: mouse IgG, rIgG: rat IgG
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2.2.3. RNA extraction
For  RNA extraction  HUVECs  were  cultured  in  8.5 cm2 (or  21 cm2)  dishes.  Medium was 
removed and the cells were washed twice with cold PBS. Remaining PBS was removed and 
cells were lysed in 350 µl (or 900 µl) TRIzol. Lysate was collected into an Eppendorf tube 
using a cell scraper, homogenised by vortexing and transferred into a Phase Lock Gel tube 
(Eppendorf, Hamburg, Germany) tube. 0.2 volume of chloroform was added to the lysate, and 
phases were mixed by vigorous shaking for 1 min. Phases were separated by centrifugation at 
18,000 g for 15 min at 12°C. The upper aqueous phase containing the RNA (~200 µl) was 
mixed with 96-100% ethanol (110 µl) and transferred onto RNeasy MinElute Spin Columns of 
RNeasy MicroKit (8.5 cm2 dish) or RNeasy MiniKit (21 cm2 dish). Further steps were carried 
out according to the manufacturer’s manual. RNA was eluted by centrifugation with 2x12 µl 
RNase-free water (1 min, 10,000 g, 20°C). RNA concentration was measured at 260 nm with 
the NanoDrop spectrophotometer and adjusted to 100 ng/µl for (q)RT-PCR or 625 ng/µl for 
microarray.
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Figure 5.  CysLT2-R-  and  PAR-1-mediated  Ca2+ signals. HUVECs  were  loaded  with  the  Ca2+-indicator 
Fluo4-AM and stimulated with  (A)  100 nM LTD4 or  (B) 10 nM thrombin. The arrows show the time point of 
agonist  addition.  Changes in  [Ca2+]ic are  in  proportion to  fluorescence intensity,  which was recorded with a 
confocal laser scanning microscope every 1.5 s during a 3 min interval.
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2.2.4. Microarray
To determine gene expression patterns of the agonists, microarray analyses were performed. 
For standardization, only male cords were used. HUVECs were cultured in 21 cm2 dishes for 8 
days in  the 1st  passage.  After  stimulation with 100 nM LTD4,  10 nM thrombin or  solvent 
control, RNA was extracted as described and RNA integrity was determined on RNA 6000 
Nano LabChips  using the  Agilent  BioAnalyzer  2100 machine (Agilent  Technologies,  Palo 
Alto, CA) according to the manufacturer’s instructions.
RNA was reverse transcribed into cDNA, which was then in vitro transcribed into cRNA. After 
fragmentation, cRNA was hybridized on HG-U133A chips. Genechips were scanned with the 
GeneChip® Scanner 3000 (Affymetrix, Santa Clara, CA) using the GCOS software. cRNA 
preparation, hybridization and scanning were kindly performed by Christine Ströhl and Markus 
Hildner according to standard Affymetrix protocols and using the microarray platform of the 
Institute for Vascular Medicine.
2.2.4.1. Terms
Probe: a 25mer oligonucleotide synthesized on the array surface.
Perfect match probe (PM): a 25mer that is complementary to the sequence to be hybridized.
Mismatch probe (MM): a 25mer with a mismatch in the 13th position; the 13th nucleotide is 
the Watson-Crick complement of the 13th base in the perfect match probe. Using the mismatch 
probes makes it possible to estimate a cross-hybridization background for each PM sequence.
Probe cell: a square-shaped spot on the array containing probes with a unique sequence.
Probe pair: a PM and a MM probe in a probe set that have the same sequence except for the 
13th nucleotide in the MM.
Probe set: 11 probe pairs (on the U133A array) corresponding to the same target sequence 
(transcript).
2.2.4.2. Raw data: signal, call, detection p value
The scanner generates the .dat file containing the fluorescence intensity of the chip in a range 
of 0-65,000. It is displayed as an image with 256 colors, which makes it possible to check 
visible  quality  of  the  chip  (presence  of  bubbles  or  scratches,  high  regional  or  overall 
background) and to control grid alignment. In the grid each square delineates a probe cell (7x7 
pixels). A background value is calculated for every cell (global background adjustment). Noise 
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value is calculated from the global background variation. After background subtraction and 
noise correction, the adjusted intensity is computed for each probe cell (stored in the .cel file). 
To  adjust  the  PM  intensity  an  ideal  mismatch  (IM)  value  is  calculated:  if  PM > MM, 
IM = MM,  if  PM ≤ MM,  an  IM  value  is  estimated  using  the  one-step  Tukey’s  biweight 
algorithm. The adjusted PM intensities are logarithmized, and a weighted mean is calculated 
for each probe set. The anti-log of this value is the signal intensity value. In order to make the 
arrays comparable, the mean signal intensity of every array was adjusted to a trimmed mean of 
500. To this end, signal mean was calculated by discarding the highest and lowest 2% of all 
signal intensity values on a genechip, and the scaling factor (SF) for each array was computed: 
SF = 500 / trimmed signal mean. Every signal intensity value on a chip was multiplied by the 
SF and this value was given as the signal value for analysis.
For each probe pair, a relative difference of the PM and MM intensities can be calculated. 
Using the one-sided Wilcoxon’s signed rank test a  p value can be calculated for the whole 
probe set. It describes the significance of the result for the whole probe set. Setting two cut-off 
values defines three intervals for making the call. The call can answer the question of whether 
a certain transcript is detectable in the sample. With these three intervals the program defines 
three calls: Absent, if  p > 0.065 (not detectable, i.e. not expressed or the expression is below 
the  threshold  level);  Present,  if  p ≤ 0.05  (the  transcript  is  expressed  and  detectable);  in 
uncertain cases (e.g. noisy probe sets),  where 0.05 < p ≤ 0.065, a Marginally present call is 
given. The three parameters belonging to each probe set (signal value, detection  p value and 
call) are stored in the .chp file and can be exported for analysis with other programs.
2.2.4.3. Genechip quality control
Quality  control  parameters,  i.e.  background,  SF,  noise,  3'/5'  ratios  of  GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) and actin, spiked oligo controls, and % Present 
calls, were checked for each sample before the analysis. To ensure that the quality of the RNA 
samples and assays was acceptable and comparable, 3'/5' ratios of housekeeping genes, SF and 
% Present calls were compared from each experiment (Table 3).
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2.2.4.4. Analysis
Raw data were filtered according to stringent filter criteria. To compare stimulated samples 
with control, the following criteria were set: signal intensity value >150 and detection p value 
<0.065 for at least three of four samples in either the control or the stimulated group; and fold 
change calculated from the groups’ signal means >2.5. The signal intensity value of 150 was 
chosen  based  on the  results  of  previous  experiments,  and  the  detection  p value  limit  was 
chosen as recommended by Affymetrix. This combination gave a fine threshold estimation to 
exclude probe sets with Absent call and to keep data of genes with low expression. To declare 
a probe set regulated, the fold change threshold was arbitrarily set to 2.5. Filtered probe set lists 
were  further  analyzed  using  the  GeneSpring(TM) expression  analysis  software  (version  7.2, 
Silicon  Genetics,  Redwood  City,  CA).  Raw  data  were  normalized  per  probe  set,  and 
differentially  expressed  probe  sets  were  identified  using  a  one-way,  two-level  analysis  of 
variance (ANOVA) with Benjamini-Hochberg correction for multiple testing (p < 0.05).  In 
case of genes represented by more than one probe set, the one with the lowest ANOVA p value 
was  used  for  heatmap  generation.  Lists  of  potentially  regulated  genes  were  generated  by 
filtering data without further statistical analysis. Filtering criteria are given in table legends. 
29
Sample 3'/5' ratio of GAPDH
3'/5' ratio
of Actin Scaling Factor (SF) % Present Call
Affymetrix
recommendation <3 <3
SF discrepancies
should be <3-fold
>30%; similar within 
one experiment
C1 0.81 1.02 2.041 49.2
L1 0.81 1.05 2.143 49.9
T1 0.90 1.03 3.026 44.6
C2 0.89 1.10 3.209 41.3
L2 0.91 1.13 2.751 49.4
T2 0.84 1.26 2.685 49.0
LT2 0.91 1.00 2.663 46.1
C3 0.83 1.08 1.674 51.7
L3 0.83 1.07 2.052 51.0
T3 0.87 1.15 1.779 50.3
LT3 0.81 1.09 1.997 49.5
C4 0.79 1.12 1.687 46.6
L4 0.76 1.08 1.372 50.3
T4 0.73 1.01 1.603 47.1
LT4 0.91 1.00 1.920 47.7
Table 3. Numerical quality control parameters of the genechips of the 1 h samples.
C: control, L: LTD4, T: thrombin, LT: LTD4 + thrombin
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Probe sets were designated using the Affymetrix annotation tables. Analysis of data on LTD4 
plus thrombin treated samples compared to LTD4 or thrombin alone was kindly performed by 
Dörte Radke.
2.2.5. Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
In order to confirm the results obtained by microarray analysis and to quantify gene regulation, 
qRT-PCR analyses were performed. Total RNA was reverse transcribed, and cDNA transcript 
number  was  evaluated  by  quantitative  PCR.  Standard  fragments  for  the  calibration  were 
prepared by semi-quantitative PCR.
2.2.5.1. Rerverse transcription
For 60 µl reaction, 3 µg RNA dissolved in 30 µl water was mixed with oligo dT(12-18) primer 
(8 µl 25 pmol/µl) and denatured (4 min, 72°C). After cooling down to 42°C, 22 µl reverse-
transcription (RT) mix was added. RT ran for 1 h at 42°C and a final denaturation step was 
performed at 94°C for 10 min.
RT mix for 60 µl reaction:
1.15 µl nuclease-free water
11.70 µl 5x RT buffer
3.90 µl dNTP mix (2.5 mM of each dNTP)
1.45 µl RNase Inhibitor (RNaseOUT; 40 U/µl)
1.45 µl 0.1 M dithiotreitol
1.75 µl AMV (15 U/µl)
0.60 µl BSA (10 µg/µl)
2.2.5.2. Primer design
Primers  were  either  taken  from  literature  or  selected  using  the  Primer3  software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).  The  following  aspects  were 
considered: a primer length of 18–27 nucleotides; a product size of 100–300 bp; a Tm (melting 
temperature) for the primer of 67–71°C; a Tm for the product of <86°C; a GC content of the 
primer of 50–65%; both primers had G or C at the 3' end. In case of genes with more transcript 
variants, the primer pair was oriented to recognize all known splice variants. For establishing 
the PCR conditions, the annealing temperature (AT) was calculated as follows:
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AT = (Tm-3' primer + Tm-5' primer) / 2–4, where primer Tm = 4(G+C) + 2(A+T)
Depending on the first  PCR result,  conditions were empirically optimized for each primer. 
Primers and conditions used in this work are summarized in Table 4.
2.2.5.3. Semi-quantitative PCR
For primer establishment and standard fragment preparation for qRT-PCR, semi-quantitative 
RT-PCR was performed with the following profile:  initial  denaturation 30 s  99°C,  2.5 min 
94°C; cycling: 30 s 94°C, 30 s AT, 30 s 72°C and a final elongation: 3 min 72°C. The reaction 
ran for 25-35 cycles depending on the estimated expression of the gene. At the end of the 
reaction, samples were mixed with 10x stop solution. The size and quality of the amplified 
band(s) were analyzed by electrophoresis on 2w/v% agarose gel. For size orientation a DNA 
mass ladder was used. The bands were visualized by UV light and cut out from the gel. To 
elute the cDNA for reamplification, gel pieces were incubated in 200 µl nuclease-free water at 
4°C overnight.
PCR mix for 25 µl reaction:
14.1 µl nuclease-free water
1.0 µl RT-cDNA
2.0 µl dNTP (2.5 mM of each dNTPs)
0.8 µl 50 mM MgCl2 (final concentration: 1.5 mM)
4.0 µl Primer mix (3 µM of both primers)
2.5 µl 10x PCR buffer
0.3 µl BSA (10 µg/µl)
0.3 µl Platinum Taq polymerase (5 U/µl)
2.2.5.4. Reamplification and clean-up of the standard fragment
To gain a considerable cDNA amount, the fragment cut out from the gel was reamplified. The 
PCR profile was optimized according to the results  of the establishing PCR. The size and 
quality of the amplified fragment was checked by electrophoresis on 2w/v% agarose gel using 
2 µl from the sample. If the reamplification led to unspecific bands, the reaction was repeated 
with more stringent conditions by adjusting the AT or the MgCl2 concentration. The fragment 
was cleaned up using the MSB Spin PCRapace purification kit according to the manufacturer’s 
instruction.  cDNA  concentration  was  measured  at  260 nm  with  the  NanoDrop  spectro-
photometer and adjusted to 70 ng/µl.
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PCR mix for 100 µl reaction:
56.0 µl from the eluted cDNA
18.5 µl primer mix (3 µM of both primers)
10.0 µl dNTP (2.5 mM of each dNTPs)
10.0 µl 10x PCR buffer
3.5 µl 50 mM MgCl2
1.0 µl BSA (10 µg/µl)
1.0 µl Platinum Taq DNA Polymerase (5 U/µl)
2.2.5.5. Sequencing
The  PCR  product  was  sequenced  by  MWG-Biotech  (Ebersberg,  Germany).  Samples  and 
primers were sent to the firm according to its protocol. The provided sequence was verified 
using the blastn program (http://www.ncbi.nlm.nih.gov/BLAST/).
2.2.5.6. qPCR
qPCRs were carried out with a Rotor-Gene 2000 thermocycler (Corbett Research, Mortlake, 
Australia)  and  SYBR Green I  as  fluorescent  dye.  Reaction  conditions  were  individually 
optimized for each primer pair. The amplified fragments were quantified via standard curves in 
the range of 8-2,500,000 ssDNA molecules in 40-cycle-reactions. Standards were diluted from 
the purified and sequenced fragments according to the following conversion: 1 µg 1,000 bp 
dsDNA = 1.52 pmol = 3.04 pmol ssDNA. Quality of the reactions and fragments was verified 
by analyzing amplification efficiency and melting curves. GAPDH was measured as reference 
gene  for  normalization.  Results  are  expressed  as  target  gene  transcripts  /  1,000  GAPDH 
transcripts.
qPCR mix for 25 µl reaction:
12.75 µl nuclease-free water
2.00 µl RT-cDNA
2.00 µl dNTP (2.5 mM of each dNTPs)
0.90 µl 50 mM MgCl2
4.00 µl primer mix (3 µM of both primers)
2.50 µl 10x PCR buffer
0.25 µl BSA (10 µg/µl)
0.30 µl Platinum Taq DNA polymerase (5 U/µl)
0.30 µl SYBR Green I (diluted 1:400 in RT buffer)
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Gene Primer sequences Product size [bp] AT [°C]
ADAMTS1 5': CCATGTAGCCCAGATTCCACCT
3': CGCTGTTTCACTTCGATGTTGG
224 64
CD55 5': TGGCCCACCACCTGAATGC
3': GCGTCCCAAGCAAACCTGTCAAC
290 66
CXCL2 5': GAATCTACTTGCACACTCTCCC
3': GACATGTGATATGTCATCACGAAG
156 63
CysLT1-R 5': GTGCCGCCTCAGCACCTATGC
3': CGGACTTCTGCATTCTAAGGACAG
545 68
CysLT2-R 5': GATCTCCTGTTCATAAGCACGCTTC
3': GCAGGCAGCCCACCACCAAGGC
385 69
DSCR1 (pan) 5': GCACGCAGCGACTGACACCA
3': CCTCGTCGCGTGCCAGTTCA
174 66
     1-7-8-9 5': GTGTTCGTGGACGGCCTGTG
3': CCTCGTCGCGTGCCAGTTCA
548 67
     2-7-8-9 5': CAGACATTGAGCGGCGACGTG
3': CCTCGTCGCGTGCCAGTTCA
618 67
     3-7-8-9 5': GGCTGCTGCCAATACAACACCAC
3': TTCCATCCCACTGGCGGAGAG
309 64
     5-7-8-9 5': CGTGGGTCTGTAGCGCTTTCACTG
3': TTCCATCCCACTGGCGGAGAG
389 64
     6-7-8-9 5': CCGCGCTTGCTAGCAGTGAAC
3': TTCCATCCCACTGGCGGAGAG
368 64
EGR1 5': GAGTTGGAATGTTGTAGTTACC
3': GCAATAAAGCGCATTCAATGTG
158 58
EGR2 5': ACTCTCCGCCACCGCCTCCT
3': CACCCGCAGGGTGTCCAGTG
281 63
EGR3 5': TCACCACCTGCGCCTGAGGA
3': CTGGCCGGCGTGAAAGGTTG
192 68
EGR4 5': GGCCTCCCTGGGCTCCTGAC
3': CAGCCACGCCACTGCTTCCA
175 65
E-selectin 5': GCTCTGCAGCTCGGACATGTGG
3': GGCAGCTGCTGGCAGGAACA
201 66
GAPDH 5': TCGGAGTCAACGGATTTGGTCGTA
3': ATGGACTGTGGTCATGAGTCCTTC
520 66
IL-8 5': CTTGGCAGCCTTCCTGATTT
3': CTCAGCCCTCTTCAAAAACT
265 59
NR4A1 5': CCTCCACGCCCAGCTTCCAG
3': GGGCCGGTGGGAGGACTGAA
172 69
NR4A2 5': GTCCGGACAGCAGTCCTCCA
3': GCTGTGCTGCACCTGGAAGC
172 65
NR4A3 5': CGAACCTGCGAGGGCTGCAAG
3': GAGTCTGTTAAAGCTCGGACAAG
308 60
TF 5': CGATCTCGCCGCCAACTGGT
3': GATTGACGGGTTTGGGTTCCCACT
214 66
Table  4.  Primers  used  in  PCRs. Primer  sequences  from the  literature  are:  cysLT1-R,  cysLT2-R,  GAPDH 
[Spanbroek 2003], CXCL2 [Zhao 2004], NR4A3 5' [Martinez-Gonzalez 2003], NR4A3 3' [Satoh 2002].
AT: annealing temperature
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2.2.6. Protein extraction and concentration measurement
2.2.6.1. Lysis in Laemmli buffer
HUVECs were grown in 8.5 cm2 dishes. Medium was removed and cells were rinsed twice 
with ice-cold PBS. Cells were lysed in 150 µl Laemmli buffer. The lysate was collected with a 
cell scraper, transferred to a 1.5 ml tube, homogenized by thorough pipetting and boiled for 
5 min at 100°C. To fragment genomic DNA, the lysate was sonicated 3x 5 s (G. Heinemann 
Ultraschall-  und Labortechnik,  Schwäbisch  Gmünd,  Germany)  on  ice.  After  centrifugation 
(10,000 g, 2 min, 20°C) the supernatant was aliquoted and stored at –20°C.
2.2.6.2. Lysis in Tris-Triton buffer
HUVECs were grown in 21 cm2 dishes. Medium was removed and cells were rinsed twice with 
ice-cold Tris buffer. Cells were scraped in 1 ml Tris-Triton buffer, transferred to a 1.5 ml tube, 
and centrifuged (500 g, 5 min, 4°C). Supernatant was removed and cells were lysed in 70 µl 
Tris-Triton  buffer  on  ice  for  15 min  by  intermittent  vortexing.  Lysate  was  centrifuged  at 
15,000 g for 15 min at 1°C. 60 µl from the supernatant was mixed with 15 µl 5x Laemmli 
buffer  and boiled for  5 min at  100°C.  After  centrifugation (10,000 g,  2 min,  20°C) it  was 
aliquoted and stored at –20°C.
2.2.6.3. Protein concentration measurement
Protein concentration was determined by amidoblack staining. 0.1 mg/ml – 1.0 mg/ml BSA in 
Laemmli buffer was used as standard. Samples were measured both undiluted and diluted in 
1:10. 1-µl drops were applied onto nitrocellulose membrane. After drying, the membrane was 
stained in amidoblack staining solution for 5 min, rinsed with water, and destained. The wet 
membrane was put between clear foils and scanned using a common flatbed scanner at 180 dpi, 
greyscale.  Dots  were  densitometrically  analyzed  by  the  IP  LabGel  program  (Lifescience 
Software Resource, Long Lake, USA), and concentration was calculated by interpolating onto 
a standard curve. Lysate concentration was adjusted to 1 µg/µl.
2.2.7. SDS-polyacrylamide gel electrophoresis and Western blot
For gel  preparation,  electrophoresis  and transfer,  the  Mini-PROTEAN 3 System (Bio-Rad, 
Munich, Germany) was used. HUVEC extracts (10 µg protein in 10 µl) were separated on a 
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10% denaturing polyacrylamide gel at 120 V for 90 min, and transferred onto nitrocellulose 
membrane (GE Healthcare,  Freiburg,  Germany) by 300 mA for 90 min.  For estimating the 
molecular weight, biotinylated protein ladder (Cell Signaling, Danvers, MA) was used.
2.2.7.1. Ponceau Red staining
After the transfer, protein bands were visualized to determine if they had migrated uniformly 
and evenly. The membrane was stained in Ponceau Red staining solution for 5 min at 20°C on 
a shaker and then destained with distilled water until the protein bands were clearly visible. 
The wet membrane was put between clear foils and scanned by a common flatbed scanner.
2.2.7.2. Immunostaining
The  membrane  was  incubated  in  blocking  solution  at  4°C  overnight.  For  early  growth 
response 1 (EGR1), anti-EGR1 antibody was diluted in blocking solution (Table 5), and the 
membrane was incubated for 1 h at 20°C. For TF, anti-TF antibody was diluted in blocking 
solution  (Table 5),  and  the  membrane  was  incubated  for  2 h  at  20°C.  After  washing  with 
Tween-PBS (3x 10 min, 20°C),  the membrane was incubated with secondary antibody and 
with anti-biotin antibody for the protein ladder for 1 h at 20°C (Table 5). The membrane was 
washed  with  Tween-PBS  (3x  10 min,  20°C)  and  finally  with  PBS  (5 min,  20°C). 
Immunoreactive bands were detected by CDP-Star reagent (Applied Biosystems, Darmstadt, 
Germany).  CDP-Star  is  a  chemiluminescent  substrate  for  alkaline phosphatase (AP).  Upon 
dephosphorylation by AP the substrate  changes to an unstable intermediate  product  whose 
decomposition results in light emission. Light production lasted up to 24 h allowing optimal 
detection using X-ray films (GE Healthcare). Films were developed using Kodak reagents.
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Antibody Dilution
rabbit anti-EGR1 Santa Cruz Biotechnology (Santa Cruz, CA) 1:6,000
rabbit anti-TF American Diagnostica (Pfungstadt, Germany) 1:4,000
goat anti-rabbit AP Santa Cruz Biotechnology 1:5,000
goat anti-biotin AP Cell Signaling 1:5,000
Table 5. Antibodies and their dilution used in Western blotting. AP: alkaline phosphatase
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2.2.8. IL-8 ELISA
Cells were cultured in 24-well-plates. Prior to stimulation, the medium was replaced with fresh 
medium without growth factors in order to remove the IL-8 produced continuously by the cells. 
HUVECs were stimulated with 100 nM LTD4 or with 100 U/ml TNFα or with 0.05% ethanol 
as solvent control. After the indicated intervals, supernatants were collected and the cells were 
lysed for qRT-PCR. 1 ml of  the supernatant  was centrifuged at  500 g for  5 min at  4°C to 
remove  cell  debris,  and  aliquots  were  stored  at  –80°C until  processing.  For  IL-8  protein 
measurement  the  BD OptEIA Human  IL-8  ELISA Kit  II  was  used,  which  contains  IL-8 
specific capture antibody coated on a 96-well  plate.  Standards (in 0–100 pg/ml range) and 
sample dilutions were added to the wells. After washing, streptavidin-horseradish peroxidase 
conjugate  mixed  with  biotinylated  anti-human  IL-8  antibody  was  added.  The  ELISA was 
developed  using  3,3',5,5'-tetramethylbenzidine  (TMB)  substrate  solution.  The  reaction  was 
stopped  with  1 M  phosphoric  acid,  and  absorbances  were  measured  at  450 nm  with  a 
microplate reader.
2.2.9. TF procoagulant activity assay
HUVECs were cultured in 8.5 cm2 dishes and lysed in 150 µl  TF lysis  buffer.  Lysate was 
harvested with a cell scraper and sonicated (5x 3 s) on ice. Samples were spun down and stored 
at  –80°C  until  processing.  Procoagulant  activity  was  determined  by  a  chromogenic  assay 
(Actichrome TF), which measures the peptidyl activity of human TF. Lysates were mixed with 
human FVIIa and human FX and incubated at 37°C, allowing the formation of the TF/FVIIa 
complex, and the complex to convert the human FX to FXa. The amount of FXa generated was 
measured by its ability to cleave a highly specific chromogenic substrate (Spectrozyme FXa) 
added to the reaction mixture. The cleaved substrate released a para-nitroaniline chromophore 
into the reaction solution,  thus changing its  color to yellow. The reaction was stopped by 
adding glacial  acetic acid, and absorbance was read at  405 nm by a microplate reader.  TF 
concentration was calculated from a standard curve generated using known amounts of active 
human TF.
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2.2.10. Flow cytometry
To examine the surface expression of marker molecules for EC characterization, cells were 
detached by incubation in PBS containing 0.2% EDTA for 5 min at 37°C. For measurement of 
CD55 expression, HUVECs were stimulated with 100 nM LTD4 or 10 nM thrombin for various 
time points, and cells were harvested by trypsin-EDTA. 2x 05 cells / samples were stained with 
specific monoclonal antibodies or appropriate isotype controls (Table 6) for 15 min on ice. 
After washing with FACS buffer (400 g, 5 min, 4°C), cells were incubated with fluorochrome-
conjugated secondary antibodies (Table 6) for 15 min on ice. Cells were washed, resuspended 
in 500 µl FACS buffer and measured with a FACSCalibur flow cytometer (BD Biosciences). 
Cell population was defined based on forward scatter – side scatter characteristics, and 10,000 
cells were routinely counted. Data were analyzed with the CellQuest program.
2.2.11. Immunofluorescence
Cells were cultured on plastic coverslips (Nunc, Wiesbaden, Germany) in 24-well-plates. After 
stimulation, the cells were rinsed with HBSS at 20°C and air-dried. Samples were stored at –
80°C until processing. After thawing, the cells were allowed to rehydrate in PBS for 5 min at 
20°C, fixed in 4% formaldehyde in PBS for 10 min at 20°C, and permeabilized in 0.5% Triton 
X-100 in PBS for 5 min at 20°C. The samples were incubated with anti-EGR1 (1:100 in 0.25% 
BSA-PBS) for 30 min at 20°C. After washing with PBS, the cells were incubated with Cy3-
conjugated anti-rabbit antibody (1:600; Dianova, Hamburg, Germany) for 30 min at 20°C, and 
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Antibody Dilution/concentration
rat anti-EPCR Sanbio (Beutelsbach, Germany) 5 µg/ml
rat IgG R&D Systems 5 µg/ml
goat anti-rat FITC Dianova 1:50
mouse anti-CD31 (IgG1) DakoCytomation (Hamburg, Germany) 1:100
mouse anti-vWF (IgG1) DakoCytomation 1:100
mouse IgG1 DakoCytomation 1:100
goat anti-mouse PE Dianova 1:100
mouse anti-CD55 (IgG2a) BD Biosciences 5 µg/ml
mouse IgG2a BD Biosciences 5 µg/ml
rat anti-mouse IgG2a+b BD Biosciences 1:20
Table 6. Antibodies used in flow cytometry. FITC: fluorescein isothiocyanate, PE: phycoerythrin
Materials and methods
the DNA was stained with 4',6-diamidino-2-phenylindole (DAPI). The samples were scanned 
using a Zeiss Axiovert 200 microscope equipped with a LSM 510 laser scanner head.
2.2.12. Statistics
Data are expressed as mean ± SEM. Statistical evaluation was performed by Student t test for 
paired data with Microsoft Excel and a p value < 0.05 was considered significant.
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3.1. LTD4-induced gene signatures
To  identify  cysLT2-R-regulated  genes  in  ECs,  microarray  experiments  were  performed. 
Changes in the expression of more than 14,500 genes could be monitored in parallel using the 
Affymetrix U133A genechips. HUVECs were stimulated with 100 nM LTD4 or with 0.05% 
ethanol  as  solvent  control.  10 nM  (1 U/ml)  thrombin  was  used  as  positive  control.  After 
stimulation, total RNA was isolated, reverse transcribed into cDNA and  in vitro transcribed 
into cRNA, which was hybridized to the arrays. The samples were scanned and data were 
analyzed  using  the  GeneSpring  expression  analysis  software.  Data  are  published  in  the 
National Center for Biotechnology Information’s (NCBI) Gene Expression Omnibus (GEO) 
database under the accession number GSE3589.
The first experiment investigating the time points 1 h, 6 h and 24 h showed that the strongest 
changes in gene expression in response to LTD4 occur at 1 h (Fig. 6). Therefore, three further 
experiments  were performed at  the 1 h time point,  also including samples  stimulated with 
100 nM LTD4 and 10 nM thrombin together to examine the possibility of cooperation between 
the agonists.
To identify LTD4-regulated genes, four data sets from independent umbilical cord preparations 
were analyzed at the 1 h time point using stringent filter criteria. Pre-filtering threshold values 
were set as follows: signal value >150 and detection  p value <0.065 at least in three of four 
samples in either the control or the stimulated group. Probe sets were further filtered by the 
fold change parameter calculated from the groups’ signal means >2.5. The resulting list  of 
probe sets was statistically tested using one-way ANOVA with correction for multiple testing 
(Benjamini-Hochberg).  Differentially  expressed  genes  were  determined  by  the  ANOVA  p 
value (p < 0.05). LTD4 significantly up-regulated 37 genes represented by 48 probe sets at least 
2.5-fold,  and  there  were  no  genes  down-regulated  >2.5-fold.  LTD4-induced genes  encode, 
among others, transcription factors, e.g. members of the EGR (early growth response), NR4A 
(nuclear  receptor  subfamily 4  group A)  and  KLF  (Krüppel-like  factor)  transcription  factor 
families; chemokines, e.g. IL-8 and CXCL2 (CXC chemokine ligand 2); signalling molecules, 
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e.g. regulator of G protein signalling 2 and DSCR1 (Down syndrome critical region gene 1); 
the  adhesion  molecule  E-Selectin;  the  metalloprotease  ADAMTS1  (a  disintegrin-like  and 
metalloprotease with thrombospondin motif 1, type 1); growth factors, e.g. HBEGF (heparin-
binding EGF-like growth factor) and bone morphogenic protein 2; and (TF). Several of these 
genes are implicated in inflammatory processes [Kachigian 2006, Martínez-Gonzalez 2005, 
Suzuki  2005,  Gerszten 1999, Levi 2006]  (Fig. 7).  The expression patterns of these 37 up-
regulated  genes  are  displayed  in  Fig. 7,  and  Table 7  in  the  Appendix.  For  comparison, 
thrombin data for these genes are also shown. The heatmap shows normalized signal intensities 
encoded  by  colours:  green  represents  no  or  very  low  expression,  yellow  shows  medium 
expression and red corresponds to high expression.
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Figure 6. Gene expression patterns induced by LTD4 and thrombin. HUVECs were stimulated with 100 nM 
LTD4 or 10 nM thrombin and microarray analyses at the indicated time points were performed. Changes in gene 
expression are shown as scatterplots. Dots in plots A-C indicate means of signal intensities of four umbilical 
cords; in plots D-I signal values of single chip experiments are presented. Lines depict 2.5-fold changes.
Results
3.1.1. LTD4-induced early genes resemble those activated by thrombin
Early gene signatures in response to LTD4 and thrombin were highly similar. Compared to the 
control, in both stimulated samples several genes were up-regulated (Fig. 6A and B, dots over 
the line depicting 2.5-fold changes). For thrombin, some genes were down-regulated at 1 h 
(Fig. 6B, dots beneath the line). If the LTD4- and thrombin-induced gene expression patterns 
are  plotted  against  each  other,  there  are  only  few genes  outside  of  the  lines  marking  the 
2.5-fold changes (Fig. 6C). Thus, under the given conditions the majority of genes regulated by 
the two agonists are identical, though the extent of induction is different.
For the analysis of thrombin-induced gene signatures the same criteria were used as for LTD4. 
Thrombin  treatment  for  1 h  resulted  in  49  up-regulated  and  7  down-regulated  probe  sets, 
corresponding to 34 up-regulated and 5 down-regulated genes. Genes up-regulated by LTD4 
were also up-regulated by thrombin and vice versa, even though the fold change in some cases 
did not reach our 2.5-fold threshold.  For the 37 LTD4-regulated genes displayed in Fig. 7, 
induction by LTD4 and thrombin highly correlated (Pearson correlation coefficient,  r = 0.90). 
When comparing the lists of genes regulated by LTD4 and thrombin using less stringent criteria 
(fold  change  >2.0;  without  statistical  test),  the  similarity  between  the  effects  of  the  two 
agonists becomes even more apparent (Tables 8 and 9 in the Appendix).
At 6 h and 24 h thrombin was a more potent agonist than LTD4, but these late effects were 
weak compared to the 1 h results. Genes stimulated by thrombin at later time points were also 
induced by LTD4, though at  a  lower  level  (Fig. 6D-I,  and Tables 10-13 in  the  Appendix). 
However, since there were only few genes up-regulated by LTD4 at 6 h and 24 h, these late 
gene signatures were not further analyzed.
3.1.2. LTD4 and thrombin added together augment gene expression
On HUVECs both LTD4 and thrombin activate  G protein-coupled receptors,  cysLT2-R and 
PAR-1, respectively [Lötzer 2003, Coughlin 2000]. Stimulation of HUVECs with LTD4 and 
thrombin  alone  resulted  in  a  highly  similar  gene  expression  pattern.  To  examine  whether 
concomitant  activation  of  cysLT2-R  and  PAR-1  leads  to  stronger  gene  activation,  gene 
signatures  of  LTD4 plus  thrombin-stimulated  cells  were  examined  by  microarray  analysis 
(Table 14 in the Appendix).
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Figure 7. LTD4-induced early genes in HUVECs. The heatmap shows normalized signal intensities of genes 
up-regulated >2.5-fold by 100 nM LTD4 at 1 h. Data of these genes after stimulation with 10 nM thrombin are 
shown for comparison. Column numbers correspond to umbilical cord preparations. Signal intensity values are 
presented in Table 7 in the Appendix.
Figure 8. Enhancement of gene expression by LTD4 + thrombin. The scatterplots show expression of the 68 
probe sets induced more strongly via LTD4 + thrombin together compared to LTD4 (A) or thrombin (B) alone. 
Dots  represent  means  of  signal  intensities  of  three  umbilical  cord  preparations;  lines  indicate  no  change in 
expression.
Results
Probe sets up-regulated by LTD4 or thrombin alone were evaluated regarding their induction by 
the two agonists together. Probe sets up-regulated by at least one agonist were defined based 
on the previously described lists of significantly up-regulated probe sets by LTD4 (48 probe 
sets) and by thrombin (49 probe sets). The combined list contained 68 probe sets encoding 50 
genes.  For  these  probe  sets,  induction  by  LTD4 plus  thrombin  was  significantly  higher 
compared to induction by each agonist alone (Wilcoxon signed rank test,  p < 0.001). Signal 
intensity  pairs  (both  agonists  together  against  a  single  agonist)  of  the  68  probe  sets  are 
displayed in Fig. 8 and Table 15 in the Appendix. Dots above the line represent probe sets with 
higher signal intensity value after  LTD4 plus thrombin treatment than in response to LTD4 
(Fig. 8A) or thrombin alone (Fig. 8B). These data show that LTD4 and thrombin added together 
had a stronger effect on gene expression than the agonists alone and that this combination did 
not induce additional genes.
3.1.3. Validation of the microarray results by qRT-PCR
In order to confirm the microarray data and to further characterize the effects of LTD4, the 
following genes were selected: NR4A1, NR4A2, NR4A3, EGR1, EGR2, EGR3, IL-8, CXCL2, 
DSCR1, ADAMTS1, E-Selectin, cyclooxygenase 2 (data not shown, K. Lötzer and A. J. R. 
Habenicht, manuscript in preparation) and TF. Induction of these genes was determined by 
qRT-PCR from RNA aliquots of the samples used for the microarray analyses. For qRT-PCR, 
external  standards were prepared.  Sequences of  the standard fragments  were confirmed by 
sequencing and blasting NCBI’s Nucleotide Database, and via melting curve analysis. GAPDH 
was chosen as a reference gene for normalization. Relative expression is given as transcript 
numbers / 1,000 GAPDH transcripts for each gene (Fig. 9). Both microarray and qRT-PCR 
showed  the  same  qualitative  result. The  LTD4-triggered  up-regulation  of  each  gene  was 
confirmed  in  four  independent  HUVEC  cultures  by  the  two  methods,  and  in  the  further 
experiments.  However,  the  extent  of  gene  induction  varied  between the  cord  preparations 
(Fig. 9), which may be due to the biological variance. Kinetics of mRNA up-regulation for 
NR4A1,  NR4A2,  NR4A3,  EGR1,  EGR2,  EGR3,  IL-8,  CXCL2,  DSCR1,  ADAMTS1, 
E-Selectin and TF was measured in two independent cord preparations (representative data are 
shown in Figures 12, 13, 14, 15, and 17).
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Figure 9. Validation of the microarray data via qRT-PCR. HUVECs were stimulated with 100 nM LTD4 or 
10 nM thrombin for 1 h. Aliquots of RNA samples prepared for microarray analyses were reverse transcribed into 
cDNA, and transcript levels of 12 genes were determined by qRT-PCR and normalized to GAPDH transcripts. 
Column patterns represent the four different umbilical cord preparations. C: control, L: LTD4, T: thrombin. LTD4-
stimulated samples show in each case more transcripts compared to the corresponding control samples.
Results
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Figure 10. Effects of cycloheximide on LTD4-induced genes. To identify immediate-early genes in response to 
LTD4, cells were stimulated with 100 nM LTD4 in the presence and absence of 10 µg/ml cycloheximide for 1 h 
and  mRNA levels  were  measured  by  qRT-PCR.  C:  control,  L:  LTD4,  CH:  cycloheximide,  L+CH:  LTD4 + 
cycloheximide. Results of a single experiments are shown.
Results
3.1.4. LTD4 stimulates immediate-early genes
Transcript kinetics after LTD4 stimulation was measured for each selected gene (see below). In 
all  cases,  transcript  level peaked at  approximately 60 min.  Since many of the up-regulated 
genes are immediate-early genes in other agonist-response systems [Bravo 1990, Liu 2003], we 
examined  whether  the  protein  synthesis  inhibitor  cycloheximide  blocks  their  induction  by 
LTD4.  All  12 genes were induced by LTD4,  also in  the presence  of  cycloheximide.  Thus, 
transcription  of  these  genes  did  not  require  newly  synthesized  proteins,  and  they  are 
immediate-early genes in response to LTD4 (Fig. 10).
3.1.5. LTD4-induced gene signatures are the result of cysLT2-R stimulation
In order to clarify receptor involvement in LTD4-triggered gene signatures, cysLT-R transcript 
levels  were  measured  in  several  umbilical  cord  preparations  by  qRT-PCR.  Considerable 
amount  of  cysLT2-R  mRNA  was  detected  in  these  cells,  whereas  cysLT1-R  was  barely 
expressed (Table 16). Expression of the recently described putative cysLT-R, GPR17, was not 
determined  by  qRT-PCR.  Both  probe  sets  referring  to  GPR17  had  Absent  calls  in  our 
microarray  experiments  (data  published  in  the  NCBI  GEO  database,  Acc. Nr.  GSE3589), 
which, in concert with the receptor characterics obtained from transfectants [Ciana 2006], do 
not support a role for GPR17 in HUVECs. To gain further evidence for the selective activation 
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Transcripts / 103 GAPDH
(Mean ± SEM) 
CysLT1-R 0.0075 ± 0.0035
CysLT2-R 9.03 ± 2.00
Table 16. CysLT-R transcripts in HUVECs. CysLT1-R and cysLT2-R transcripts were measured by qRT-PCR 
in HUVECs derived from four umbilical cord preparations used for the microarray experiments.
Figure 11. Effect of Montelukast on LTD4-induced gene expression. HUVECs were preincubated with 2 µM 
Montelukast for 1 h, and after stimulation with 100 nM LTD4 for 1 h, mRNA levels were measured by qRT-PCR. 
C: control, L: LTD4, M+L: Montelukast + LTD4. There was no difference between vehicle- and Montelukast-
treated samples. Data are representative of three independent experiments.
Results
of  the  cysLT2-R,  the  effects  of  a  cysLT1-R  inhibitor (which  also  inhibits  GPR17)  were 
examined on LTD4-mediated transcriptional events. Similar to the Ca2+ signals [Lötzer 2003], 
LTD4-initiated gene expression in HUVECs was not affected by Montelukast,  as shown by 
qRT-PCR data of selected LTD4-induced genes (Fig. 11). These data confirm that cysLTs act 
via the cysLT2-R in HUVECs.
3.2. Characterization of LTD4-induced early genes
3.2.1. LTD4 induces the EGR and NR4A transcription factors
Among the 37 LTD4-stimulated genes, 14 encode transcription factors (Fig. 7, Table 7 in the 
Appendix).  Two  transcription  factor  families,  EGR  and  NR4A,  were  chosen  for  detailed 
analyses because they were strongly up-regulated as judged by the fold changes, and they may 
contribute to vascular inflammation [Khachigian 2006, Martínez-Gonzalez 2005].
Three members of the EGR family, EGR1, EGR2 and EGR3, were induced by LTD4 as well as 
by thrombin (Fig. 7). The fourth member of this transcription factor family, EGR4, was also 
studied, however neither LTD4 nor thrombin had an effect on its expression (data not shown). 
EGR1  was  the  most  strongly  up-regulated  member,  and  it  was  also  highly  expressed  in 
unstimulated cells (Fig. 12A, left axis). EGR1 showed maximal expression around 30 min and 
reached baseline level around 2 h. EGR3 was weakly expressed and EGR2 transcripts were 
barely detectable in control samples (Fig. 12A, right axis). EGR2 and EGR3 were induced with 
similarly rapid kinetics as EGR1, but at a lower level. Transcript levels of EGR1 and EGR3 
differed by a factor of 10, and that of EGR1 and EGR2 by a factor of 100.
Since EGR1 was strongly induced at a high mRNA level by LTD4, expression of EGR1 was 
also followed at the protein level by Western blotting (Fig. 12B). EGR1 protein was strongly 
up-regulated compared to the unstimulated control at 1 h. At later time points it appeared as a 
protein doublet on the blot and reached baseline level after 4 h. Cellular localization of EGR1 
was studied by confocal laser scanning microscopy (Fig. 12C). In unstimulated cells, EGR1 
was weakly expressed and was distributed throughout the cytoplasm, whereas in LTD4-  or 
TNFα-treated  cells  EGR1  showed  stronger  expression  and  was  localized  in  the  nucleus. 
Comparable induction of EGR1 by LTD4 and TNFα was observed at 1 h both by Western 
blotting and microscopy.
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Figure 12. LTD4 induces the EGR transcription factor family. A)  HUVECs were stimulated with 100 nM 
LTD4 and transcript kinetics of EGR1, EGR2 and EGR3 was measured by qRT-PCR. EGR1 was expressed and 
induced at an approximately 10-fold higher level than EGR3 and 100-fold higher level than EGR2.  B) Protein 
kinetics of EGR1 in response to LTD4 was determined by Western blotting. 100 U/ml TNFα was used as positive 
control. Results are representative of three independent experiments.  C) Cellular localization of EGR1 protein 
was investigated by confocal laser scanning microscopy. After stimulation with 100 nM LTD4 or 100 U/ml TNFα 
for 1 h, EGR1 localized in the nucleus, whereas in unstimulated samples its distribution was restricted to the 
cytoplasm. EGR1 is shown in red; DNA was stained with DAPI (blue).
Figure 13. Induction of the NR4A transcription factors by LTD4. HUVECs were stimulated with 100 nM 
LTD4 and transcript kinetics of NR4A1, NR4A2 and NR4A3 was measured by qRT-PCR.
Results
Within  the  NR4A  transcription  factor  family  all  three  members  were  induced  by  LTD4 
(Fig. 13). NR4A1 was the most strongly stimulated member, though differences in the extent 
of up-regulation were not as pronounced as in the EGR family. In stimulated samples, NR4A1 
was expressed at ~5-fold higher level than NR4A2 and NR4A3. However, induction in the 
different umbilical cord preparations was variable. Though NR4A1 was strongly up-regulated 
by LTD4 and the mRNA level in stimulated cells hinted at considerable protein amount, it was 
not detectable by Western blotting in our hands (data not shown).
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Time 
point Gene symbol
Transcription 
factor family Motif and position
1 h ADAMTS1 NR4A, EGR AAA GGT CA found at –2721
GCG GGG GCG found at –1472
ARID5B NR4A AAA GGT CA found at –4433
DSCR1 NR4A AAA GGT CA found at –4004
EGR2 EGR GCG GGG GCG found at –984
F3 EGR GCG GGG GCG found at –83
GEM EGR GCG GGG GCG found at –70
KCNJ2 NR4A AAA GGT CA found at –4353
KLF2 EGR GCG GGG GCG found at –261
NDRG1 EGR GCG GGG GCG found at –50
NEDD9 EGR GCG GGG GCG found at –227
NR4A1 NR4A AAA GGT CA found at –2977
NR4A2 EGR GCG GGG GCG found at –1434
6 h ALDH1A2 NR4A AAA GGT CA found at –2032
DSCR1 NR4A AAA GGT CA found at –4004
ZNF451 NR4A AAA GGT CA found at –624
24 h ANK2 NR4A AAA GGT CA found at –2204
Table 17. EGR and NR4A binding sites in the promoter of LTD4-induced genes. Promoter regions (defined 
as –5000 - +100 bp) of genes up-regulated >2.5-fold by LTD4 at different time points were searched for binding 
motifs  of  the  EGR  and  NR4A  transcription  factor  families.  Position  of  GCG G/TGG GCG  (EGR)  and 
AAA GGT CA (NR4A) sites is indicated. Gene symbols are: ARID5B: AT rich interactive domain 5B; F3: tissue 
factor;  GEM: GTP binding protein  overexpressed  in  skeletal  muscle;  KCNJ2:  potassium inwardly-rectifying 
channel, subfamily J, member 2; NDRG1: N-myc downstream regulated gene 1; NEDD9: neural precursor cell 
expressed,  developmentally  downregulated 9;  ALDH1A2:  aldehyde  dehydrogenase 1  family,  member A2; 
ZNF451: zinc finger protein 451; ANK2: ankyrin 2, neuronal
Results
Both  transcription  factor  families  have  characteristic  consensus  DNA-binding  sites: 
GCG G/TGG GCG (EGR family) [Silverman 1999] and AAA GGT CA (NR4A family) [Maira 
1999]. In order to identify genes that might be regulated by these transcription factors in our 
system, genes up-regulated >2.5-fold by LTD4 at 1 h, 6 h and 24 h were screened for these 
consensus sites. The promoter region was arbitrarily defined as –5000 - +100 bases. Search 
results are presented in Table 17. EGR binding sites were found in the promoter region of 
NR4A2, EGR2, KLF2, TF, whereas NR4A responsive element were found to be present in the 
NR4A1 and DSCR1 promoters.  The  ADAMTS1 promoter  contains  binding  sites  for  both 
transcription factor families. It  was not further investigated whether these binding sites are 
active in ECs.
3.2.2. LTD4 up-regulates inflammatory genes in HUVECs
Among  the  LTD4-induced  genes  there  are  several  ones,  which  encode  proteins  that  play 
important roles in inflammation of the vessel wall by attracting leukocytes and promoting their 
attachment of or by contributing to rearrangement of the extracellular matrix. IL-8, CXCL2, 
E-Selectin and ADAMTS1 were chosen for detailed analysis.
LTD4 up-regulated  IL-8  and  CXCL2  (also  called  macrophage  inflammatory  protein 2α, 
Mip-2α), two chemokines of the same family. Both IL-8 and CXCL2 were also expressed in 
unstimulated  cells,  showed  rapid  induction  in  response  to  LTD4 and  returned  to  baseline 
expression at  4 h (Fig. 14).  IL-8 protein was measured in HUVEC culture supernatants  by 
ELISA. The fact that secreted IL-8 protein appeared to accumulate in the culture medium, 
whereas IL-8 transcripts in the cells did not, explains why the ratio of IL-8 protein amounts in 
stimulated versus unstimulated samples declined more slowly than the mRNA ratio (Fig. 14B). 
The maximal induction of IL-8 protein was detected 2 h after stimulation (Fig. 14C).
The  adhesion  molecule  E-Selectin  and  the  metalloprotease  ADAMTS1  showed  prolonged 
mRNA kinetics in response to  LTD4 when compared to other genes (Fig. 15). Both mRNAs 
reached  maximum  level  between  60-90 min  and  returned  to  baseline  level  ~8 h  after 
stimulation.
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Figure 14. Up-regulation of IL-8 and CXCL2 by LTD4. A) Induction of IL-8 and CXCL2 mRNA by 100 nM 
LTD4 as measured by qRT-PCR. Both chemokines showed similar kinetics, but expression of CXCL2 was higher. 
B) Kinetics of fold changes in IL-8 mRNA and protein. Cells were stimulated with LTD4 for the indicated time 
points,  IL-8 protein was determined from culture supernatant  by ELISA and cells  were  lysed for  qRT-PCR 
analyses.  C) IL-8 protein content of HUVECs supernatant measured 2 h after stimulation by LTD4.  Columns 
show  means  of  quadruplicate  samples  ± SEM  (p<0.005;  Student  t test).  Data  are  representative  of  three 
independent experiments.
Figure 15.  E-Selectin  and  ADAMTS1  kinetics  upon  LTD4-stimulation. HUVECs  were  stimulated  with 
100 nM LTD4 and transcript levels of E-Selectin (A) and ADAMTS1 (B) were determined by qRT-PCR.
Results
3.2.3. LTD4-mediated induction of DSCR1
DSCR1 encodes a protein   also called calcipressin   that is an endogenous inhibitor of 
calcineurin [Parry 2003, Harris 2005]. Calcineurin is a phosphatase and acts as an essential 
regulator  of  the  transcription  factor  NFAT  (nuclear  factor  of  activated  T  cells).  Upon 
dephosphorylation,  NFAT  translocates  to  the  nucleus  and  regulates  transcription  of 
inflammatory  genes  [Hogan  2003].  DSCR1  was  strongly  induced  by  LTD4 in  HUVECs 
(Figures 7 and 9), which raises the possibility that DSCR1 is part of an endogenous feedback 
mechanism of inflammation.
Due to alternative splicing, DSCR1 has several transcript variants (TVs) with tissue or cell 
type-specific distribution [Harris 2005]. The DSCR1 gene encodes nine exons according to the 
NCBI RefSeq Database, though publications generally mention only seven. Exon 4 has not yet 
been detected at the protein level and exon 6 has been cloned only recently (Fig. 16A). Each 
TV consists of four exons. The first exon in the TVs is variable, but the last three, exons 7–9, 
are constant. This common 3' sequence is translated into the C-terminal region of the protein, 
which is responsible for calcineurin binding. Thus, the TVs encode distinct protein isoforms 
differing from each other only in the N-terminal region (Fig. 16B).
When analyzed by qRT-PCR, DSCR1 reached maximal mRNA level ~60 min after  LTD4-
stimulation and declined to baseline level after 6 h (Fig. 17A). However, the probe sets on the 
U133A  array  and  the  primers  used  for  validation  do  not  differentiate  between  the  TVs. 
Therefore,  to  identify  which  TVs  are  expressed  in  LTD4-stimulated  HUVECs,  transcript 
variant specific primers were designed. This RT-PCR approach revealed expression of four of 
the five known TVs, including the TV 6-7-8-9, which has not yet been detected in HUVECs 
(Fig. 17B).
3.3.3.1. Involvement of NFAT in LTD4-induced gene expression
Cyclosporin A  (CsA)  is  a  widely  used  immunosuppressive  drug,  which,  via  binding  to 
calcineurin,  inhibits  dephosphorylation  of  NFAT  and  its  subsequent  translocation  to  the 
nucleus [Hogan 2003].
A putative alternative promoter sequence of DSCR1 located 5' from exon 5 contains several 
NFAT binding sites (Fig. 16A) [Harris 2005]. To investigate whether NFAT participates in 
LTD4-induced  DSCR1 up-regulation,  HUVECs  were  preincubated  with  200 ng/ml  CsA or 
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solvent  control  for  2 h  prior  to  stimulation  with  LTD4,  and  mRNA level  of  DSCR1 was 
determined  by  qRT-PCR  (Fig. 17C).  CysLT2-R-mediated  up-regulation  of  DSCR1  was 
completely abolished by CsA. This result confirms that DSCR1 induction by LTD4 depends 
solely  on  NFAT and  suggests  that  the  5-7-8-9  TV,  which  has  NFAT binding  sites  in  its 
alternative promoter, is the predominantly expressed and regulated DSCR1 isoform.
Upon  stimulation  with  vascular  endothelial  growth  factor  (VEGF),  NFAT  regulates 
transcription  of  proinflammatory  and  proangiogenic  genes  in  ECs  such  as  IL-8,  MCP-1, 
E-Selectin, ICAM-1 (intercellular adhesion molecule 1), NR4A1, NR4A2, NR4A3 and EGR3 
[Liu 2003, Minami 2004a]. LTD4 induced several of these genes, and inhibition of DSCR1 
induction by CsA provides indirect evidence for NFAT activation by LTD4. To study the role 
of  NFAT in LTD4-triggered gene expression,  the  mRNA level  of  several  LTD4-stimulated 
genes was measured in the presence and absence of CsA (Table 18). Induction of ADAMTS1, 
CXCL2, EGR3, IL-8, NR4A1, NR4A2 and NR4A3 was reduced, but not diminished in the 
presence of CsA (Table 18, data above the line). For transcriptional regulation of these genes, 
additional mechanisms and transcription factors are probably involved in cysLT2-R-mediated 
up-regulation. By contrast, LTD4-induced up-regulation of EGR1, E-Selectin and TF was even 
more pronounced in  the presence of  CsA (Table 18,  data  below the  line)  indicating  other 
regulatory  mechanism(s).  However,  these  results  need  to  be  confirmed  in  additional 
experiments.
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Gene Control CsA LTD4 LTD4+CsA
ADAMTS1 15.78 13.38 328.69 78.11
CXCL2 2.33 2.43 22.93 15.38
EGR3 0.14 0.15 71.75 17.42
IL-8 4.01 3.15 28.23 14.52
NR4A1 1.49 1.74 224.74 88.25
NR4A2 0.07 0.13 28.92 4.55
NR4A3 0.06 0.05 4.34 1.02
EGR1 37.20 37.14 165.66 662.83
E-Selectin 2.12 2.29 5.68 12.08
TF 4.20 3.51 44.85 90.26
Table 18. Effect of CsA on LTD4-induced gene induction. HUVECs were preincubated with 200 ng/ml CsA or 
solvent control for 2 h, subsequently stimulated with 100 nM LTD4 for 1 h, and mRNA levels were determined by 
qRT-PCR. Data of a representative experiment are shown as transcript numbers / 103 GAPDH.
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Figure 16. Gene structure and splice variants of DSCR1. A) Exon composition of the DSCR1 genes according 
to the NCBI databases. Numbers in brackets show exon numbering used in the literature. The arrow marks a 
region, which contains several binding sites for the transcription factor NFAT and might function as an alternative 
promoter. B) Known transcript variants of DSCR1 and the corresponding proteins.
Figure 17. DSCR1 expression in HUVECs. A) DSCR1 kinetics in response to 100 nM LTD4. B) RT-PCR data 
of DSCR1 transcript variants in LTD4-stimulated HUVECs. Transcript variant specific primers were used under 
conditions described in Methods, and cDNA was separated on 2 % agarose gel.  C) Effect of CsA on LTD4-
induced DSCR1 up-regulation. HUVECs were preincubated with 200 ng/ml CsA for 2 h, then stimulated with 
100 nM LTD4 for 1 h. DSCR1 mRNA was measured by qRT-PCR. Data are representative of three independent 
experiments. C: control, CsA: cyclosporin A, L: LTD4, L+CsA: LTD4 + cyclosporin A
Results
3.2.4. LTD4 triggers TF expression and cell-associated procoagulant activity
TF is the key initiator of the extrinsic pathway of the blood coagulation cascade [Mackman 
2004]. TF is absent on ECs under physiological conditions, but vascular injury or inflammation 
leads to its expression on the cell surface [Levi 2006].
LTD4 induced TF mRNA and protein up-regulation in HUVECs. TF mRNA peaked around 
60 min  and then  slowly  declined  to  basal  level  between 6-8 h  (Fig. 18A).  TF protein  had 
delayed  kinetics  compared  to  the  mRNA,  with  maximal  expression  at  6 h  (Fig. 18B).  To 
determine functional relevance of TF up-regulation by LTD4, procoagulant activity assay was 
performed  with  whole  cell  lysates.  HUVECs were  stimulated  with  100 nM LTD4 for  6 h, 
because maximal  protein expression was detected at  this  time point.  Cells  were lysed and 
procoagulant activity was determined by a commercially available kit, which uses recombinant 
FVIIa,  recombinant  FX and a  specific  substrate  for  FXa.  Cell-associated  TF procoagulant 
activity was increased approximately 4-fold in LTD4-stimulated samples (Fig. 18C).
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Figure 18.  Up-regulation  of  TF  and  procoagulant  activity  by  LTD4.  A) LTD4-induced  TF  mRNA  was 
measured by qRT-PCR. TF transcripts peaked at ~60 min and reached baseline level at 6 h. B) Immunoblot of TF 
protein  6 h  after  stimulation  with  100 nM  LTD4.  100 U/ml  TNFα was  used  as  positive  control.  Blot  is 
representative of two experiments. C) Procoagulant activity of HUVECs at 6 h after LTD4-stimulation, measured 
from whole cell lysates. Data are means ± SEM of eight samples derived from three umbilical cord preparations 
(p < 0.01; Student t test). C: control, L: LTD4, T: TNFα
Results
3.3. Late genes regulated by LTD4
LTD4 mediates rapid reactions in ECs such as PAF production, PGI2 release, vWF secretion 
and P-Selectin surface expression [McIntyre 1986, Cramer 1983, Datta 1995]. In line with 
literature data, the majority of LTD4-induced transcriptional changes in ECs were early effects, 
and gene signatures of later time points showed only a few regulated genes (Fig. 6). Analysis 
of  these  data  revealed  up-regulation  of  the  complement  protein  CD55  (also  called  decay 
accelerating factor for complement) and down-regulation of the cysLT2-R by LTD4 (Tables 10 
and 11 in the Appendix). These two effects were further investigated.
3.3.1. Induction of the complement regulator CD55 by LTD4
The membrane-bound complement regulators CD55, CD46 (membrane cofactor protein) and 
CD59 (protectin) are responsible for attenuating complement activation on self surfaces and 
thus  inhibiting complement-mediated lysis  of  host  cells  [Brooimans 1992,  Janeway 2001]. 
Vasoactive agonists such as thrombin, histamine and VEGF are known to induce CD55 on 
endothelial cells [Lidington 2000, Tsuji 1994, Mason 2004].
Microarray data of LTD4-stimulated HUVECs showed a moderate induction of CD55, but no 
difference  in  CD46 and CD59 expression compared to  the  control  (Table 19).  To confirm 
CD55  up-regulation  by  LTD4 and  to  examine  its  kinetics,  CD55  transcript  levels  were 
measured by qRT-PCR in LTD4-stimulated HUVECs. CD55 mRNA peaked at approximately 
6 h and stayed elevated during 48 h (Fig. 19A). Expression of CD55 on the cell surface was 
measured by flow cytometry using a specific antibody. CD55 protein increase appeared 12 h 
after stimulation and was diminished at 24 h. At 12 h CD55 induction by LTD4 and thrombin 
were comparable (Fig. 19B), but the effect of thrombin was still detectable at 24 h (data not 
shown).
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Affymetrix 
probe set ID
1 h 6 h 24 h
Control LTD4 Control LTD4 Control LTD4
CD55 201925_s_at 1219 2126 1006 2167 1120 1503
201926_s_at 1307 2393 1342 2645 1329 1822
CD46 207549_x_at 3014 2773 2863 2804 2949 2829
208783_s_at 2340 2409 2308 2350 2398 2182
CD59 200983_x_at 8944 9014 10009 10499 10103 10940
200984_s_at 6718 6669 6728 6767 6942 7958
200985_s_at 6578 6733 6656 7028 6985 7162
212463_at 2877 2852 3103 3125 2954 3186
Table 19. Signal intensities of the complement regulators CD55, CD46, CD59. All three genes are represented 
with more than one probe set on the U133A genechip. Every probe set had Present call and detection  p value 
<0.065 (not shown). Data are from a single experiment.
Figure 19. LTD4-induced up-regulation of the complement inhibitor CD55. A) HUVECs were stimulated 
with 100 nM LTD4 for the indicated time points and mRNA kinetics of CD55 was measured by qRT-PCR. Data 
of a single experiment are shown.  B) CD55 protein expression on the cell  surface was investigated by flow 
cytometry at 12 h after stimulation. LTD4-mediated CD55 induction was compared to that triggered by 10 nM 
thrombin. Data are representative of two independent experiments.
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3.3.2. Down-regulation of the cysLT2-R mRNA by LTD4
One of the few genes down-regulated by LTD4 is its own receptor. Microarray data at 6 h and 
24 h showed reduced expression of the cysLT2-R in the LTD4-stimulated samples (Tables 10 
and 11 in the Appendix). mRNA kinetics determined by qRT-PCR revealed rapid cysLT2-R 
down-regulation with a minimum at 4-6 h after stimulation, which was followed by a long 
recovery phase. During the monitored interval (48 h), cysLT2-R mRNA did not reach the level 
measured in unstimulated samples (Fig. 20).
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Figure 20.  LTD4-mediated  down-regulation  of  cysLT2-R  mRNA. HUVECs  were  stimulated  with  100 nM 
LTD4 for the indicated time points, and cysLT2-R mRNA levels were determined by qRT-PCR. Results of a 
single experiment are shown.
Discussion
Data obtained in this work can be summarized as follows: stimulation of ECs with LTD4 led to 
a proinflammatory and prothrombotic endothelial phenotype highly resembling that induced by 
thrombin. The actions of LTD4 on HUVECs’ phenotype include up-regulation of transcription 
factors involved in vascular biology, chemokine formation and secretion, induction of adhesion 
molecules and enhancement of TF activity. Up-regulation of potentially important genes that 
may  protect  the  vascular  wall,  i.e.  DSCR1  and  CD55,  was  also  observed.  Concomitant 
activation of cysLT2-R by LTD4 and PAR-1 by thrombin resulted in enhanced gene expression 
compared to LTD4 and thrombin alone. 
4.1. Potential role of LTD4-induced transcription factors in cardio-
vascular pathobiology
Activation of the cysLT2-R in HUVECs led to up-regulation of several transcription factors. 
Among  others,  members  of  the  EGR,  NR4A  and  KLF  transcription  factor  families  were 
induced by LTD4 at 1 h as shown by microarray analyses (Fig. 7).
LTD4 up-regulated three members of the EGR family with similar mRNA kinetics (Fig. 12A). 
Their  expression  levels,  however,  were  markedly  different,  which  may  reflect  functional 
differences  of  the  proteins.  EGR1 was  the  most  strongly  expressed  and induced  member, 
indicating a more important role for EGR1 than for the other two EGRs. EGR2 level was 
~100-fold  lower  than  that  of  EGR1,  even  when  up-regulated  by  LTD4.  This  may  be 
characteristic for EGR2 in vascular cells, since a similarly low level of EGR2 expression in 
ECs was observed upon treatment with VEGF and thrombin [Liu 2003, Minami 2004a]. EGR3 
up-regulation by LTD4 was higher than that of EGR2, but ~10-fold lower than EGR1. This is 
comparable to VEGF- and thrombin-induced EGR3 expression in ECs  [Liu 2003,  Minami 
2004a,  2004b]. Even though our  data  suggest  involvement  of  EGR2 and EGR3 in LTD4-
induced  endothelial  inflammatory  responses,  and  their  presence  has  also  been  reported  in 
VEGF- and thrombin-stimulated vessel  wall  cells  [Liu 2003,  Minami 2004a,  2004b],  their 
unique role(s) in ECs and vascular biology remains to be determined. The EGRs bind the same 
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GC-rich element  [Silverman 1999],  therefore it  is  difficult  to  distinguish,  which genes are 
regulated by which EGR member. As EGR2 levels were marginal, the importance of EGR2 in 
cysLT2-R-triggered endothelial activation is questionable. The relatively strong induction of 
EGR3  in  parallel  with  EGR1  may  implicate  their  redundant  function  in  LTD4-mediated 
transcriptional changes, which is supported by the similar induction patterns by other agonists 
[Liu 2003, Minami 2004b]. Furthermore, the EGR1-/- EGR3-/- double knockout mice die before 
birth, but both single knockouts, EGR1-/- and EGR3-/-, produce live adults [Adamson 2001], 
pointing to a redundant role of EGR1 and EGR3 in vivo.
In contrast to EGR2 and EGR3, EGR1 appears important in vascular biology. LTD4-triggered 
EGR1  induction  was  also  confirmed  at  the  protein  level  (Fig. 12B,  C).  At  its  highest 
expression,  1 h  after  stimulation,  EGR1  localized  in  the  nucleus  as  demonstrated  by 
immunofluorescence.  Though  the  transcriptional  activity  of  EGR1  was  not  investigated, 
translocation of EGR1 into the nucleus and up-regulation of genes with EGR-binding sites in 
their promoter (Table 17) point to a relevant role for EGR1 in LTD4-stimulated endothelial 
gene expression.
The importance of EGR1 in the vascular system is underlined by a number of reports that show 
EGR1 expression in vessel wall  cells and identify EGR1 target genes involved in vascular 
biological processes. These genes include PDGF-A, PDGF-B, TF, M-CSF, TGFβ, TNFα, IL-2, 
p53, uPA (urokinase-type plasminogen activator), ICAM-1, PPARγ (peroxisome proliferative 
activated  receptor γ),  VEGF  and  fibronectin  [reviewed  in  Khachigian  1998  and  2006, 
Silverman 1999]. In our system several LTD4-induced genes contain EGR binding sites in their 
promoter  (Table 17).  In  addition  to  TF,  a  known  EGR1  target  gene  [Bavendiek  2002, 
Armesilla  1999,  Mechtcheriakova  1999],  we  found  two  other  genes,  for  which  EGR1-
dependent  induction  was  reported  in  EGR1-transfected  HUVECs  [Fu  2003].  GEM  (GTP 
binding protein overexpressed in skeletal muscle) and ATF3 (activation transcription factor 3) 
were strongly up-regulated in  our  system both by LTD4 and thrombin (Fig. 7).  GEM is  a 
member of the small G protein family, which can interact with high-voltage-activated (L-type) 
Ca2+ channels  [Béguin  2001].  By  inhibiting  the  L-type  Ca2+ channel  activity,  GEM  may 
regulate  extracellular  Ca2+-triggered  processes  or  signals  such  as  the  oscillation  in  [Ca2+]ic 
following endothelial cysLT2-R activation [Lötzer 2003]. ATF3, a transcriptional repressor, is 
implicated in ECs as a survival factor [Kawauchi 2002]. Thus, ATF3 may contribute to the 
enhanced [3H]-thymidin  incorporation  observed  in  LTD4-stimulated  HUVECs (unpublished 
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data C. Kramer, K. Lötzer, A. J. R. Habenicht). Since the promoter region of ATF3 does not 
contain the consensus EGR binding site, ATF3 might be regulated by EGR1 indirectly, or, 
alternatively, ATF3 is up-regulated by LTD4 independent of EGR1.
EGR1 is implicated in hypoxic and ischemic injuries in the vasculature of vital organs such as 
brain, lung, heart and kidney [reviewed in Khachigian 2006]. EGR1 is expressed at a low level 
in the arterial wall under physiological conditions but it  is rapidly induced by a variety of 
stimuli and under pathological conditions [reviewed in Khachigian 1998 and 2006, Silverman 
1999]. CysLT2-R stimulation by LTD4 led to EGR1 induction in ECs (Fig. 12), and previous 
results of other members in our group showed that LTD4 also up-regulates EGR1 in monocytes 
via  the  cysLT1-R  (data  published  in  Zhao  et  al.  [2004]  and  in  the  NCBI  GEO database, 
Acc. Nr.:  GSE1644).  Since  transcripts  of  both  cysLT-Rs  are  expressed  in  atherosclerotic 
lesions  [Spanbroek 2003,  Qiu  2006a],  our  data  suggest  that  cysLTs  can  contribute  to  the 
activated phenotype of plaque forming cells by EGR1 induction. Expression of EGR1 in the 
vessel wall results in the transcription of proinflammatory and procoagulant genes [McCaffrey 
2000,  Harja  2004],  thus,  cysLTs – in  concert  with other  EGR1-inducing agonists  –  might 
influence  disease  progression.  However,  data  on  cysLT  formation  and  cell-type  specific 
cysLT-R expression in vivo are needed to confirm this hypothesis.
All three members of the NR4A transcription factor family were induced by LTD4 in HUVECs 
in our experiments (Fig. 13). The orphan nuclear receptors NR4A1 (Nur77 or nerve growth 
factor-induced B, NGFI-B), NR4A2 (Nurr-1) and NR4A3 (NOR-1) form a subfamily of the 
steroid / thyroid receptor superfamily [reviewed in Martínez-Gonzalez 2005]. Expression of 
the three NR4As has been shown in ECs of atherosclerotic lesions, but not of normal artery, by 
in situ hybridization [Arkenbout 2003]. Thus, our in vitro data on the induction of the NR4A 
members by LTD4 in ECs may connect LTs with pathological states of the vessel wall and 
suggest  a  role  for  them in  atherogenesis.  However,  further  investigations  are  required  to 
determine the  in vivo relevance of this finding, since LTD4 is not unique in activation of all 
three NR4As in ECs; e.g. the potent endothelial mitogen, VEGF, produces a highly similar 
pattern [Liu 2003].
It is difficult to dissect the actions of individual NR4A proteins, because they bind the same 
consensus DNA motif and, in addition, may form heterodimers with each other [Martínez-
Gonzalez 2005]. The only known NR4A target in ECs is the plasminogen activator inhibitor 1 
(PAI-1,  SERPINE1).  Induction  of  PAI-1  via  NR4A1  in  TNFα-stimulated  HUVECs,  and 
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colocalization of NR4A1 and PAI-1 proteins in ECs and VSMCs in atherosclerotic coronary 
artery have recently been demonstrated [Gruber 2003]. Even though both LTD4 and VEGF up-
regulate NR4A1 (and the other two NR4As) in HUVECs, PAI-1 was not induced by LTD4 
(data  published  in  NCBI  GEO  Acc.  Nr.:  GSE3589)  nor  by  VEGF  [Minami  2004a].  By 
contrast, thrombin in our experiments up-regulated both NR4A1 and PAI-1 (Tables 9, 12 and 
13 in the Appendix). Since we could not show NR4A1 expression at the protein level, we are 
presently unable to comment further whether the effects of LTD4 have functional implications 
for vascular biology. Other NR4A targets in ECs might be some of the LTD4-induced genes 
containing the consensus NR4A responsive element in their promoter, such as ADAMTS1, 
NR4A1 and zinc finger protein 451 (Table 17), several of which are also stimulated by VEGF 
[Liu 2003, Minami 2004a].
Several members of a third family of transcription factors, namely the KLFs were up-regulated 
by LTD4 or thrombin. Of the 16 known KLF family members, KLF2, KLF4, KLF5 and KLF6 
are implicated in vascular development and pathobiology [reviewed in Suzuki 2005]. Both 
LTD4 and  thrombin  up-regulated  KLF2,  KLF4  and  KLF6  (Fig. 7  and  Tables 8,  9  in  the 
Appendix) in HUVECs. KLF2 is  restricted to  ECs in the vessel  wall  and thought to  be a 
protective factor in vascular diseases, whereas KLF4 and KLF6 are more widely expressed in 
the vasculature, but their role in ECs is not characterized [Suzuki 2005].
KLF2 is uniquely and strongly expressed in ECs during embryonic development and in adults 
under  physiological  conditions  [Suzuki  2005],  and can  be  induced by  constitutive laminar 
shear stress [Dekker 2002].  In vitro data on overexpressed KLF2 support the hypothesis that 
KLF2  counteracts  inflammatory  and  thrombotic  processes  in  ECs  [SenBanerjee  2004, 
Bhattacharya 2005, Lin 2006]. Thus, LTD4-induced KLF2 may play a role in controlling the 
proinflammatory endothelial phenotype resulting from cysLT2-R activation. KLFs, similar to 
the EGR transcription factors, bind GC-rich DNA motifs, however, the sequence specificities 
for the KLFs have not yet been identified [Suzuki 2005]. It is possible that KLF2 can compete 
with the EGRs in DNA binding and thus reduce their activity. According to our microarray 
data, LTD4 induced KLF2 more strongly than thrombin (Table 7 in the Appendix). This may be 
responsible for the moderate effect of LTD4  in comparison to thrombin  on genes such as 
E-selectin, vascular cell adhesion molecule 1 (VCAM-1), TF and IL-8 (Fig. 9 and Tables 8, 9, 
11 and 12 in the Appendix), all of which showed reduced or inhibited expression in KLF2-
transfected  HUVECs  [SenBanerjee  2004,  Bhattacharya  2005,  Lin  2006].  Therefore,  KLF2 
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might  be  part  of  the  feedback mechanisms causing  the short  term endothelial  response  to 
cysLT2-R  activation  compared  to  the  longer  reaction  induced  by  PAR-1  stimulation  by 
thrombin (Fig. 6).
4.2. LTD4-induced genes in leukocyte recruitment and extracellular 
matrix rearrangement
Besides  up-regulation  of  transcription  factors,  LTD4 stimulation  rendered  the  endothelial 
phenotype adhesive for platelets and leukocytes. The previously described early transcription-
independent effects of LTD4, such as P-selectin expression, vWF secretion [Datta 1995] and 
PAF synthesis [McIntyre 1986], are mainly responsible for platelet adhesion and activation and 
are involved in the initiation of neutrophil attachment. In our experiments, LTD4 stimulation 
resulted in induction and secretion of the chemokines IL-8 and CXCL2 (Fig. 14), up-regulation 
of E-selectin (Fig. 15A) and a moderate VCAM-1 induction (Table 8 in the Appendix). These 
LTD4-induced  transcriptional  changes  may  implicate  LTs  in  the  activation  cascade  of  the 
attached platelets  and leukocytes,  initiation  of  their  transmigration  as  well  as  attraction of 
further inflammatory cells to vascular disturbances.
Selectins  mediate  the  first  step  in  leukocyte  extravasation  and  platelet  adhesion.  In  ECs 
P-selectin  is  rapidly expressed by releasing the preformed protein from the Weibel-Palade 
bodies in response to inflammatory stimuli. By contrast, E-selectin is present only on activated 
ECs  and  its  expression  requires  mRNA  and  protein  synthesis,  and  thus  appears  delayed 
compared to P-selectin [Janeway 2001]. E-selectin is up-regulated in ECs by several stimuli, 
e.g.  proinflammatory  cytokines,  LPS,  lymphotoxin  [Bevilacqua  1987],  and  thrombin 
[Kaplanski 1997]. Since both E- and P-selectins are important in activated T cell homing into 
inflamed tissues [reviewed in Ley 2004], LTD4 may be involved in enhancement of vascular 
inflammation via induction of selectins on ECs. Deletion of P- and E-selectin in atherosclerotic 
mouse  models  results  in  decreased  number  of  infiltrating  monocytes  and  reduced  lesion 
development [Collins 2000, Dong 1998]. The increased amount of cell adhesion molecules 
such as ICAM-1, VCAM-1, P-selectin and E-selectin is characteristic for vascular diseases 
associated with inflammation [Gimbrone 1997,  Libby 2002].  Thus,  induction of  P-selectin 
expression and up-regulation of E-selectin and VCAM-1 by LTD4 support a proinflammatory 
and proatherogen role for LTs in vascular diseases.
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Adhesion molecules, although very important for accumulation of leukocytes, are not sufficient 
to trigger their firm adhesion. To promote leukocyte attachment under flow conditions, chemo-
kines produced by activated ECs are also necessary [Gerszten 1999]. IL-8 is secreted by ECs 
in response to numerous stimuli,  e.g. LPS, TNFα, IL-1β, VEGF or thrombin [Luster 1998, 
Minami 2004a, 2004b]. It was first characterized as a potent neutrophil attracting factor [Luster 
1998],  but  recent  data  show that  IL-8 plays  a  relevant  role  in  monocyte adhesion as  well 
[Gerszten 1999]. Besides recruiting leukocytes, IL-8 is involved in their transmigration through 
the  endothelial  monolayer  [Lee  2002].  The  related  chemokine,  CXCL2 (growth-related 
oncogene β, GROβ or macrophage inflammatory protein 2, MIP2), is a chemotactic factor for 
PMNs,  including  basophils  [Geiser  1993].  Since  stimulation  of  the  endothelial  cysLT2-R 
resulted in up-regulation of IL-8 and CXCL2, our data suggest that LTs can mediate leukocyte 
attachment  on  the  endothelium and  extravasation  into  the  inflamed  vessel  wall.  IL-8  and 
CXCL2 can also activate the attached PMNs [Geiser 1993], which may result in further LT 
production. It has been recently demonstrated that IL-8 exerts angiogenic effects on ECs in an 
autocrine  manner  via  binding  to  its  receptors  CXCR1 and  CXCR2 [Li  2003].  These  two 
chemokine receptors were expressed but not regulated in our experiments (data published in 
the  NCBI  GEO database  Acc. Nr.:  GSE3589),  suggesting  an  indirect  protective  effect  for 
endothelial cysLT2-R activation.
Activation of the endothelium and pathological states of the vessel wall are associated with 
extracellular  matrix  (ECM)  reorganization  as  cells  proliferate,  migrate  and  differentiate. 
Several types of proteases are involved in these changes of the extracellular content, among 
them members  of  a  newly  described  metalloprotease  family,  the  ADAMTS.  Its  founding 
member,  ADAMTS1,  was  strongly  induced  by  LTD4 in  our  in  vitro system  (Fig. 15B). 
ADAMTS1 is  present  in  normal  human  tissues  and  throughout  the  cardiovascular  system 
[Porter 2005, Jönsson-Rylander 2005]. However, it is considered an inflammation-associated 
gene  [Kuno  1997].  Cultured  ECs  up-regulate  ADAMTS1 in  response  to  proinflammatory 
stimuli  [Norata  2004,  Minami  2004a].  LTD4 induced  ADAMTS1  not  only  in  ECs  but, 
according to data from other members of our group, also in the monocytic cell line MonoMac-
6 via the cysLT1-R (data published in the NCBI GEO database Acc. Nr.: GSE1644).
Recently,  tissue  factor  pathway  inhibitor 2  (TFPI-2)  has  been  identified  as  a  substrate  of 
ADAMTS1 [Torres-Collado 2006].  TFPI-2 is  implicated in  the physiological  regulation of 
ECM degradation and reorganization as an inhibitor of plasmin, trypsin, kallikrein, FXa and 
the TF-FVIIa complex [Chand 2005]. Versican, another substrate of ADAMTS1 [Sandy 2001], 
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is abundantly present in normal vessel wall, whereas human aortic aneurysm is associated with 
decreased versican levels  [reviewed in Wight 2004].  Thus,  LTD4-induced ADAMTS1 may 
lead to imbalanced ECM remodeling, which accompanies vascular disorders. LTs have already 
been  implicated  in  the  pathogenesis  of  aortic  aneurysm  [Zhao  2004].  Apolipoprotein  E 
(ApoE)-/- 5-LO-/- mice show reduced aortic aneurysm formation and matrix metalloprotease 
activity  compared  to  ApoE-/-,  suggesting an  indirect  effect  of  the  5-LO pathway on  ECM 
degrading enzymes. Up-regulation of ADAMTS1 by LTD4 indicate novel mechanisms of LT 
actions in vascular diseases.
Another aspect  of ADAMTS1 function is that it  can exert  anti-angiogenic effects on ECs. 
When bound to the EC surface via CD36, ADAMTS1 prevents VEGF-VEGFR interaction 
[Luque 2003]. This raises the possibility that LTs could have protective rather than injurious 
effects. Thus, via induction of ADAMTS1 secretion, LTs might negatively regulate intimal 
neovascularisation — a process necessary for plaque growth or neointima formation in states 
of vascular diseases.
4.3. Procoagulant EC phenotype evoked by LTD4
Stimulation of HUVECs with LTD4 resulted in the up-regulation of  TF mRNA, protein and 
cell-associated  procoagulant  activity  (Fig. 18).  ECs do  not  express  TF under  physiological 
conditions [Wilcox 1989], but TF can be induced by tissue injury or by various agonists such 
as TNFα, IL-1β, CD40 ligand, serotonin, histamine, thrombin, oxidized low density lipoprotein 
(LDL), VEGF [Camera 1999, Bavendiek 2002, reviewed in Steffel 2006]. Signaling pathways 
of  the diverse agonists  that  induce TF in HUVECs converge on four transcription factors, 
namely EGR1, NFAT, nuclear factor κ B (NFκB) and activator protein 1 (AP-1) [Moll 1995, 
Bavendiek 2002, Armesilla 1999, Mechtcheriakova 1999].
Induction and nuclear translocation of EGR1 by LTD4 was proved (Fig. 12). Although direct 
binding of LTD4-induced EGR1 to the TF promoter was not investigated, EGR1 may mediate 
LTD4-induced TF transcription.  This  is  supported  by the facts  that  i) EGR1 up-regulation 
precedes the TF mRNA peak (Figures 12A and 18A),  and  ii) EGR1 protein is present  in 
unstimulated HUVECs (Fig. 12B), which can explain that TF is an immediate-early gene in 
response to LTD4 in our system (Fig. 10).
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The role of NFAT in LTD4-induced TF up-regulation does not seem relevant, since inhibition 
of NFAT with CsA induced TF mRNA even more strongly than LTD4 alone (Table 18). That 
this is not uncommon for inflammatory stimuli, is supported by the results of Hölschermann et 
al. (2001), who showed similar effect for LPS, TNFα and ionomycin in CsA-treated HUVECs. 
Cooperation  between  transcription  factors  on  TF  induction  in  HUVECs  has  also  been 
described.  TF  stimulation  by  VEGF  [Armesilla  1999,  Mechtcheriakova  1999]  or  by  an 
oxidized phospholipid component of oxidized LDL [Bochkov 2002] requires both NFAT and 
EGR1, but in contrast to our data with LTD4, blocking of NFAT by CsA results in reduced TF 
expression and activity. This further strengthens the hypothesis that up-regulation of TF by 
LTD4 is independent of NFAT.
Although thrombin-induced transcriptional changes involve NFκB [Minami 2004b] and our 
data  revealed high similarities  between the LTD4-  and thrombin-activated  gene  signatures, 
translocation  of  NFκB  could  not  be  shown  in  ECs  in  response  to  LTD4 by  immuno-
histochemistry (unpublished data, S. Jahn, K. Lötzer & A. J. R. Habenicht).
Thus, our data suggest that LTD4-triggered TF induction is mediated by EGR1 and does not 
require NFκB or NFAT. The fact that the mechanisms of TF up-regulation in response to LTD4 
differ from those induced by thrombin and VEGF supports a distinct role for cysLTs and the 
cysLT2-R in EC biology.
Up-regulation of TF mRNA by LTD4 was followed by TF protein expression with a maximum 
at 6 h after stimulation (Fig. 18B). For LTD4-induced TF protein detection whole cell lysates 
were used, but in addition to the cellular TF protein, TF can be released from ECs either in the 
form of microparticles [Mallat 2000] or as alternatively spliced soluble TF [Szotowski 2005]. 
Since the primer pair used in this work (Table 4) does not differentiate between the membrane 
bound and soluble isoforms and the amount of released TF protein was not determined, our 
data do not necessarily correlate with the total amount of the LTD4-induced TF protein, and the 
effects of LTD4 are not directly comparable with those of TNFα.
ECs,  though synthesize  TF protein  in  response  to  a  number  of  stimuli,  do  not  express  it 
immediately on the cell surface [Camera 1999, Hölschermann 2001]. TF protein is distributed 
in  three  cellular  pools:  surface  (active)  TF,  cytoplasmic  TF,  and  latent  or  encrypted  TF 
[Schecter 1997, Steffel 2006]. In addition, surface or surface-associated proteins can prevent 
TF binding to FVII/VIIa [Bhattacharjee 2005]. Therefore, our aim was to investigate whether 
LTD4-mediated TF up-regulation may trigger procoagulant activity. Using a specific system 
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that mimicks the extrinsic coagulation pathway (Fig. 2), we could show that the LTD4-induced 
increase in TF protein was accompanied by TF-dependent procoagulant activity of the cells. 
Though  these  results  point  to  the  cysLT2-R-mediated  induction  of  active  TF,  further 
investigations are needed to determine the cellular distribution of TF and the mechanism(s) 
required for its surface appearance.
Independent of its cellular distribution, up-regulated TF is a marker for disturbed hemostatic 
balance of ECs and has been implicated in the pathogenesis of multiple vascular disorders such 
as ischemia / reperfusion injury [Erlich 2000, Mackman 2003], thrombosis [Mackman 2004], 
atherosclerosis [Steffel 2006] or disseminated intravascular coagulation [Levi 2006]. Our data 
suggest that cysLTs increase the active TF pool in ECs, and thus, LTs may contribute in vivo to 
the  prothrombotic  state  of  the  endothelium during  vascular  diseases  in  concert  with  other 
agonists from the inflammatory microenvironment.
4.4. LTD4-induced CD55 may protect ECs against enhanced 
complement activation
The complement system is an effector component of the innate immune response, and consists 
of inactive soluble proteins as well as soluble and membrane-bound regulators. The mechanism 
of complement activation is similar to that of the coagulation cascade [Janeway 2001], and 
cross-talk between the two systems has been demonstrated [Huber-Lang 2006]. Complement 
activation is enhanced during inflammation. To prevent tissue damage caused by complement-
mediated lysis,  host  cells,  especially those in contact with blood, express several  regulator 
molecules [Janeway 2001]. ECs constitutively express the complement regulators CD46, CD55 
and CD59 [Brooimans 1992].
Among the few genes regulated by LTD4 at  later  time points  is  the complement  regulator 
CD55 with a maximal fold change of ~3 (Fig. 19A and Table 19). LTD4-triggered CD55 up-
regulation was moderate  at  the protein level  (Fig. 19B),  though similar  to  numerous  other 
agonists  that  stimulate  CD55 in  ECs,  such  as  TNFα,  IFNγ [Mason 1999],  VEGF [Mason 
2004], histamine [Tsuji 1994], or thrombin [Lidington 2000]. CD55 inhibits the complement 
cascade at the level of the central component, C3, by inactivating the C3 and C5 convertases 
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[Fujita  1987].  Since  the  efficiency  of  the  complement  system  is  built  on  the  amplifying 
activation  mechanism,  a  small  change  in  regulator  protein  amount  is  sufficient  to  reduce 
complement  activity.  LTD4-induced CD55 therefore  provides  enhanced protection  for  ECs 
against  autologous  complement  attack.  Furthermore,  attenuating  the  complement  cascade 
reduces  liberation  of  the  vasoactive  anaphylatoxins,  C3a  and  C5a  [Janeway  2001, 
Schraufstatter 2002].
In addition to its increased surface expression in response to a number of agonists, CD55 can 
be released into the environment and accumulate in the ECM [Tsuji 1994, Hindmarsh 1998]. 
Shedding and deposition in the ECM is induced only by stimuli that activate PKC, i.e. phorbol 
myristate acetate, wheat germ agglutinin or histamine, but not by other potent EC agonists such 
as TNFα, IL-1β and IL-4 [Tsuji 1994, Hindmarsh 1998]. Although LTD4-dependent CD55 
release was not investigated here, the fact that cysLT2-R stimulation increases [Ca2+]ic leading 
to PKC activation (unpublished data C. Kramer, K. Lötzer & A. J. R. Habenicht), suggests that 
LTD4 may also  enhance  CD55 shedding  and secretion.  Moreover,  CD55 showed  elevated 
mRNA levels for 48 h (Fig. 19A), whereas CD55 protein expression returned to baseline levels 
by  24 h.  This  hints  to  CD55  release,  which  could  explain  the  discrepancies  between  the 
induction of CD55 mRNA and surface protein in response to LTD4.
4.5. Negative feedback mechanisms of cysLT2-R activation may 
involve DSCR1
One  of  the  most  strongly  up-regulated  genes  in  LTD4-stimulated  HUVECs  was  DSCR1 
(Figures 9 and 17).  The DSCR1 protein (also called calcipressin 1,  modulatory calcineurin-
interacting protein 1, regulator of calcineurin, or Adapt78) is involved in protection against 
oxidative  and  calcium-mediated  stress  [Ermak  2002]. Stimuli  causing  increased  [Ca2+]ic 
activate  the  calcineurin–NFAT  system,  and  among  other  inflammatory  genes,  up-regulate 
DSCR1 [Liu 2003, Minami 2004a, Yao 2004]. DSCR1, in turn, blocks calcineurin and the 
NFAT-dependent pathway, forming a negative feedback loop [Hesser 2004, Iizuka 2004].
DSCR1 has several TVs due to alternative splicing and a putative alternative promoter [Harris 
2005]. Four of the five known TVs were detected in LTD4-stimulated HUVECs (Fig. 17B). 
This confirms data  of others on endothelial  expression of the TVs with exon composition 
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1-7-8-9, 2-7-8-9 and 5-7-8-9. Furthermore, it shows for the first time the presence of the TV 
6-7-8-9 in ECs. Since the protein isoforms corresponding to the various TVs have the same 
C-terminal part  responsible for calcineurin binding,  they may have the same function.  The 
variable N-terminal domain may be involved in regulation or interaction with other proteins 
but its importance in ECs has not yet been clarified. The most strongly up-regulated TV by 
LTD4, containing the exons 5-7-8-9, is the one also induced by thrombin and VEGF in ECs 
[Minami  2004a].  Thus,  this  DSCR1  isoform  may  have  a  similar  function  in  controlling 
signaling pathways of cysLT2-R, PAR-1 and the VEGF receptor KDR (kinase insert domain 
receptor).
To study the possible role of the endogenous calcineurin inhibitor DSCR1 in LTD4-dependent 
EC activation, we used the exogenous calcineurin inhibitor CsA. Preincubation of HUVECs 
with  CsA and  subsequent  LTD4-stimulation  resulted  in  lower  expression  of  inflammatory 
genes, such as IL-8, CXCL2, ADAMTS1, NR4A1, NR4A2, NR4A3 and EGR3 (Table 18). 
This  indicates  involvement  of  the  Ca2+–calcineurin–NFAT  pathway  in  cysLT2-R-mediated 
transcriptional changes. Thus, NFAT-mediated transcription of these genes in LTD4-stimulated 
HUVECs may be repressed via the concomitantly synthesized DSCR1. This hypothesis is in 
line with literature data. Blocking the calcineurin–NFAT pathway in ECs by CsA addition [Liu 
2003]  or  DSCR1  overexpression  [Minami  2004a]  resulted  in  lower  induction  of 
proinflammatory  and  proangiogenic  genes  (e.g.  NR4A1,  NR4A2,  NR4A3,  EGR3,  IL-8, 
E-selectin) and higher induction of ADAMTS1 after stimulation with thrombin or VEGF. In 
our experiments, the majority of the LTD4-induced genes were regulated similarly, with the 
exception of ADAMTS1 and E-selectin. When the calcineurin–NFAT pathway was blocked by 
CsA and HUVECs were stimulated with LTD4, ADAMTS1 expression was strongly reduced, 
suggesting a role for NFAT, whereas E-selectin transcription did not seem to require NFAT 
activity as its expression was higher than in untreated cells (Table 18). These data point to a 
general  negative regulation of  inflammatory genes  via  DSCR1 in ECs with some agonist-
dependent differences.
LTD4 (100 nM)  induced  DSCR1  more  strongly  than  thrombin  (10 nM)  (Fig. 9)  or  VEGF 
(25 ng/ml;  control: 70,  LTD4: 2,234,  VEGF: 906  transcripts  /  1,000  GAPDH  measured  by 
qRT-PCR), and the majority of the genes examined were regulated through NFAT (Table 18), 
suggesting that  the relatively short  term effects  of  LTD4 on ECs are  due to  the action of 
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DSCR1. Although VEGF, thrombin and LTD4 trigger highly similar gene signatures at 1 h, the 
differences in  signaling pathways and in gene expression intensities strongly influence the 
response of ECs to the given stimuli.
4.6. LTD4 stimulation leads to cysLT2-R down-regulation in ECs
Besides desensitization, internalization and recycling, which are characteristic of most GPCRs, 
transcriptional and translational changes may also contribute to receptor availability. There is 
no published data on the kinetics and mechanisms of cysLT2-R desensitization, and only few 
studies  investigated  cysLT2-R  mRNA  or  protein  regulation  [Mellor  2003,  Lötzer  2003, 
Sjöström  2003].  In  our  experiments,  LTD4 had  a  negative  feedback  effect  on  cysLT2-R. 
Stimulation with LTD4 led to strong decrease in cysLT2-R mRNA (Fig. 20, Tables 10 and 11 in 
the  Appendix).  Though  cysLT2-R  protein  was  not  directly  measured,  functional  surface-
expressed cysLT2-R was also reduced, as indicated by the lack of [Ca2+]ic increase in response 
to  repeated  LTD4 addition:  HUVECs stimulated  with  100 nM LTD4 did  not  produce  Ca2+ 
signals  at  1 h,  6 h  or  24 h  after  the  first  LTD4 stimulus,  even  if  the  culture  medium was 
replaced to remove LTD4 after the first stimulation (unpublished data, C. Kramer, K. Lötzer & 
A. J. R. Habenicht). Via reducing cysLT2-R expression, cysLTs may control EC activation and 
prevent escalation of the inflammatory response. This receptor down-regulation, however, is 
not a general LT attribute, since LTB4 up-regulates BLT1-R and has no effect on BLT2-R in 
HUVECs [Qiu 2006b].
4.7. Comparison of LTD4- and thrombin-induced gene expression 
patterns
Endothelial  cysLT2-R-activated  genes  gave  rise  to  a  proinflammatory  and  prothrombotic 
phenotype. These early gene signatures of LTD4 resembled those of thrombin determined in 
parallel  (Figures 6  and 7).  In  addition to  previously described shared activities  of  the two 
agonists, their gene expression patterns at 1 h after stimulation showed high similarity, and 
significantly  up-regulated  genes  at  this  time  point  strongly  correlated.  The  two  later  time 
points, i.e. 6 h and 24 h, did not show this uniformity since the effects of LTD4 were less potent 
than those of thrombin. This might be explained by the strong counter-regulatory mechanisms 
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activated by LTD4 including the feedback loop with the calcineurin inhibitor DSCR1 and the 
down-regulation of cysLT2-R. Although attenuation of the Ca2+–calcineurin–NFAT pathway 
via  DSCR1 is  also  triggered by  PAR-1 activation [Minami  2004a],  based on  the  stronger 
induction of DSCR1 by LTD4 (Fig. 9), our data suggest a more powerful inhibition in the case 
of cysLT2-R activation. Furthermore, thrombin responsiveness can be restored in a shorter time 
due to the pre-synthesized PAR-1 pool [Ellis 1999] and unchanged PAR-1 transcript levels 
(data published in NCBI GEO Acc. Nr.: GSE3589).
Other differences between thrombin and LTD4 can be seen when looking at the kinetics of the 
activated genes. LTD4-induced transcripts showed an early peak and returned to baseline level 
soon  after  stimulation,  whereas  several  thrombin  stimulated  genes  reached  their  mRNA 
maximum later and stayed at an elevated level for longer periods of time. Thrombin induced 
IL-8  and  E-selectin  with  prolonged  kinetics  (with  a  maximum at  ~4 h)  [Kaplanski  1997] 
compared to those induced by LTD4 (Figures 14A and 15A). Up-regulation of VCAM-1 by 
LTD4 already appeared at 1 h (Table 8 in the Appendix), whereas in the case of thrombin it 
became apparent after 4 h (Table 12 and [Minami 2004b]). These data suggest similar but not 
identical actions for LTD4 and thrombin. CysLT2-R stimulation caused early and rapid changes 
in the endothelium, and PAR-1 activation by thrombin led to a later and somewhat longer 
response,  which  may  reflect  distinct  biological  roles  for  these  receptors  in  vascular 
inflammation.
The fact that stimulation of cysLT2-R or PAR-1 led to the activation of nearly the same genes 
may be an indication of  similar  G protein utilization.  Endothelial  PAR-1 can interact  with 
multiple types of G proteins such as Gi/o, Gq, G12/13 [Gilchrist 2001, Vanhauwe 2002], whereas 
no data is published on endothelial cysLT2-R. The increase in [Ca2+]ic in response to LTD4 
stimulation [Lötzer 2003] as well as the NFAT-mediated up-regulation of DSCR1 and other 
genes point to the involvement of Gq, but additional G proteins may also mediate signals from 
the cysLT2-R.
That the gene signatures induced by LTD4 and thrombin are not the results of general G protein 
activation, is supported by the analysis of VEGF-induced gene signatures [Minami 2004a, Liu 
2003, Abe 2001]. Early genes induced by activation of the high affinity VEGF receptor, KDR, 
a receptor tyrosine kinase, show high similarity to those induced by thrombin [Minami 2004a]. 
Since  none  of  these  microarray  datasets  are  publicly  available  and  we  did  not  perform 
microarray experiments with VEGF-stimulated HUVECs, a complete and direct comparison 
71
Discussion
with our data is not possible. Still, the majority of the most strongly induced early genes by 
LTD4 and  VEGF  are  identical  (Table 20).  In  the  study  from  Liu  et  al.  (2003)  the  same 
microarray technology and genechip type was used as  in  our  experiments,  more than two 
samples per group were analyzed, and fold change values are published. Therefore, it was best 
fit for showing the likeness between VEGF and LTD4. VEGF is a potent endothelial mitogen 
and  survival  factor  [Ferrara  2001],  and  thrombin  induces  endothelial  proliferation  and 
migration [Tsopanoglou 2004, Minami 2004b]. The high similarity of VEGF’s and thrombin’s 
early gene signatures and their divergence from those of other agonists such as TNFα [Minami 
2004a]  might  indicate  “angiogenic  gene  expression  patterns”.  Since  LTD4-induced  gene 
signatures resemble those of thrombin and VEGF, our data are consistent with the hypothesis 
that LTD4 may act as an angiogenic factor. This is supported by studies reporting angiogenic 
effects of LTD4 such as increased collagenous protein biosynthesis and vascular density in the 
chick corioallantoic membrane [Tsopanoglou 1994], and induction of HUVEC proliferation 
[Fierro  2002].  Endothelial  cysLT2-R-mediated  angiogenic  processes  might  be  relevant  in 
pathological angiogenesis during vascular diseases or in wound healing and neoangiogenesis 
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Gene
VEGF LTD4
45 min 90 min 60 min
ADAMTS1 4 3 9
DSCR1 8 10 16
HBEGF 3 3 7
DUSP1 5 5
DUSP5 3 3 2
EGR2 6 9
EGR3 10 10 22
F3 19 17
IL8 7 3 8
KCNJ2 3 3 3
MAP3K8 4 9 6
NR4A1 8 5 33
NR4A2 12 17 47
NR4A3 7 26
PTGS2 3 4 15
STC1 4 2
Table 20. The most strongly induced genes by VEGF and LTD4. The columns show fold changes in gene 
expression after  VEGF [Liu 2003] or  LTD4 stimulation. In case of VEGF, data represent  the result  of three 
microarray experiments (for details see Liu 2003), and for LTD4 four datasets were analyzed. HBEGF: heparin-
binding EGF-like growth factor; DUSP1: dual specificity phosphatase 1; DUSP5: dual specificity phosphatase 5; 
F3: tissue factor; KCNJ2: potassium inwardly-rectifying channel, subfamily J, member 2;  MAP3K8: mitogen 
activated protein kinase kinase kinase 8; PTGS2: cyclooxygenase 2; STC1: stanniocalcin 1
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after  vascular  injury.  The  inflammatory reaction of  the injured vessel  wall  can trigger  the 
production and release of progenitor cells from the bone marrow and other tissues [reviewed in 
Goldschmidt-Clermont 2005]. Homing, anchorage and integration of these progenitors depend 
on microenvironmental effects, where locally produced agonists including LTs may play an 
important role.
Treatment  of ECs with LTD4 and thrombin together resulted in enhanced gene expression 
compared to either agonist alone (Fig. 8, Table 14 in the Appendix). These data suggest that 
concomitant  stimulation  of  the  endothelial  cysLT2-R  and  PAR-1  may  augment  the 
inflammatory response of ECs. This may be relevant in vivo during inflammatory states in the 
vasculature, e.g. thrombus formation or atherosclerotic plaque disruption when conversion of 
prothrombin to thrombin and production of LTs directly by leukocytes or via transcellular 
metabolism  by  platelets  and  ECs  are  simultaneously  initiated  [Maclouf  1989,  Qiu  2006a, 
Cirino 1996].
4.8. Conclusions
This study aimed to understand transcriptional and selected tranlational events resulting from 
activation of the cysLT2-R in ECs and to interpret  these effects  in the context of vascular 
biology.  The  diversity  of  LTD4-induced  gene  signatures  points  to  a  comprehensive  early 
proinflammatory and prothrombotic EC phenotype. In addition to identifying genes responsible 
for the inflammatory actions of LTs, the analysis of LTD4-triggered gene signatures revealed 
genes and regulatory mechanisms that can control EC activation and thus limit inflammation. 
Investigating cysLT-induced gene expression patterns in ECs shed more light on cysLT2-R 
actions in a non-transfectant system. These data may provide insight into the mechanisms of 
LT effects in vascular disorders.
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Summary
LTs, i.e. LTB4 and the cysLTs, are lipid mediators with potent biological activities. LTs are 
generated either endogenously by activated leukocytes from arachidonic acid in response to 
inflammatory stimuli or via transcellular metabolism from leukocyte-derived LTA4. LTs are 
viewed  mainly  as  inflammatory  mediators,  thereby  contributing  to  a  variety  of  disease 
conditions. They have many biological effects, the most prominent of which are chemotactic, 
vasoactive  and smooth muscle  contracting activities.  CysLT actions  are  mediated by three 
cysLT-Rs that are differentially expressed on leukocytes and on blood vessel wall cells.  The 
cysLT2-R is selectively expressed by ECs, implying functions in the cardiovascular system.
To delineate  cysLT2-R-mediated transcriptional  changes  in  ECs,  HUVECs were  stimulated 
with LTD4 and gene signatures were determined by microarray analyses. Thrombin, the potent 
vasoactive  agonist,  was  used  for  comparison.  LTD4 led  to  an  early  proinflammatory  and 
prothrombotic gene expression pattern highly resembling that induced by thrombin activation 
of PAR-1. When added together, LTD4 and thrombin generally enhanced gene expression. The 
most strongly induced genes by LTD4 included transcription factors of the EGR and NR4A 
families, CXC chemokines, intracellular regulators such as DSCR1, adhesion molecules such 
as  E-selectin,  the  metalloprotease  ADAMTS1,  the  blood  coagulation  initiator  TF,  and  the 
complement regulator CD55. Induction of these genes was confirmed and their mRNA kinetics 
was determined by qRT-PCR. LTD4 stimulation also resulted in up-regulation of EGR1 protein 
and  its  translocation  to  the  nucleus,  IL-8  protein  secretion  into  the  culture  medium,  TF 
expression  and  TF-dependent  cell-associated  procoagulant  activity  as  well  as  increased 
amounts of cell surface CD55.
This  study  is  the  first  to  characterize  cysLT2-R-triggered  endothelial  gene  signatures.  It 
provides  evidence  for  the  potential  transcription-  and  translation-dependent  inflammatory 
actions of cysLTs in the vasculature in vivo.
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Zusammenfassung
Leukotriene (LTe), d.h. LTB4 und die Cysteinylleukotriene (cysLTe) LTC4, LTD4 und LTE4, 
sind  hochaktive  Lipidmediatoren.  LTe  werden  entweder  von  aktivierten  Leukozyten  nach 
inflammatorischen Stimuli endogen aus Arachidonsäure synthetisiert oder durch transzelluläre 
Metabolisierung des von Leukozyten stammenden LTA4 produziert. LTe sind als Mediatoren 
inflammatorischer  Reaktionen  bekannt  und  werden  mit  verschiedenen  Erkrankungen  in 
Zusammenhang gebracht. LTe haben viele biologische Effekte, von denen die bedeutendsten 
die chemotaktischen und vasoaktiven Wirkungen sowie der Einfluß auf die Kontraktion glatter 
Muskelzellen sind. Ihre Funktionen üben CysLTe durch drei CysLT-Rezeptoren (CysLT-Ren) 
aus, die von Blutleukozyten und Gefäßwandzellen differentiell exprimiert werden. Endothel-
zellen (ECs) exprimieren selektiv den CysLT2-R, was auf eine Funktion im kardiovaskulären 
System hindeutet.
Um  die  CysLT2-R-initiierten  transkriptionellen  Änderungen  in  ECs  zu  verfolgen  wurden 
HUVECs (ECs aus der humanen Umbilikalvene) mit LTD4 stimuliert und die Gensignaturen 
mittels Microarrayanalysen untersucht. Thrombin, das als Prototyp vasoaktiver Agonisten in 
HUVECs gilt, wurde zum Vergleich genutzt. LTD4 induzierte ein proinflammatorisches und 
prothrombotisches Genexpressionsmuster, welches große Ähnlichkeiten zu dem von Thrombin 
über die Aktivierung des PAR-1 induzierten Muster zeigte. Die kombinierte Stimulation mit 
LTD4 und Thrombin ergab eine verstärkte  Genexpression.  Zu den am stärksten aktivierten 
Genen  von  LTD4 gehörten  Transkriptionsfaktoren  der  Familien  EGR  und  NR4A,  CXC 
Chemokine, intrazelluläre Regulatoren wie DSCR1, Adhäsionsmoleküle wie E-Selektin, die 
Metalloprotease ADAMTS1, der Initiator der Gerinnungskaskade TF (Gewebsthromboplastin) 
und der Komplementregulator CD55. Quantitative RT-PCR Analysen bestätigten die Induktion 
dieser Gene und klärten ihre mRNA Kinetik auf. Die Inkubation mit LTD4 führte ebenfalls zur 
Hochregulation des EGR1 Proteins und dessen Translokation in den Zellkern, der Sekretion 
des  IL-8  Proteins  in  das  Kulturmedium,  der  Expression  von  TF  Protein  und  der  davon 
abhängigen prothrombotischen Aktivität der Zellen sowie der erhöhten Expression des CD55 
an der Zelloberfläche.
Die vorliegende Arbeit charakterisierte endotheliale Gensignaturen des CysLT2-Rs. Die Daten 
geben  somit  Hinweise  auf  potentielle  transkriptions-  und  translationsabhängige  inflam-
matorische Wirkungen der CysLTe im kardiovaskulären System in vivo.
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5-LO 5-lipoxygenase
AA arachidonic acid
ADAMTS1 a disintegrin-like and metalloproteinase with thrombospondin motif 1, type 1
AT Annealing temperature
ATF3 activation transcription factor 3
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[Ca2+]ic intracellular Ca2+ concentration
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DSCR1 Down syndrome critical region gene 1
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GPCR G protein coupled receptor
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MCP-1 monocyte chemoattractant protein 1
NCBI National Center for Biotechnology Information
NFAT nuclear factor of activate T cells
NFκB nuclear factor κ B
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NR4A nuclear receptor subfamily 4, group A
PAF platelet-activating factor
PAI plasminogen activator inhibitor
PAR protease activated receptor
PGI2 prostacyclin
PKC protein kinase C
PMN polymorphonuclear cell
SF scaling factor
TF tissue factor
TGF tumor growth factor
TNF tumor necrosis factor
TV transcript variant
VCAM vascular cell adhesion molecule
VEGF vascular endothelial growth factor
VSMC vascular smooth muscle cell
vWF von Willebrand factor
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Table 7. Signal intensity values of 37 genes up-regulated by LTD4 as displayed in Fig. 9.  Columns show signal intensity values without 
normalization.
Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4 Thrombin
1 2 3 4 1 2 3 4 1 2 3 4
200632_s_at N-myc downstream 
regulated gene 1
NDRG1 1228 1604 1253 1234 2556 4199 4990 2905 1537 1873 5324 2876
208078_s_at SNF1-like kinase SNF1LK 501 446 210 477 969 2812 3467 1347 538 823 5645 1509
219371_s_at Kruppel-like factor 2 
(lung)
KLF2 1034 1284 810 1328 2684 4258 3037 1746 1235 2196 5401 2194
221841_s_at Kruppel-like factor 4 (gut) KLF4 244 391 634 428 727 2092 3032 740 579 1612 6120 2057
201041_s_at dual specificity 
phosphatase 1
DUSP1 1600 1993 1762 1603 5020 11782 9382 5228 5068 6151 11030 7007
212614_at AT rich interactive domain 
5B (MRF1-like)
ARID5B 415 494 406 555 1561 2457 1979 1318 1662 1613 2495 1440
201531_at zinc finger protein 36, C3H 
type, homolog (mouse)
ZFP36 321 358 311 190 1124 5220 2724 1983 1757 2037 2435 2629
210764_s_at cysteine-rich, angiogenic 
inducer, 61
CYR61 1273 947 727 679 5102 13985 8499 5249 12498 16029 14958 12197
203821_at heparin-binding EGF-like 
growth factor
HBEGF 446 236 186 396 1661 2768 2840 2184 2320 1772 5184 3718
204748_at prostaglandin-
endoperoxide synthase 2 
PTGS2 94 301 366 366 1280 7185 4429 3452 707 1170 3789 2847
A
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4 Thrombin
1 2 3 4 1 2 3 4 1 2 3 4
200632_s_at N-myc downstream 
regulated gene 1
NDRG1 1228 1604 1253 1234 2556 4199 4990 2905 1537 1873 5324 2876
(prostaglandin G/H 
synthase and 
cyclooxygenase)
205249_at early growth response 2 
(Krox-20 homolog, 
Drosophila)
EGR2 70 122 64 111 409 1196 976 863 355 244 1382 592
202150_s_at neural precursor cell 
expressed, developmentally 
down-regulated 9
NEDD9 918 917 348 450 2244 2272 2429 1193 2594 1828 3074 2271
218880_at FOS-like antigen 2 FOSL2 286 349 93 241 774 703 1117 419 840 396 1322 561
206765_at potassium inwardly-
rectifying channel, 
subfamily J, member 2
KCNJ2 971 727 661 865 2533 3134 2832 1948 1821 1545 2393 1981
214438_at H2.0-like homeo box 1 
(Drosophila)
HLX1 742 641 386 524 2250 3120 2389 1455 1818 1701 2169 1185
221031_s_at hypothetical protein 
DKFZp434F0318
DKFZP43
4F0318
1029 937 259 453 2450 3734 2555 1671 1924 1430 3513 1685
214508_x_at cAMP responsive element 
modulator
CREM 570 560 437 642 1622 1520 1584 824 908 612 1692 760
207980_s_at Cbp/p300-interacting CITED2 345 217 448 370 1246 897 810 714 738 858 1513 726
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4 Thrombin
1 2 3 4 1 2 3 4 1 2 3 4
200632_s_at N-myc downstream 
regulated gene 1
NDRG1 1228 1604 1253 1234 2556 4199 4990 2905 1537 1873 5324 2876
transactivator, with 
Glu/Asp-rich carboxy-
terminal domain, 2
202340_x_at nuclear receptor subfamily 
4, group A, member 1
NR4A1 56 112 130 74 2089 3897 4835 1356 720 721 5543 1029
206115_at early growth response 3 EGR3 89 125 61 99 1134 2834 2776 1421 577 603 3720 1246
204622_x_at nuclear receptor subfamily 
4, group A, member 2
NR4A2 65 145 44 90 2999 5264 5600 2273 667 847 6917 799
208370_s_at Down syndrome critical 
region gene 1
DSCR1 317 357 339 543 5927 7143 6541 5558 3129 1941 4974 2375
202388_at regulator of G-protein 
signalling 2, 24kDa
RGS2 97 414 368 491 1161 2293 2154 1533 458 744 2076 693
209959_at nuclear receptor subfamily 
4, group A, member 3
NR4A3 22 50 26 37 935 1154 1216 265 59 64 2336 44
204472_at GTP binding protein 
overexpressed in skeletal 
muscle
GEM 90 146 108 276 290 358 746 466 265 127 625 707
222162_s_at a disintegrin-like and 
metalloprotease (reprolysin 
type) with thrombospondin 
ADAMTS
1
562 316 510 956 2480 4939 7324 5268 757 910 7585 4226 A
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4 Thrombin
1 2 3 4 1 2 3 4 1 2 3 4
200632_s_at N-myc downstream 
regulated gene 1
NDRG1 1228 1604 1253 1234 2556 4199 4990 2905 1537 1873 5324 2876
type 1 motif, 1
200797_s_at myeloid cell leukemia 
sequence 1 (BCL2-related)
MCL1 1963 1773 2281 1797 3412 7218 8922 3526 5688 7732 13834 7266
202672_s_at activating transcription 
factor 3
ATF3 315 333 228 291 650 1748 1394 528 2162 1718 3222 2370
201694_s_at early growth response 1 EGR1 424 616 461 703 804 2221 1584 1798 1032 1956 3234 2634
202859_x_at Interleukin 8 IL8 125 190 157 361 816 2578 928 2736 4417 2411 2344 6428
204363_at coagulation factor III 
(thromboplastin, tissue 
factor)
F3 14 34 22 21 354 387 377 438 194 207 97 227
205027_s_at mitogen-activated protein 
kinase kinase kinase 8
MAP3K8 7 27 36 35 163 187 163 127 82 130 41 77
205290_s_at bone morphogenetic 
protein 2
BMP2 2187 1579 893 1426 4325 5675 3806 3555 3470 2288 2296 2562
206211_at selectin E (endothelial 
adhesion molecule 1)
SELE 21 30 6 107 201 164 66 246 378 92 34 122
209774_x_at chemokine (C-X-C motif) 
ligand 2
CXCL2 104 176 102 676 818 3522 418 2408 882 453 513 1128
205960_at pyruvate dehydrogenase 
kinase, isoenzyme 4
PDK4 360 509 487 328 999 1398 1532 572 521 572 730 293
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4 Thrombin
1 2 3 4 1 2 3 4 1 2 3 4
200632_s_at N-myc downstream 
regulated gene 1
NDRG1 1228 1604 1253 1234 2556 4199 4990 2905 1537 1873 5324 2876
214446_at elongation factor, RNA 
polymerase II, 2
ELL2 77 45 139 84 209 211 449 215 55 29 421 212
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Table 8. Probe sets up-regulated (A) and down-regulated (B) >2-fold by LTD4 at 1 h. Data were filtered according to the following criteria: 
detection p-value <0.065 at least in three of four samples in either the control or the stimulated group; signal value >150 at least in three of four  
samples in either the control or the stimulated group; fold change calculated from the signal means >2.0. Mean signals of four experiments are 
shown. n.a.: not annotated
A) Probe sets up-regulated >2-fold by LTD4 at 1 h
Affymetrix
probe set ID
Gene title
Gene 
symbol
Mean 
control
Mean
LTD4
Fold change 
LTD4/control
204621_s_at nuclear receptor subfamily 4, group A, member 2 NR4A2 25 2682 104.5
216248_s_at nuclear receptor subfamily 4, group A, member 2 NR4A2 61 4791 77.8
204622_x_at nuclear receptor subfamily 4, group A, member 2 NR4A2 86 4034 46.9
202340_x_at nuclear receptor subfamily 4, group A, member 1 NR4A1 93 3044 32.8
209959_at nuclear receptor subfamily 4, group A, member 3 NR4A3 33 892 26.4
206115_at early growth response 3 EGR3 93 2041 21.8
204363_at coagulation factor III (thromboplastin, tissue factor) F3 23 388 16.9
208370_s_at Down syndrome critical region gene 1 DSCR1 388 6292 16.2
204748_at prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase)
PTGS2 281 4086 14.5
205249_at early growth response 2 (Krox-20 homolog, Drosophila) EGR2 91 861 9.4
201531_at zinc finger protein 36, C3H type, homolog (mouse) ZFP36 295 2763 9.4
210764_s_at cysteine-rich, angiogenic inducer, 61 CYR61 906 8208 9.1
207978_s_at nuclear receptor subfamily 4, group A, member 3 NR4A3 115 1002 8.7
222162_s_at a disintegrin-like and metalloprotease (reprolysin type) with 
thrombospondin type 1 motif, 1
ADAMTS1 585 5002 8.5
100
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Affymetrix
probe set ID
Gene title
Gene 
symbol
Mean 
control
Mean
LTD4
Fold change 
LTD4/control
202859_x_at Interleukin 8 IL8 208 1764 8.5
201044_x_at dual specificity phosphatase 1 DUSP1 47 373 7.9
203821_at heparin-binding EGF-like growth factor HBEGF 316 2363 7.5
215253_s_at Down syndrome critical region gene 1 DSCR1 464 3390 7.3
209774_x_at chemokine (C-X-C motif) ligand 2 CXCL2 264 1791 6.8
201289_at cysteine-rich, angiogenic inducer, 61 CYR61 1135 7114 6.3
205027_s_at mitogen-activated protein kinase kinase kinase 8 MAP3K8 26 159 6.1
208078_s_at SNF1-like kinase SNF1LK 408 2148 5.3
202388_at regulator of G-protein signalling 2, 24kDa RGS2 342 1785 5.2
201041_s_at dual specificity phosphatase 1 DUSP1 1739 7852 4.5
206211_at selectin E (endothelial adhesion molecule 1) SELE 40 169 4.2
38037_at heparin-binding EGF-like growth factor HBEGF 218 880 4.0
214438_at H2.0-like homeo box 1 (Drosophila) HLX1 573 2303 4.0
212614_at AT rich interactive domain 5B (MRF1-like) ARID5B 467 1828 3.9
221031_s_at hypothetical protein DKFZp434F0318 DKFZP434
F0318
669 2602 3.9
221841_s_at Kruppel-like factor 4 (gut) KLF4 424 1647 3.9
202672_s_at Activating transcription factor 3 ATF3 291 1079 3.7
209967_s_at cAMP responsive element modulator CREM 517 1711 3.3
206765_at potassium inwardly-rectifying channel, subfamily J, member 2 KCNJ2 806 2612 3.2
211506_s_at Interleukin 8 IL8 173 550 3.2
214446_at Elongation factor, RNA polymerase II, 2 ELL2 86 271 3.1
A
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Affymetrix
probe set ID
Gene title
Gene 
symbol
Mean 
control
Mean
LTD4
Fold change 
LTD4/control
218880_at FOS-like antigen 2 FOSL2 242 753 3.1
202150_s_at neural precursor cell expressed, developmentally down-
regulated 9
NEDD9 658 2034 3.1
202149_at neural precursor cell expressed, developmentally down-
regulated 9
NEDD9 697 2112 3.0
204472_at GTP binding protein overexpressed in skeletal muscle GEM 155 464 3.0
200797_s_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 1953 5769 3.0
209357_at Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2
CITED2 328 959 2.9
201694_s_at early growth response 1 EGR1 551 1601 2.9
205290_s_at bone morphogenetic protein 2 BMP2 1521 4340 2.9
200632_s_at N-myc downstream regulated gene 1 NDRG1 1329 3662 2.8
205960_at pyruvate dehydrogenase kinase, isoenzyme 4 PDK4 420 1125 2.7
207980_s_at Cbp/p300-interacting transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 2
CITED2 345 916 2.7
219371_s_at Kruppel-like factor 2 (lung) KLF2 1114 2930 2.6
214508_x_at cAMP responsive element modulator CREM 552 1387 2.5
207283_at n.a. 264 657 2.5
36711_at v-maf musculoaponeurotic fibrosarcoma oncogene homolog F 
(avian)
MAFF 1768 4383 2.5
200798_x_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 1624 4013 2.5
220266_s_at Kruppel-like factor 4 (gut) KLF4 202 500 2.5
A
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Affymetrix
probe set ID
Gene title
Gene 
symbol
Mean 
control
Mean
LTD4
Fold change 
LTD4/control
207630_s_at cAMP responsive element modulator CREM 992 2427 2.4
213260_at Forkhead box C1 FOXC1 1314 3204 2.4
212558_at sprouty homolog 1, antagonist of FGF signaling (Drosophila) SPRY1 599 1440 2.4
200796_s_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 424 1018 2.4
205289_at bone morphogenetic protein 2 BMP2 1287 3089 2.4
204011_at sprouty homolog 2 (Drosophila) SPRY2 510 1189 2.3
209074_s_at TU3A protein TU3A 127 293 2.3
218541_s_at chromosome 8 open reading frame 4 C8orf4 150 345 2.3
204135_at downregulated in ovarian cancer 1 DOC1 551 1259 2.3
204285_s_at phorbol-12-myristate-13-acetate-induced protein 1 PMAIP1 196 430 2.2
208960_s_at Kruppel-like factor 6 KLF6 879 1925 2.2
218886_at PAK1 interacting protein 1 PAK1IP1 98 215 2.2
208415_x_at inhibitor of growth family, member 1 ING1 228 498 2.2
212665_at TCDD-inducible poly(ADP-ribose) polymerase TIPARP 531 1154 2.2
218881_s_at FOS-like antigen 2 FOSL2 216 461 2.1
201170_s_at basic helix-loop-helix domain containing, class B, 2 BHLHB2 1039 2212 2.1
209457_at dual specificity phosphatase 5 DUSP5 1213 2533 2.1
205409_at FOS-like antigen 2 FOSL2 145 296 2.0
203868_s_at vascular cell adhesion molecule 1 VCAM1 163 331 2.0 A
ppendix
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B) Probe sets down-regulated >2-fold by LTD4 at 1 h
Affymetrix 
probe set ID
Gene title
Gene 
symbol
Mean 
control
Mean
LTD4
Fold change 
−control/LTD4
201008_s_at thioredoxin interacting protein TXNIP 2090 958 -2.2
201009_s_at thioredoxin interacting protein TXNIP 2729 1260 -2.2
215521_at polyhomeotic like 3 (Drosophila) PHC3 144 71 -2.0
208937_s_at inhibitor of DNA binding 1, dominant negative helix-loop-
helix protein
ID1 2806 1395 -2.0
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Table 9. Probe sets up-regulated (A) and down-regulated (B) >2-fold by thrombin at 1 h. Data were filtered according to the following 
criteria: detection p-value <0.065 at least in three of four samples in either the control or the stimulated group; signal value >150 at 
least in three of four samples in either the control or the stimulated group; fold change calculated from the signal means >2.0. Mean 
signals of four experiments are shown.
A) Probe sets up-regulated >2-fold by thrombin at 1 h
Affymetrix 
probe set ID
Gene title
Gene 
symbol
Mean 
control
Mean 
thrombin
Fold change 
thrombin/control
202768_at FBJ murine osteosarcoma viral oncogene homolog B FOSB 25 3250 126.4
204621_s_at nuclear receptor subfamily 4, group A, member 2 NR4A2 25 1459 56.8
216248_s_at nuclear receptor subfamily 4, group A, member 2 NR4A2 61 2693 43.8
204622_x_at nuclear receptor subfamily 4, group A, member 2 NR4A2 86 2307 26.8
202340_x_at nuclear receptor subfamily 4, group A, member 1 NR4A1 93 2003 21.6
202859_x_at interleukin 8 IL8 208 3900 18.7
206115_at early growth response 3 EGR3 93 1536 16.4
210764_s_at cysteine-rich, angiogenic inducer, 61 CYR61 906 13920 15.4
203821_at heparin-binding EGF-like growth factor HBEGF 316 3248 10.3
201289_at cysteine-rich, angiogenic inducer, 61 CYR61 1135 10610 9.3
202672_s_at Activating transcription factor 3 ATF3 291 2368 8.1
208370_s_at Down syndrome critical region gene 1 DSCR1 388 3104 8.0
204748_at prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase)
PTGS2 281 2128 7.6
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Mean 
control
Mean 
thrombin
Fold change 
thrombin/control
201531_at zinc finger protein 36, C3H type, homolog (mouse) ZFP36 295 2214 7.5
205249_at early growth response 2 (Krox-20 homolog, 
Drosophila)
EGR2 91 643 7.0
211506_s_at interleukin 8 IL8 173 1204 6.9
207978_s_at nuclear receptor subfamily 4, group A, member 3 NR4A3 115 793 6.9
38037_at heparin-binding EGF-like growth factor HBEGF 218 1407 6.4
221841_s_at Kruppel-like factor 4 (gut) KLF4 424 2591 6.1
222162_s_at a disintegrin-like and metalloprotease (reprolysin 
type) with thrombospondin type 1 motif, 1
ADAMTS1 585 3369 5.8
208078_s_at SNF1-like kinase SNF1LK 408 2128 5.2
204135_at downregulated in ovarian cancer 1 DOC1 551 2782 5.0
204222_s_at GLI pathogenesis-related 1 (glioma) GLIPR1 51 255 5.0
215198_s_at caldesmon 1 CALD1 145 656 4.5
220266_s_at Kruppel-like factor 4 (gut) KLF4 202 907 4.5
200797_s_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 1953 8630 4.4
215199_at caldesmon 1 CALD1 117 517 4.4
201041_s_at dual specificity phosphatase 1 DUSP1 1739 7313 4.2
201466_s_at v-jun sarcoma virus 17 oncogene homolog (avian) JUN 283 1165 4.1
201694_s_at early growth response 1 EGR1 551 2213 4.0
202270_at guanylate binding protein 1, interferon-inducible, 
67kDa 
GBP1 64 251 3.9
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Mean 
control
Mean 
thrombin
Fold change 
thrombin/control
212614_at AT rich interactive domain 5B (MRF1-like) ARID5B 467 1802 3.9
202150_s_at neural precursor cell expressed, developmentally 
down-regulated 9
NEDD9 658 2441 3.7
218541_s_at chromosome 8 open reading frame 4 C8orf4 150 549 3.7
200796_s_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 424 1502 3.5
200798_x_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 1624 5724 3.5
208960_s_at Kruppel-like factor 6 KLF6 879 3000 3.4
215253_s_at Down syndrome critical region gene 1 DSCR1 464 1535 3.3
204470_at chemokine (C-X-C motif) ligand 1 (melanoma 
growth stimulating activity, alpha)
CXCL1 135 446 3.3
209101_at connective tissue growth factor CTGF 5531 18122 3.3
202149_at neural precursor cell expressed, developmentally 
down-regulated 9
NEDD9 697 2280 3.3
208119_s_at zinc finger protein 505 ZNF505 129 422 3.3
201739_at serum/glucocorticoid regulated kinase SGK 1045 3371 3.2
218880_at FOS-like antigen 2 FOSL2 242 779 3.2
221031_s_at hypothetical protein DKFZp434F0318 DKFZP434F
0318
669 2137 3.2
208961_s_at Kruppel-like factor 6 KLF6 1540 4841 3.1
202269_x_at guanylate binding protein 1, interferon-inducible, 
67kDa 
GBP1 187 585 3.1 Appendix
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Mean 
control
Mean 
thrombin
Fold change 
thrombin/control
214438_at H2.0-like homeo box 1 (Drosophila) HLX1 573 1718 3.0
202388_at regulator of G-protein signalling 2, 24kDa RGS2 342 992 2.9
209357_at Cbp/p300-interacting transactivator, with Glu/Asp-
rich carboxy-terminal domain, 2
CITED2 328 932 2.8
201465_s_at v-jun sarcoma virus 17 oncogene homolog (avian) JUN 185 525 2.8
209774_x_at chemokine (C-X-C motif) ligand 2 CXCL2 264 743 2.8
204472_at GTP binding protein overexpressed in skeletal 
muscle
GEM 155 431 2.8
207980_s_at Cbp/p300-interacting transactivator, with Glu/Asp-
rich carboxy-terminal domain, 2
CITED2 345 958 2.8
214085_x_at GLI pathogenesis-related 1 (glioma) GLIPR1 302 825 2.7
204011_at sprouty homolog 2 (Drosophila) SPRY2 510 1342 2.6
219371_s_at Kruppel-like factor 2 (lung) KLF2 1114 2756 2.5
202067_s_at low density lipoprotein receptor (familial 
hypercholesterolemia)
LDLR 192 475 2.5
201464_x_at v-jun sarcoma virus 17 oncogene homolog (avian) JUN 1581 3866 2.4
218881_s_at FOS-like antigen 2 FOSL2 216 519 2.4
202241_at tribbles homolog 1 (Drosophila) TRIB1 712 1712 2.4
206765_at potassium inwardly-rectifying channel, subfamily J, 
member 2
KCNJ2 806 1935 2.4
203751_x_at jun D proto-oncogene JUND 381 887 2.3
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Mean 
control
Mean 
thrombin
Fold change 
thrombin/control
201693_s_at early growth response 1 EGR1 268 623 2.3
212418_at E74-like factor 1 (ets domain transcription factor) ELF1 543 1234 2.3
218995_s_at endothelin 1 EDN1 1492 3370 2.3
200632_s_at N-myc downstream regulated gene 1 NDRG1 1329 2902 2.2
220990_s_at likely ortholog of rat vacuole membrane protein 1 VMP1 1223 2646 2.2
202014_at protein phosphatase 1, regulatory (inhibitor) subunit 
15A
PPP1R15A 413 880 2.1
202068_s_at low density lipoprotein receptor (familial 
hypercholesterolemia)
LDLR 1672 3509 2.1
204221_x_at GLI pathogenesis-related 1 (glioma) GLIPR1 138 280 2.0
203140_at B-cell CLL/lymphoma 6 (zinc finger protein 51) BCL6 381 769 2.0
215206_at Exostoses (multiple) 1 EXT1 230 463 2.0
B) Probe sets down-regulated >2-fold by thrombin at 1 h
Affymetrix 
probe set ID
Gene title Gene symbol
Mean 
control
Mean 
thrombin
Fold change 
−control/thrombin
201367_s_at zinc finger protein 36, C3H type-like 2 ZFP36L2 876 208 -4.2
202887_s_at DNA-damage-inducible transcript 4 DDIT4 1963 523 -3.7
201368_at zinc finger protein 36, C3H type-like 2 ZFP36L2 4562 1399 -3.3
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Affymetrix 
probe set ID
Gene title Gene symbol
Mean 
control
Mean 
thrombin
Fold change 
−control/thrombin
208937_s_at inhibitor of DNA binding 1, dominant negative 
helix-loop-helix protein
ID1 2806 870 -3.2
201369_s_at zinc finger protein 36, C3H type-like 2 ZFP36L2 666 233 -2.9
209905_at homeo box A9 HOXA9 438 166 -2.6
209602_s_at GATA binding protein 3 GATA3 195 76 -2.6
203395_s_at hairy and enhancer of split 1, (Drosophila) HES1 1098 431 -2.5
201010_s_at thioredoxin interacting protein TXNIP 3484 1397 -2.5
203394_s_at hairy and enhancer of split 1, (Drosophila) HES1 1347 544 -2.5
201008_s_at thioredoxin interacting protein TXNIP 2090 866 -2.4
201009_s_at thioredoxin interacting protein TXNIP 2729 1138 -2.4
207826_s_at inhibitor of DNA binding 3, dominant negative 
helix-loop-helix protein
ID3 2898 1294 -2.2
205020_s_at ADP-ribosylation factor-like 4A ARL4A 2031 956 -2.1
207474_at SNF related kinase SNRK 187 90 -2.1
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Table 10. Probe sets up-regulated (A) and down-regulated (B) >2-fold by LTD4 at 6 h.  Data were filtered according to the following 
criteria: detection p-value <0.065 and signal value >150 in either the control or the stimulated group; fold change >2.0. Results of one 
experiment are shown.
A) Probe sets up-regulated >2-fold by LTD4 at 6 h
Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4
Fold change 
LTD4/Control
206942_s_at pro-melanin-concentrating hormone PMCH 16 1227 77.7
220351_at chemokine (C-C motif) receptor-like 1 CCRL1 36 245 6.7
205902_at potassium intermediate/small conductance calcium-activated 
channel, subfamily N, member 3
KCNN3 118 662 5.6
207016_s_at aldehyde dehydrogenase 1 family, member A2 ALDH1A2 537 2263 4.2
215012_at zinc finger protein 451 ZNF451 77 281 3.7
204818_at hydroxysteroid (17-beta) dehydrogenase 2 HSD17B2 83 302 3.6
212927_at SMC5 structural maintenance of chromosomes 5-like 1 
(yeast)
SMC5L1 53 174 3.3
210946_at phosphatidic acid phosphatase type 2A PPAP2A 259 821 3.2
202388_at regulator of G-protein signalling 2, 24kDa RGS2 147 430 2.9
212730_at desmuslin DMN 382 1107 2.9
218935_at EH-domain containing 3 EHD3 507 1412 2.8
208370_s_at Down syndrome critical region gene 1 DSCR1 307 818 2.7
209147_s_at phosphatidic acid phosphatase type 2A PPAP2A 466 1235 2.6
214987_at GRB2-associated binding protein 1 GAB1 67 176 2.6
202291_s_at matrix Gla protein MGP 2960 7428 2.5
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4
Fold change 
LTD4/Control
203282_at glucan (1,4-alpha-), branching enzyme 1 (glycogen 
branching enzyme, Andersen disease, glycogen storage 
disease type IV)
GBE1 825 2051 2.5
206103_at ras-related C3 botulinum toxin substrate 3 (rho family, small 
GTP binding protein Rac3)
RAC3 67 164 2.5
201641_at bone marrow stromal cell antigen 2 BST2 63 153 2.4
215930_s_at CTAGE family, member 5 CTAGE5 67 159 2.4
203023_at hypothetical protein HSPC111 HSPC111 97 227 2.3
220037_s_at extracellular link domain containing 1 XLKD1 394 909 2.3
207015_s_at aldehyde dehydrogenase 1 family, member A2 ALDH1A2 178 404 2.3
206167_s_at Rho GTPase activating protein 6 ARHGAP6 97 219 2.3
34206_at centaurin, delta 2 CENTD2 233 522 2.2
211993_at WNK lysine deficient protein kinase 1 WNK1 86 190 2.2
213388_at phosphodiesterase 4D interacting protein (myomegalin) PDE4DIP 89 197 2.2
219534_x_at cyclin-dependent kinase inhibitor 1C (p57, Kip2) CDKN1C 115 249 2.2
220241_at transmembrane and coiled-coil domains 3 TMCO3 84 181 2.2
201925_s_at decay accelerating factor for complement (CD55, Cromer 
blood group system)
DAF 1006 2167 2.2
201860_s_at plasminogen activator, tissue PLAT 238 512 2.2
205903_s_at potassium intermediate/small conductance calcium-activated 
channel, subfamily N, member 3
KCNN3 151 325 2.1
213853_at zinc finger, CSL-type containing 3 ZCSL3 229 491 2.1
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4
Fold change 
LTD4/Control
210723_x_at hypothetical protein MGC4771 MGC4771 75 161 2.1
210195_s_at pregnancy specific beta-1-glycoprotein 1 PSG1 78 165 2.1
213629_x_at metallothionein 1F (functional) MT1F 164 344 2.1
204596_s_at stanniocalcin 1 STC1 1297 2707 2.1
209277_at Tissue factor pathway inhibitor 2 TFPI2 818 1694 2.1
214844_s_at docking protein 5 DOK5 381 786 2.1
212306_at cytoplasmic linker associated protein 2 CLASP2 479 985 2.1
207936_x_at ret finger protein-like 3 RFPL3 170 346 2.0
215054_at erythropoietin receptor EPOR 244 496 2.0
219059_s_at extracellular link domain containing 1 XLKD1 581 1164 2.0
B) Probe sets down-regulated >2-fold by LTD4 at 6 h
Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4
Fold change
–Control/LTD4
48030_i_at chromosome 5 open reading frame 4 C5orf4 2274 273 -8.3
213033_s_at Nuclear factor I/B NFIB 874 224 -3.9
204162_at kinetochore associated 2 KNTC2 160 53 -3.0
204573_at carnitine O-octanoyltransferase CROT 334 113 -2.9
219336_s_at activating signal cointegrator 1 complex subunit 1 ASCC1 309 110 -2.8
214829_at aminoadipate-semialdehyde synthase AASS 193 69 -2.8
218179_s_at FLJ12716 protein FLJ12716 274 100 -2.7
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4
Fold change
–Control/LTD4
207891_s_at three prime repair exonuclease 2 TREX2 180 66 -2.7
220813_at cysteinyl leukotriene receptor 2 CYSLTR2 624 231 -2.7
204833_at ATG12 autophagy related 12 homolog (S. cerevisiae) ATG12 162 61 -2.7
204535_s_at RE1-silencing transcription factor REST 226 96 -2.4
222278_at hypothetical LOC389393 LOC389393 309 133 -2.3
213264_at Poly(rC) binding protein 2 PCBP2 288 127 -2.3
219805_at hypothetical protein FLJ22965 FLJ22965 152 69 -2.2
209821_at chromosome 9 open reading frame 26 (NF-HEV) C9orf26 767 352 -2.2
214787_at c-myc promoter binding protein MYCPBP 234 108 -2.2
207361_at HMG-box transcription factor 1 HBP1 163 76 -2.1
47560_at latrophilin 1 LPHN1 687 324 -2.1
219383_at hypothetical protein FLJ14213 FLJ14213 171 81 -2.1
204098_at RNA binding motif protein, X-linked 2 RBMX2 421 202 -2.1
211241_at annexin A2 pseudogene 3 ANXA2P3 389 187 -2.1
220732_at DEP domain containing 2 DEPDC2 254 123 -2.1
218643_s_at postsynaptic protein CRIPT CRIPT 155 75 -2.1
207542_s_at aquaporin 1 (channel-forming integral protein, 28kDa) AQP1 4729 2345 -2.0
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Table 11. Probe sets up-regulated (A) or down-regulated (B) >2-fold by LTD4 at 24 h.  Data were filtered according to the following 
criteria: detection p-value <0.065 and signal value >150 in either the control or the stimulated group; fold change >2.0. Results of one 
experiment are shown. n.a.: not annotated
A) Probe sets up-regulated >2-fold by LTD4 at 24 h
Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4
Fold change 
LTD4/Control
206942_s_at pro-melanin-concentrating hormone PMCH 100 650 6.5
214617_at perforin 1 (pore forming protein) PRF1 27 153 5.7
210615_at neuropilin 1 NRP1 44 184 4.2
204197_s_at runt-related transcription factor 3 RUNX3 47 193 4.1
207191_s_at immunoglobulin superfamily containing leucine-rich repeat ISLR 53 210 3.9
210809_s_at periostin, osteoblast specific factor POSTN 114 427 3.7
204340_at chromosome X open reading frame 12 CXorf12 74 264 3.6
202921_s_at ankyrin 2, neuronal ANK2 76 239 3.2
208266_at chromosome 8 open reading frame 17 C8orf17 50 157 3.1
202291_s_at matrix Gla protein MGP 3100 9590 3.1
214880_x_at caldesmon 1 CALD1 177 543 3.1
215057_at CDNA FLJ44451 fis, clone UTERU2023039 58 170 2.9
218444_at asparagine-linked glycosylation 12 homolog (yeast, alpha-
1,6-mannosyltransferase)
ALG12 75 215 2.9
219503_s_at transmembrane protein 40 TMEM40 84 233 2.8
204116_at interleukin 2 receptor, gamma (severe combined 
immunodeficiency)
IL2RG 136 373 2.7
213622_at collagen, type IX, alpha 2 COL9A2 62 168 2.7
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4
Fold change 
LTD4/Control
214529_at thyroid stimulating hormone, beta TSHB 107 280 2.6
201860_s_at plasminogen activator, tissue PLAT 153 395 2.6
208138_at gastrin GAST 92 236 2.6
206734_at jerky homolog-like (mouse) JRKL 155 394 2.5
208246_x_at Thymidine kinase 2, mitochondrial TK2 206 522 2.5
208588_at apoptosis inhibitor FKSG2 87 220 2.5
60794_f_at zinc finger protein 587 ZNF587 66 162 2.4
202500_at DnaJ (Hsp40) homolog, subfamily B, member 2 DNAJB2 90 217 2.4
213605_s_at Glucuronidase, beta-like 1 C6orf216 102 247 2.4
206167_s_at Rho GTPase activating protein 6 ARHGAP6 80 193 2.4
201242_s_at ATPase, Na+/K+ transporting, beta 1 polypeptide ATP1B1 130 302 2.3
202774_s_at splicing factor, arginine/serine-rich 8 (suppressor-of-white-
apricot homolog, Drosophila)
SFRS8 362 801 2.2
203213_at Cell division cycle 2, G1 to S and G2 to M CDC2 282 623 2.2
213873_at n.a. 80 176 2.2
202995_s_at fibulin 1 FBLN1 80 174 2.2
220558_x_at tetraspanin 32 TSPAN32 115 250 2.2
205939_at cytochrome P450, family 3, subfamily A, polypeptide 7 CYP3A7 91 199 2.2
214033_at ATP-binding cassette, sub-family C (CFTR/MRP), member 
6
ABCC6 70 152 2.2
208617_s_at protein tyrosine phosphatase type IVA, member 2 PTP4A2 1047 2273 2.2
207591_s_at AT rich interactive domain 1A (SWI- like) ARID1A 77 165 2.1
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4
Fold change 
LTD4/Control
214057_at Myeloid cell leukemia sequence 1 (BCL2-related) MCL1 92 195 2.1
204081_at neurogranin (protein kinase C substrate, RC3) NRGN 238 503 2.1
211892_s_at prostaglandin I2 (prostacyclin) synthase PTGIS 85 178 2.1
211685_s_at neurocalcin delta NCALD 79 167 2.1
218712_at chromosome 1 open reading frame 109 C1orf109 78 163 2.1
207152_at neurotrophic tyrosine kinase, receptor, type 2 NTRK2 169 354 2.1
222155_s_at G protein-coupled receptor 172A GPR172A 162 338 2.1
214379_at BMX non-receptor tyrosine kinase BMX 82 171 2.1
213654_at TAF5-like RNA polymerase II, p300/CBP-associated factor 
(PCAF)-associated factor, 65kDa
TAF5L 322 668 2.1
219102_at reticulocalbin 3, EF-hand calcium binding domain RCN3 142 295 2.1
213976_at CDKN1A interacting zinc finger protein 1 CIZ1 85 175 2.1
208370_s_at Down syndrome critical region gene 1 DSCR1 358 740 2.1
210564_x_at CASP8 and FADD-like apoptosis regulator CFLAR 361 747 2.1
209176_at SEC23 interacting protein SEC23IP 142 294 2.1
209642_at BUB1 budding uninhibited by benzimidazoles 1 homolog 
(yeast)
BUB1 101 208 2.1
204887_s_at polo-like kinase 4 (Drosophila) PLK4 123 252 2.1
209172_s_at centromere protein F, 350/400ka (mitosin) CENPF 95 193 2.0
210484_s_at tumor necrosis factor receptor superfamily, member 10c, 
decoy without an intracellular domain 
TNFRSF10
C 
158 322 2.0
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4
Fold change 
LTD4/Control
216490_x_at similar to dJ408B20.3 (novel protein similar to 60S acidic 
ribosomal protein P2 (RPLP2))
LOC442175 76 155 2.0
214519_s_at relaxin 2 RLN2 78 158 2.0
218746_at TAP binding protein-like TAPBPL 98 198 2.0
213215_at MRNA full length insert cDNA clone EUROIMAGE 42138 192 387 2.0
204918_s_at myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 3
MLLT3 82 164 2.0
B) Probe sets down-regulated >2-fold by LTD4 at 24 h
Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4
Fold change
–Control/LTD4
221586_s_at E2F transcription factor 5, p130-binding E2F5 279 31 -8.9
217588_at cation channel, sperm associated 2 CATSPER2 174 31 -5.7
219077_s_at WW domain containing oxidoreductase WWOX 312 57 -5.5
219661_at RAN binding protein 17 RANBP17 255 89 -2.9
216514_at n.a. 191 67 -2.8
201396_s_at small glutamine-rich tetratricopeptide repeat (TPR)-
containing, alpha
SGTA 182 67 -2.7
204349_at cofactor required for Sp1 transcriptional activation, subunit 
9, 33kDa
CRSP9 152 56 -2.7
214314_s_at eukaryotic translation initiation factor 5B EIF5B 158 60 -2.6
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control LTD4
Fold change
–Control/LTD4
216882_s_at nebulette NEBL 210 83 -2.5
207831_x_at deoxyhypusine synthase DHPS 177 75 -2.4
213074_at Interleukin-1 receptor-associated kinase 1 binding protein 1 IRAK1BP1 675 288 -2.3
215825_at Clone 24487 mRNA sequence 236 103 -2.3
212475_at KIAA0241 protein KIAA0241 254 112 -2.3
203098_at chromodomain protein, Y-like CDYL 495 220 -2.3
202432_at protein phosphatase 3 (formerly 2B), catalytic subunit, beta 
isoform (calcineurin A beta)
PPP3CB 602 268 -2.2
218569_s_at kelch repeat and BTB (POZ) domain containing 4 KBTBD4 211 103 -2.0
205887_x_at mutS homolog 3 (E. coli) MSH3 182 89 -2.0
212060_at U2-associated SR140 protein SR140 269 132 -2.0
209469_at glycoprotein M6A GPM6A 161 80 -2.0
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Table 12. Probe sets up-regulated (A) or down-regulated (B) >2-fold by thrombin at 6 h. Data were filtered according to the following 
criteria: detection p-value <0.065 and signal value >150 in either the control or the stimulated group; fold change >2.0. Results of one 
experiment are shown. n.a.: not annotated
A) Probe sets up-regulated >2-fold by thrombin at 6 h
Affymetrix 
probe set ID
Gene title Gene symbol Control Thrombin
Fold change 
Thrombin/Control
214446_at elongation factor, RNA polymerase II, 2 ELL2 21 177 8.6
204222_s_at GLI pathogenesis-related 1 (glioma) GLIPR1 47 356 7.5
206211_at selectin E (endothelial adhesion molecule 1) SELE 47 339 7.2
202859_x_at interleukin 8 IL8 164 1119 6.8
203836_s_at mitogen-activated protein kinase kinase kinase 5 MAP3K5 46 245 5.4
203868_s_at vascular cell adhesion molecule 1 VCAM1 80 333 4.2
210764_s_at cysteine-rich, angiogenic inducer, 61 CYR61 1119 4382 3.9
204748_at prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase)
PTGS2 84 324 3.9
202627_s_at serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1
SERPINE1 3515 13468 3.8
201242_s_at ATPase, Na+/K+ transporting, beta 1 polypeptide ATP1B1 245 917 3.7
202638_s_at intercellular adhesion molecule 1 (CD54), human rhinovirus 
receptor
ICAM1 251 913 3.6
211506_s_at interleukin 8 IL8 127 406 3.2
203666_at chemokine (C-X-C motif) ligand 12 (stromal cell-derived 
factor 1)
CXCL12 248 791 3.2 A
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Affymetrix 
probe set ID
Gene title Gene symbol Control Thrombin
Fold change 
Thrombin/Control
202637_s_at intercellular adhesion molecule 1 (CD54), human rhinovirus 
receptor
ICAM1 355 1114 3.1
210939_s_at glutamate receptor, metabotropic 1 GRM1 60 186 3.1
201243_s_at ATPase, Na+/K+ transporting, beta 1 polypeptide ATP1B1 325 972 3.0
214844_s_at docking protein 5 DOK5 381 1134 3.0
221085_at tumor necrosis factor (ligand) superfamily, member 15 TNFSF15 97 282 2.9
219973_at arylsulfatase J ARSJ 82 236 2.9
220116_at potassium intermediate/small conductance calcium-activated 
channel, subfamily N, member 2
KCNN2 141 399 2.8
213338_at Ras-induced senescence 1 RIS1 82 231 2.8
201289_at cysteine-rich, angiogenic inducer, 61 CYR61 1787 4906 2.7
213853_at zinc finger, CSL-type containing 3 ZCSL3 229 623 2.7
205599_at TNF receptor-associated factor 1 TRAF1 84 225 2.7
209373_at mal, T-cell differentiation protein-like MALL 699 1859 2.7
215495_s_at sterile alpha motif domain containing 4 SAMD4 67 178 2.7
202628_s_at serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1
SERPINE1 3762 9813 2.6
205680_at matrix metallopeptidase 10 (stromelysin 2) MMP10 359 933 2.6
205463_s_at platelet-derived growth factor alpha polypeptide PDGFA 311 806 2.6
210593_at spermidine/spermine N1-acetyltransferase SAT 63 162 2.6
216598_s_at chemokine (C-C motif) ligand 2 CCL2 1267 3139 2.5
207665_at ADAM metallopeptidase domain 21 ADAM21 95 236 2.5
A
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probe set ID
Gene title Gene symbol Control Thrombin
Fold change 
Thrombin/Control
206157_at pentraxin-related gene, rapidly induced by IL-1 beta PTX3 764 1877 2.5
213093_at protein kinase C, alpha PRKCA 102 248 2.4
215223_s_at superoxide dismutase 2, mitochondrial SOD2 317 755 2.4
218498_s_at ERO1-like (S. cerevisiae) ERO1L 166 391 2.3
213629_x_at metallothionein 1F (functional) MT1F 164 383 2.3
216256_at glutamate receptor, metabotropic 8 GRM8 88 204 2.3
208394_x_at endothelial cell-specific molecule 1 ESM1 366 850 2.3
205132_at actin, alpha, cardiac muscle ACTC 119 276 2.3
211124_s_at KIT ligand KITLG 204 470 2.3
217477_at phosphatidylinositol-4-phosphate 5-kinase, type I, beta PIP5K1B 68 156 2.3
209598_at paraneoplastic antigen MA2 PNMA2 212 488 2.3
209372_x_at tubulin, beta 2 TUBB2 118 272 2.3
218330_s_at neuron navigator 2 NAV2 286 656 2.3
218368_s_at tumor necrosis factor receptor superfamily, member 12A TNFRSF12A 433 990 2.3
206116_s_at tropomyosin 1 (alpha) TPM1 692 1580 2.3
203023_at hypothetical protein HSPC111 HSPC111 97 221 2.3
203999_at synaptotagmin I SYT1 170 386 2.3
207526_s_at interleukin 1 receptor-like 1 IL1RL1 129 289 2.2
207536_s_at tumor necrosis factor receptor superfamily, member 9 TNFRSF9 80 179 2.2
218414_s_at nudE nuclear distribution gene E homolog 1 (A. nidulans) NDE1 132 295 2.2
201246_s_at OTU domain, ubiquitin aldehyde binding 1 OTUB1 124 277 2.2
A
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Thrombin/Control
216733_s_at glycine amidinotransferase (L-arginine:glycine 
amidinotransferase)
GATM 68 151 2.2
216855_s_at heterogeneous nuclear ribonucleoprotein U (scaffold 
attachment factor A)
HNRPU 236 519 2.2
214085_x_at GLI pathogenesis-related 1 (glioma) GLIPR1 161 353 2.2
204475_at matrix metallopeptidase 1 (interstitial collagenase) MMP1 374 811 2.2
204135_at downregulated in ovarian cancer 1 DOC1 651 1411 2.2
214173_x_at chromosome 19 open reading frame 2 C19orf2 390 840 2.2
208960_s_at Kruppel-like factor 6 KLF6 1048 2251 2.1
210524_x_at n.a. 144 307 2.1
205305_at fibrinogen-like 1 FGL1 115 245 2.1
206096_at zinc finger protein 35 (clone HF.10) ZNF35 163 346 2.1
205572_at angiopoietin 2 ANGPT2 1803 3822 2.1
204200_s_at platelet-derived growth factor beta polypeptide (simian 
sarcoma viral (v-sis) oncogene homolog)
PDGFB 366 772 2.1
205232_s_at platelet-activating factor acetylhydrolase 2, 40kDa PAFAH2 98 206 2.1
201995_at exostoses (multiple) 1 EXT1 690 1452 2.1
214482_at zinc finger and BTB domain containing 25 ZBTB25 81 170 2.1
201012_at annexin A1 ANXA1 3778 7902 2.1
201058_s_at myosin, light polypeptide 9, regulatory MYL9 254 530 2.1
220542_s_at palate, lung and nasal epithelium carcinoma associated PLUNC 128 266 2.1
210723_x_at hypothetical protein MGC4771 MGC4771 75 156 2.1
A
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Gene title Gene symbol Control Thrombin
Fold change 
Thrombin/Control
221443_x_at prolactin releasing hormone PRLH 101 208 2.1
209305_s_at growth arrest and DNA-damage-inducible, beta GADD45B 124 254 2.0
209508_x_at CASP8 and FADD-like apoptosis regulator CFLAR 378 770 2.0
211456_x_at Similar to 60S ribosomal protein L35 RPL35 561 1140 2.0
823_at chemokine (C-X3-C motif) ligand 1 CX3CL1 147 300 2.0
217579_x_at ADP-ribosylation factor-like 6 interacting protein 2 ARL6IP2 212 430 2.0
B) Probe sets down-regulated >2-fold by thrombin at 6 h
Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control Thrombin
Fold change
–Control/Thrombin
214613_at G protein-coupled receptor 3 GPR3 161 30 -5.5
87100_at Abhydrolase domain containing 2 ABHD2 203 52 -3.9
222278_at hypothetical LOC389393 LOC389393 309 81 -3.8
205020_s_at ADP-ribosylation factor-like 4 ARL4 2083 557 -3.7
207542_s_at aquaporin 1 (channel-forming integral protein, 28kDa) AQP1 4729 1273 -3.7
203505_at ATP-binding cassette, sub-family A (ABC1), member 1 ABCA1 244 68 -3.6
209821_at chromosome 9 open reading frame 26 (NF-HEV) C9orf26 767 235 -3.3
202661_at inositol 1,4,5-triphosphate receptor, type 2 ITPR2 330 108 -3.1
210379_s_at tousled-like kinase 1 TLK1 166 55 -3.0
222344_at Chromosome 5 open reading frame 13 C5orf13 345 116 -3.0
209047_at aquaporin 1 (channel-forming integral protein, 28kDa) AQP1 4709 1583 -3.0
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41660_at cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo 
homolog, Drosophila)
CELSR1 163 56 -2.9
211466_at nuclear factor I/B NFIB 246 88 -2.8
201291_s_at topoisomerase (DNA) II alpha 170kDa TOP2A 176 63 -2.8
204015_s_at dual specificity phosphatase 4 DUSP4 350 125 -2.8
221735_at WD repeat domain 48 WDR48 489 179 -2.7
214787_at c-myc promoter binding protein MYCPBP 234 87 -2.7
212789_at KIAA0056 protein hCAP-D3 217 82 -2.7
205174_s_at glutaminyl-peptide cyclotransferase (glutaminyl cyclase) QPCT 217 84 -2.6
209160_at aldo-keto reductase family 1, member C3 (3-alpha 
hydroxysteroid dehydrogenase, type II)
AKR1C3 233 91 -2.6
220735_s_at SUMO1/sentrin specific peptidase 7 SENP7 230 89 -2.6
207761_s_at DKFZP586A0522 protein DKFZP586A
0522
663 260 -2.5
211789_s_at MondoA MONDOA 280 110 -2.5
209898_x_at intersectin 2 ITSN2 738 290 -2.5
209735_at ATP-binding cassette, sub-family G (WHITE), member 2 ABCG2 3051 1207 -2.5
206950_at sodium channel, voltage-gated, type IX, alpha SCN9A 338 136 -2.5
218918_at mannosidase, alpha, class 1C, member 1 MAN1C1 1881 756 -2.5
214881_s_at upstream binding transcription factor, RNA polymerase I UBTF 213 86 -2.5
201767_s_at elaC homolog 2 (E. coli) ELAC2 206 84 -2.4
208935_s_at lectin, galactoside-binding, soluble, 8 (galectin 8) LGALS8 330 137 -2.4
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Gene 
symbol
Control Thrombin
Fold change
–Control/Thrombin
214717_at hypothetical protein DKFZp434H1419 DKFZp434H
1419
268 113 -2.4
209642_at BUB1 budding uninhibited by benzimidazoles 1 homolog 
(yeast)
BUB1 204 86 -2.4
202660_at Family with sequence similarity 20, member C ITPR2 485 204 -2.4
204162_at kinetochore associated 2 KNTC2 160 67 -2.4
202437_s_at cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 357 152 -2.4
212418_at E74-like factor 1 (ets domain transcription factor) ELF1 514 220 -2.3
217703_x_at Spondin 1, extracellular matrix protein SPON1 785 339 -2.3
204071_s_at topoisomerase I binding, arginine/serine-rich TOPORS 298 130 -2.3
222145_at hypothetical protein LOC440345 LOC440345 219 96 -2.3
206363_at v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
(avian)
MAF 457 200 -2.3
205805_s_at receptor tyrosine kinase-like orphan receptor 1 ROR1 297 131 -2.3
205749_at cytochrome P450, family 1, subfamily A, polypeptide 1 CYP1A1 607 269 -2.3
202497_x_at solute carrier family 2 (facilitated glucose transporter), 
member 3
SLC2A3 808 358 -2.3
205211_s_at Ras and Rab interactor 1 RIN1 252 112 -2.3
210202_s_at bridging integrator 1 BIN1 463 208 -2.2
214620_x_at peptidylglycine alpha-amidating monooxygenase PAM 1795 806 -2.2
212019_at ribosomal L1 domain containing 1 RSL1D1 192 87 -2.2
218988_at solute carrier family 35, member E3 SLC35E3 316 143 -2.2
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Gene 
symbol
Control Thrombin
Fold change
–Control/Thrombin
219166_at chromosome 14 open reading frame 104 C14orf104 270 123 -2.2
213033_s_at Nuclear factor I/B NFIB 874 402 -2.2
37549_g_at parathyroid hormone-responsive B1 PTHB1 279 129 -2.2
205961_s_at PC4 and SFRS1 interacting protein 1 PSIP1 639 297 -2.2
221820_s_at MYST histone acetyltransferase 1 MYST1 196 91 -2.2
215028_at sema domain, transmembrane domain (TM), and cytoplasmic 
domain, (semaphorin) 6A
SEMA6A 211 98 -2.1
35179_at beta-1,3-glucuronyltransferase 3 (glucuronosyltransferase I) B3GAT3 194 91 -2.1
215447_at n.a. 789 371 -2.1
218452_at SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a-like 1
SMARCAL1 209 98 -2.1
221031_s_at hypothetical protein DKFZp434F0318 DKFZP434F0
318
1067 502 -2.1
201309_x_at chromosome 5 open reading frame 13 C5orf13 3106 1464 -2.1
219181_at lipase, endothelial LIPG 492 232 -2.1
204364_s_at chromosome 2 open reading frame 23 C2orf23 640 303 -2.1
218585_s_at denticleless homolog (Drosophila) DTL 271 130 -2.1
202498_s_at solute carrier family 2 (facilitated glucose transporter), 
member 3
SLC2A3 189 90 -2.1
213894_at KIAA0960 protein KIAA0960 1049 502 -2.1
202499_s_at solute carrier family 2 (facilitated glucose transporter), 
member 3
SLC2A3 336 161 -2.1
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40687_at gap junction protein, alpha 4, 37kDa (connexin 37) GJA4 1148 551 -2.1
209936_at RNA binding motif protein 5 RBM5 246 118 -2.1
203126_at inositol(myo)-1(or 4)-monophosphatase 2 IMPA2 157 76 -2.1
212981_s_at KIAA0738 gene product KIAA0738 181 88 -2.1
201411_s_at pleckstrin homology domain containing, family B (evectins) 
member 2
PLEKHB2 515 249 -2.1
205501_at CDNA FLJ25677 fis, clone TST04054 197 96 -2.1
213146_at jumonji domain containing 3 JMJD3 257 125 -2.1
208776_at proteasome (prosome, macropain) 26S subunit, non-ATPase, 
11
PSMD11 272 133 -2.1
205811_at polymerase (DNA directed), gamma 2, accessory subunit POLG2 210 103 -2.0
215248_at growth factor receptor-bound protein 10 GRB10 538 263 -2.0
212192_at potassium channel tetramerisation domain containing 12 KCTD12 4208 2067 -2.0
204681_s_at Rap guanine nucleotide exchange factor (GEF) 5 RAPGEF5 3047 1505 -2.0
221196_x_at chromosome X open reading frame 53 CXorf53 434 214 -2.0
202783_at nicotinamide nucleotide transhydrogenase NNT 696 344 -2.0
217527_s_at nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 2 interacting protein
NFATC2IP 729 361 -2.0
205960_at pyruvate dehydrogenase kinase, isoenzyme 4 PDK4 445 221 -2.0
208763_s_at TSC22 domain family, member 3 TSC22D3 1015 503 -2.0
219336_s_at activating signal cointegrator 1 complex subunit 1 ASCC1 309 153 -2.0
209513_s_at hydroxysteroid dehydrogenase like 2 HSDL2 259 128 -2.0
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203749_s_at retinoic acid receptor, alpha RARA 475 236 -2.0
204759_at regulator of chromosome condensation (RCC1) and BTB 
(POZ) domain containing protein 2
RCBTB2 646 321 -2.0
212366_at zinc finger protein 292 ZNF292 205 102 -2.0
205581_s_at nitric oxide synthase 3 (endothelial cell) NOS3 423 211 -2.0
208415_x_at inhibitor of growth family, member 1 ING1 518 258 -2.0
205529_s_at runt-related transcription factor 1; translocated to, 1 (cyclin 
D-related)
RUNX1T1 412 206 -2.0
204290_s_at aldehyde dehydrogenase 6 family, member A1 ALDH6A1 640 319 -2.0
213463_s_at KIAA0974 KIAA0974 210 105 -2.0
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Table 13. Probe sets up-regulated (A) or down-regulated (B) >2-fold by thrombin at 24 h. Data were filtered according to the following 
criteria: detection p-value <0.065 and signal value >150 in either the control or the stimulated group; fold change >2.0. Results of one 
experiment are shown. n.a.: not annotated.
A) Probes sets up-regulated >2-fold by thrombin at 24 h
Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control Thrombin
Fold change
Thrombin/Control
206942_s_at pro-melanin-concentrating hormone PMCH 100 1066 10.7
210628_x_at latent transforming growth factor beta binding protein 4 LTBP4 25 196 7.7
201242_s_at ATPase, Na+/K+ transporting, beta 1 polypeptide ATP1B1 130 642 4.9
220116_at potassium intermediate/small conductance calcium-activated 
channel, subfamily N, member 2
KCNN2 118 537 4.5
206775_at cubilin (intrinsic factor-cobalamin receptor) CUBN 66 290 4.4
205260_s_at acylphosphatase 1, erythrocyte (common) type ACYP1 45 191 4.2
204222_s_at GLI pathogenesis-related 1 (glioma) GLIPR1 49 201 4.1
204726_at cadherin 13, H-cadherin (heart) CDH13 134 529 4.0
211177_s_at thioredoxin reductase 2 TXNRD2 151 588 3.9
201058_s_at myosin, light polypeptide 9, regulatory MYL9 141 543 3.8
204748_at prostaglandin-endoperoxide synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase)
PTGS2 52 192 3.7
202859_x_at interleukin 8 IL8 224 818 3.6
202291_s_at matrix Gla protein MGP 3100 11265 3.6
205659_at histone deacetylase 9 HDAC9 108 380 3.5
206211_at selectin E (endothelial adhesion molecule 1) SELE 75 264 3.5
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214085_x_at GLI pathogenesis-related 1 (glioma) GLIPR1 129 437 3.4
208581_x_at metallothionein 1X MT1X 387 1311 3.4
203213_at Cell division cycle 2, G1 to S and G2 to M CDC2 282 907 3.2
202627_s_at serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1
SERPINE1 3705 11860 3.2
204340_at chromosome X open reading frame 12 CXorf12 74 238 3.2
210764_s_at cysteine-rich, angiogenic inducer, 61 CYR61 1209 3781 3.1
222155_s_at G protein-coupled receptor 172A GPR172A 162 507 3.1
208394_x_at endothelial cell-specific molecule 1 ESM1 441 1348 3.1
217165_x_at metallothionein 1F (functional) MT1F 186 542 2.9
209373_at mal, T-cell differentiation protein-like MALL 562 1626 2.9
204887_s_at polo-like kinase 4 (Drosophila) PLK4 123 343 2.8
209277_at Tissue factor pathway inhibitor 2 TFPI2 842 2316 2.8
208138_at gastrin GAST 92 254 2.8
210484_s_at tumor necrosis factor receptor superfamily, member 10c, 
decoy without an intracellular domain 
TNFRSF10C 158 426 2.7
60794_f_at zinc finger protein 587 ZNF587 66 176 2.7
221521_s_at DNA replication complex GINS protein PSF2 Pfs2 89 237 2.7
201291_s_at topoisomerase (DNA) II alpha 170kDa TOP2A 140 368 2.6
219555_s_at uncharacterized bone marrow protein BM039 BM039 93 243 2.6
202269_x_at guanylate binding protein 1, interferon-inducible, 67kDa GBP1 69 180 2.6
218368_s_at tumor necrosis factor receptor superfamily, member 12A TNFRSF12A 312 800 2.6
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203917_at coxsackie virus and adenovirus receptor CXADR 154 395 2.6
201289_at cysteine-rich, angiogenic inducer, 61 CYR61 1843 4699 2.6
204822_at TTK protein kinase TTK 83 212 2.5
203821_at heparin-binding EGF-like growth factor HBEGF 311 784 2.5
203362_s_at MAD2 mitotic arrest deficient-like 1 (yeast) MAD2L1 185 466 2.5
222266_at Chromosome 19 open reading frame 2 C19orf2 64 155 2.4
202628_s_at serpin peptidase inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1
SERPINE1 4033 9765 2.4
221059_s_at coactosin-like 1 (Dictyostelium) COTL1 305 736 2.4
222206_s_at nicalin homolog (zebrafish) NCLN 77 184 2.4
209642_at BUB1 budding uninhibited by benzimidazoles 1 homolog 
(yeast)
BUB1 101 239 2.4
215445_x_at Clone 23605 mRNA sequence 71 166 2.4
201890_at ribonucleotide reductase M2 polypeptide RRM2 355 831 2.3
218663_at chromosome condensation protein G HCAP-G 127 295 2.3
218782_s_at ATPase family, AAA domain containing 2 ATAD2 143 329 2.3
203868_s_at vascular cell adhesion molecule 1 VCAM1 119 273 2.3
218992_at chromosome 9 open reading frame 46 C9orf46 142 326 2.3
210457_x_at high mobility group AT-hook 1 HMGA1 336 768 2.3
219918_s_at asp (abnormal spindle)-like, microcephaly associated 
(Drosophila)
ASPM 194 445 2.3
204162_at kinetochore associated 2 KNTC2 112 256 2.3
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221723_s_at solute carrier family 4, sodium bicarbonate cotransporter, 
member 5
SLC4A5 92 209 2.3
214734_at exophilin 5 EXPH5 95 216 2.3
201243_s_at ATPase, Na+/K+ transporting, beta 1 polypeptide ATP1B1 380 859 2.3
211148_s_at angiopoietin 2 ANGPT2 2719 6068 2.2
219978_s_at nucleolar and spindle associated protein 1 NUSAP1 198 439 2.2
213454_at apoptosis-inducing, TAF9-like domain 1 APITD1 108 239 2.2
206429_at coagulation factor II (thrombin) receptor-like 1 F2RL1 192 426 2.2
210559_s_at cell division cycle 2, G1 to S and G2 to M CDC2 574 1267 2.2
212185_x_at metallothionein 2A MT2A 1692 3727 2.2
209891_at spindle pole body component 25 homolog (S. cerevisiae) SPBC25 84 185 2.2
205680_at matrix metallopeptidase 10 (stromelysin 2) MMP10 547 1201 2.2
206566_at solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 1
SLC7A1 116 254 2.2
204159_at cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) CDKN2C 87 190 2.2
219582_at opioid growth factor receptor-like 1 OGFRL1 233 507 2.2
217998_at pleckstrin homology-like domain, family A, member 1 PHLDA1 565 1228 2.2
222037_at MCM4 minichromosome maintenance deficient 4 (S. 
cerevisiae)
MCM4 108 234 2.2
218935_at EH-domain containing 3 EHD3 469 1016 2.2
213506_at coagulation factor II (thrombin) receptor-like 1 F2RL1 189 408 2.2
211506_s_at interleukin 8 IL8 169 364 2.2
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211163_s_at tumor necrosis factor receptor superfamily, member 10c, 
decoy without an intracellular domain
TNFRSF10C 421 907 2.2
214126_at Mitochondrial carrier triple repeat 1 MCART1 71 151 2.1
211685_s_at neurocalcin delta NCALD 79 168 2.1
202496_at autoantigen RCD-8 204 434 2.1
211456_x_at Similar to 60S ribosomal protein L35 RPL35 1038 2200 2.1
222036_s_at MCM4 minichromosome maintenance deficient 4 (S. 
cerevisiae)
MCM4 279 590 2.1
201431_s_at dihydropyrimidinase-like 3 DPYSL3 595 1256 2.1
48808_at dihydrofolate reductase DHFR 185 390 2.1
218542_at chromosome 10 open reading frame 3 C10orf3 249 524 2.1
200629_at tryptophanyl-tRNA synthetase WARS 1722 3626 2.1
214040_s_at gelsolin (amyloidosis, Finnish type) GSN 406 852 2.1
32069_at Nedd4 binding protein 1 N4BP1 139 291 2.1
204200_s_at platelet-derived growth factor beta polypeptide (simian 
sarcoma viral (v-sis) oncogene homolog)
PDGFB 454 951 2.1
204146_at RAD51 associated protein 1 RAD51AP1 74 154 2.1
210145_at phospholipase A2, group IVA (cytosolic, calcium-dependent) PLA2G4A 273 567 2.1
210052_s_at TPX2, microtubule-associated, homolog (Xenopus laevis) TPX2 512 1062 2.1
202422_s_at acyl-CoA synthetase long-chain family member 4 ACSL4 218 452 2.1
205572_at angiopoietin 2 ANGPT2 2255 4656 2.1
203235_at thimet oligopeptidase 1 THOP1 91 187 2.1
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205973_at fasciculation and elongation protein zeta 1 (zygin I) FEZ1 161 330 2.1
210298_x_at four and a half LIM domains 1 FHL1 868 1775 2.0
218887_at mitochondrial ribosomal protein L2 MRPL2 251 509 2.0
209369_at annexin A3 ANXA3 407 825 2.0
210517_s_at A kinase (PRKA) anchor protein (gravin) 12 AKAP12 4040 8127 2.0
B) Probe sets down-regulated >2-fold by thrombin at 24 h
Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control Thrombin
Fold change
–Control/Thrombin
217588_at cation channel, sperm associated 2 CATSPER2 174 17 -10.0
207542_s_at aquaporin 1 (channel-forming integral protein, 28kDa) AQP1 4492 778 -5.8
209047_at aquaporin 1 (channel-forming integral protein, 28kDa) AQP1 4757 975 -4.9
222278_at hypothetical LOC389393 LOC389393 272 71 -3.8
221735_at WD repeat domain 48 WDR48 459 123 -3.7
219935_at ADAM metallopeptidase with thrombospondin type 1 motif, 
5 (aggrecanase-2)
ADAMTS5 606 165 -3.7
202437_s_at cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 349 96 -3.6
209469_at glycoprotein M6A GPM6A 161 47 -3.4
207735_at ring finger protein 125 RNF125 172 52 -3.3
221031_s_at hypothetical protein DKFZp434F0318 DKFZP434F0
318
1261 380 -3.3
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–Control/Thrombin
205020_s_at ADP-ribosylation factor-like 4 ARL4 1882 583 -3.2
209470_s_at glycoprotein M6A GPM6A 236 76 -3.1
210025_s_at caspase recruitment domain family, member 10 CARD10 156 53 -3.0
202478_at tribbles homolog 2 (Drosophila) TRIB2 689 238 -2.9
202661_at inositol 1,4,5-triphosphate receptor, type 2 ITPR2 353 123 -2.9
206638_at 5-hydroxytryptamine (serotonin) receptor 2B HTR2B 459 162 -2.8
203973_s_at CCAAT/enhancer binding protein (C/EBP), delta CEBPD 440 158 -2.8
204596_s_at stanniocalcin 1 STC1 1228 443 -2.8
205749_at cytochrome P450, family 1, subfamily A, polypeptide 1 CYP1A1 603 218 -2.8
218918_at mannosidase, alpha, class 1C, member 1 MAN1C1 2194 796 -2.8
204620_s_at chondroitin sulfate proteoglycan 2 (versican) CSPG2 408 149 -2.7
212188_at potassium channel tetramerisation domain containing 12 KCTD12 2793 1046 -2.7
211212_s_at origin recognition complex, subunit 5-like (yeast) ORC5L 194 74 -2.6
210665_at tissue factor pathway inhibitor (lipoprotein-associated 
coagulation inhibitor)
TFPI 1090 416 -2.6
221731_x_at chondroitin sulfate proteoglycan 2 (versican) CSPG2 421 161 -2.6
219371_s_at Kruppel-like factor 2 (lung) KLF2 807 312 -2.6
216882_s_at nebulette NEBL 210 82 -2.6
201309_x_at chromosome 5 open reading frame 13 C5orf13 3228 1259 -2.6
206950_at sodium channel, voltage-gated, type IX, alpha SCN9A 350 138 -2.5
209347_s_at v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
(avian)
MAF 247 99 -2.5
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control Thrombin
Fold change
–Control/Thrombin
214417_s_at Fetuin B FETUB 215 86 -2.5
209505_at Nuclear receptor subfamily 2, group F, member 1 NR2F1 309 124 -2.5
204595_s_at stanniocalcin 1 STC1 2407 986 -2.4
218559_s_at v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
B (avian)
MAFB 795 330 -2.4
221009_s_at angiopoietin-like 4 ANGPTL4 208 87 -2.4
208033_s_at AT-binding transcription factor 1 ATBF1 232 98 -2.4
214449_s_at ras homolog gene family, member Q RHOQ 215 91 -2.4
205392_s_at chemokine (C-C motif) ligand 14 CCL14 8409 3618 -2.3
218205_s_at MAP kinase interacting serine/threonine kinase 2 MKNK2 4176 1828 -2.3
204597_x_at stanniocalcin 1 STC1 2655 1172 -2.3
205346_at ST3 beta-galactoside alpha-2,3-sialyltransferase 2 ST3GAL2 165 74 -2.2
41660_at cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo 
homolog, Drosophila)
CELSR1 172 77 -2.2
212192_at potassium channel tetramerisation domain containing 12 KCTD12 4096 1829 -2.2
204681_s_at Rap guanine nucleotide exchange factor (GEF) 5 RAPGEF5 3628 1630 -2.2
209676_at tissue factor pathway inhibitor (lipoprotein-associated 
coagulation inhibitor)
TFPI 4254 1920 -2.2
201310_s_at chromosome 5 open reading frame 13 C5orf13 7513 3401 -2.2
206363_at v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
(avian)
MAF 454 206 -2.2
218819_at DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 26 DDX26 232 105 -2.2
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control Thrombin
Fold change
–Control/Thrombin
212419_at chromosome 10 open reading frame 56 C10orf56 960 437 -2.2
214156_at myosin VIIA and Rab interacting protein MYRIP 152 69 -2.2
219488_at alpha 1,4-galactosyltransferase (globotriaosylceramide 
synthase)
A4GALT 197 91 -2.2
203886_s_at fibulin 2 FBLN2 473 218 -2.2
216100_s_at torsin A interacting protein 1 TOR1AIP1 342 159 -2.2
209730_at sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3F
SEMA3F 440 204 -2.2
209105_at nuclear receptor coactivator 1 NCOA1 338 158 -2.1
202723_s_at forkhead box O1A (rhabdomyosarcoma) FOXO1A 1641 781 -2.1
204359_at fibronectin leucine rich transmembrane protein 2 FLRT2 3589 1709 -2.1
203225_s_at riboflavin kinase RFK 2516 1200 -2.1
219880_at n.a. n.a. 206 99 -2.1
204949_at intercellular adhesion molecule 3 ICAM3 192 92 -2.1
209821_at chromosome 9 open reading frame 26 (NF-HEV) C9orf26 584 281 -2.1
214035_x_at LOC399491 protein LOC399491 1794 864 -2.1
212224_at aldehyde dehydrogenase 1 family, member A1 ALDH1A1 4625 2242 -2.1
209348_s_at v-maf musculoaponeurotic fibrosarcoma oncogene homolog 
(avian)
MAF 997 483 -2.1
205960_at pyruvate dehydrogenase kinase, isoenzyme 4 PDK4 411 203 -2.0
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Affymetrix 
probe set ID
Gene title
Gene 
symbol
Control Thrombin
Fold change
–Control/Thrombin
203551_s_at COX11 homolog, cytochrome c oxidase assembly protein 
(yeast)
COX11 348 172 -2.0
213258_at Tissue factor pathway inhibitor (lipoprotein-associated 
coagulation inhibitor)
TFPI 7502 3723 -2.0
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Table 14. Probe sets up-regulated (A) or down-regulated (B) >2-fold by LTD4 plus thrombin at 1 h. Data were filtered according to the 
following criteria: detection p-value <0.065 at least in two of three samples in either the control or the stimulated group; signal value 
>150 at least in two of three samples in either the control or the stimulated group; fold change calculated from the signal means >2.0. 
Mean signals of three experiments are shown. n.a.: not annotated
A) Probe sets up-regulated >2-fold by LTD4 plus thrombin at 1 h
Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 + Thrombin
Fold change
Control/LTD4 + Thrombin
202768_at FBJ murine osteosarcoma viral oncogene 
homolog B
FOSB 27 5351 196.3
216248_s_at nuclear receptor subfamily 4, group A, member 2 NR4A2 52 6240 119.9
204621_s_at nuclear receptor subfamily 4, group A, member 2 NR4A2 28 3247 114.1
209189_at v-fos FBJ murine osteosarcoma viral oncogene 
homolog
FOS 23 2098 90.1
204622_x_at nuclear receptor subfamily 4, group A, member 2 NR4A2 93 5306 57.1
206115_at early growth response 3 EGR3 95 4178 44.0
202340_x_at nuclear receptor subfamily 4, group A, member 1 NR4A1 105 4232 40.2
209959_at nuclear receptor subfamily 4, group A, member 3 NR4A3 37 1454 38.5
202859_x_at interleukin 8 IL8 235 6052 25.7
210764_s_at cysteine-rich, angiogenic inducer, 61 CYR61 784 18409 23.5
204363_at coagulation factor III (thromboplastin, tissue 
factor)
F3 25 592 23.0
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Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 + Thrombin
Fold change
Control/LTD4 + Thrombin
204748_at prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase)
PTGS2 344 7043 20.5
201044_x_at dual specificity phosphatase 1 DUSP1 37 738 19.9
203821_at heparin-binding EGF-like growth factor HBEGF 273 5355 19.6
208370_s_at Down syndrome critical region gene 1 DSCR1 412 7836 19.0
202672_s_at Activating transcription factor 3 ATF3 283 5091 17.9
207978_s_at nuclear receptor subfamily 4, group A, member 3 NR4A3 111 1882 16.9
205249_at early growth response 2 (Krox-20 homolog, 
Drosophila)
EGR2 98 1634 16.5
201531_at zinc finger protein 36, C3H type, homolog 
(mouse)
ZFP36 286 4517 15.8
201289_at cysteine-rich, angiogenic inducer, 61 CYR61 919 12231 13.3
222162_s_at a disintegrin-like and metalloprotease (reprolysin 
type) with thrombospondin type 1 motif, 1
ADAMTS1 593 6967 11.7
211506_s_at interleukin 8 IL8 182 1982 10.9
209774_x_at chemokine (C-X-C motif) ligand 2 CXCL2 318 3235 10.2
38037_at heparin-binding EGF-like growth factor HBEGF 214 1988 9.3
208078_s_at SNF1-like kinase SNF1LK 377 3287 8.7
215254_at Down syndrome critical region gene 1 DSCR1 96 806 8.4
218541_s_at chromosome 8 open reading frame 4 C8orf4 129 1079 8.4
202861_at period homolog 1 (Drosophila) PER1 93 767 8.2
215253_s_at Down syndrome critical region gene 1 DSCR1 509 4158 8.2
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Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 + Thrombin
Fold change
Control/LTD4 + Thrombin
221841_s_at Kruppel-like factor 4 (gut) KLF4 484 3852 8.0
201041_s_at dual specificity phosphatase 1 DUSP1 1786 13186 7.4
221031_s_at hypothetical protein DKFZp434F0318 DKFZP434F0
318
549 3766 6.8
220266_s_at Kruppel-like factor 4 (gut) KLF4 227 1500 6.6
204222_s_at GLI pathogenesis-related 1 (glioma) GLIPR1 58 384 6.6
201694_s_at early growth response 1 EGR1 593 3606 6.1
205027_s_at mitogen-activated protein kinase kinase kinase 8 MAP3K8 32 186 5.7
200796_s_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 374 2112 5.6
200797_s_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 1950 10979 5.6
204472_at GTP binding protein overexpressed in skeletal 
muscle
GEM 176 989 5.6
204135_at downregulated in ovarian cancer 1 DOC1 539 2985 5.5
202150_s_at neural precursor cell expressed, developmentally 
down-regulated 9
NEDD9 571 2985 5.2
212614_at AT rich interactive domain 5B (MRF1-like) ARID5B 485 2507 5.2
202388_at regulator of G-protein signalling 2, 24kDa RGS2 424 2098 4.9
203068_at kelch-like 21 (Drosophila) KLHL21 113 556 4.9
218880_at FOS-like antigen 2 FOSL2 228 1110 4.9
209967_s_at cAMP responsive element modulator CREM 299 1426 4.8
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Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 + Thrombin
Fold change
Control/LTD4 + Thrombin
202149_at neural precursor cell expressed, developmentally 
down-regulated 9
NEDD9 532 2520 4.7
210511_s_at inhibin, beta A (activin A, activin AB alpha 
polypeptide)
INHBA 128 606 4.7
200798_x_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 1559 7289 4.7
215199_at caldesmon 1 CALD1 114 493 4.3
208960_s_at Kruppel-like factor 6 KLF6 810 3474 4.3
214438_at H2.0-like homeo box 1 (Drosophila) HLX1 516 2206 4.3
215198_s_at caldesmon 1 CALD1 146 615 4.2
214446_at elongation factor, RNA polymerase II, 2 ELL2 89 367 4.1
206765_at potassium inwardly-rectifying channel, subfamily 
J, member 2
KCNJ2 751 3076 4.1
209357_at Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 2
CITED2 309 1239 4.0
208961_s_at Kruppel-like factor 6 KLF6 1517 5769 3.8
201739_at serum/glucocorticoid regulated kinase SGK 1173 4388 3.7
204011_at sprouty homolog 2 (Drosophila) SPRY2 500 1846 3.7
208415_x_at inhibitor of growth family, member 1 ING1 168 620 3.7
201693_s_at early growth response 1 EGR1 287 1048 3.6
205290_s_at bone morphogenetic protein 2 BMP2 1299 4728 3.6
219371_s_at Kruppel-like factor 2 (lung) KLF2 1140 3996 3.5
213684_s_at PDZ and LIM domain 5 PDLIM5 45 157 3.5
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Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 + Thrombin
Fold change
Control/LTD4 + Thrombin
202270_at guanylate binding protein 1, interferon-inducible, 
67kDa 
GBP1 54 183 3.4
209101_at connective tissue growth factor CTGF 5002 16776 3.4
217996_at pleckstrin homology-like domain, family A, 
member 1
PHLDA1 744 2439 3.3
205289_at bone morphogenetic protein 2 BMP2 1063 3450 3.2
204470_at chemokine (C-X-C motif) ligand 1 (melanoma 
growth stimulating activity, alpha)
CXCL1 141 457 3.2
200632_s_at N-myc downstream regulated gene 1 NDRG1 1363 4367 3.2
205409_at FOS-like antigen 2 FOSL2 126 404 3.2
207980_s_at Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 2
CITED2 345 1100 3.2
201466_s_at v-jun sarcoma virus 17 oncogene homolog 
(avian)
JUN 307 978 3.2
207850_at chemokine (C-X-C motif) ligand 3 CXCL3 51 162 3.2
203751_x_at jun D proto-oncogene JUND 392 1223 3.1
217997_at pleckstrin homology-like domain, family A, 
member 1
PHLDA1 431 1344 3.1
218881_s_at FOS-like antigen 2 FOSL2 204 618 3.0
214085_x_at GLI pathogenesis-related 1 (glioma) GLIPR1 334 1011 3.0
202269_x_at guanylate binding protein 1, interferon-inducible, 
67kDa 
GBP1 210 635 3.0
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Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 + Thrombin
Fold change
Control/LTD4 + Thrombin
212665_at TCDD-inducible poly(ADP-ribose) polymerase TIPARP 553 1643 3.0
203140_at B-cell CLL/lymphoma 6 (zinc finger protein 51) BCL6 425 1243 2.9
203574_at nuclear factor, interleukin 3 regulated NFIL3 406 1174 2.9
202241_at tribbles homolog 1 (Drosophila) TRIB1 798 2274 2.9
212418_at E74-like factor 1 (ets domain transcription factor) ELF1 550 1558 2.8
202067_s_at low density lipoprotein receptor (familial 
hypercholesterolemia)
LDLR 171 478 2.8
207630_s_at cAMP responsive element modulator CREM 868 2417 2.8
214056_at Myeloid cell leukemia sequence 1 (BCL2-related) MCL1 163 447 2.7
209074_s_at TU3A protein TU3A 98 268 2.7
218000_s_at pleckstrin homology-like domain, family A, 
member 1
PHLDA1 226 607 2.7
213895_at Epithelial membrane protein 1 EMP1 318 848 2.7
202014_at protein phosphatase 1, regulatory (inhibitor) 
subunit 15A
PPP1R15A 407 1066 2.6
212558_at sprouty homolog 1, antagonist of FGF signaling 
(Drosophila)
SPRY1 637 1631 2.6
36711_at v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog F (avian)
MAFF 1676 4259 2.5
208119_s_at zinc finger protein 505 ZNF505 126 320 2.5
209457_at dual specificity phosphatase 5 DUSP5 1239 2995 2.4
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Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 + Thrombin
Fold change
Control/LTD4 + Thrombin
220990_s_at likely ortholog of rat vacuole membrane protein 1 VMP1 1216 2921 2.4
207526_s_at interleukin 1 receptor-like 1 IL1RL1 477 1144 2.4
214508_x_at cAMP responsive element modulator CREM 546 1305 2.4
217998_at pleckstrin homology-like domain, family A, 
member 1
PHLDA1 411 982 2.4
213146_at jumonji domain containing 3 JMJD3 179 421 2.4
221763_at jumonji domain containing 1C JMJD1C 768 1784 2.3
203234_at uridine phosphorylase 1 UPP1 241 559 2.3
217168_s_at homocysteine-inducible, endoplasmic reticulum 
stress-inducible, ubiquitin-like domain member 1
HERPUD1 1523 3494 2.3
37028_at protein phosphatase 1, regulatory (inhibitor) 
subunit 15A
PPP1R15A 729 1664 2.3
215206_at Exostoses (multiple) 1 EXT1 226 511 2.3
201473_at jun B proto-oncogene JUNB 781 1765 2.3
201464_x_at v-jun sarcoma virus 17 oncogene homolog 
(avian)
JUN 1614 3603 2.2
204094_s_at TSC22 domain family 2 TSC22D2 552 1220 2.2
202068_s_at low density lipoprotein receptor (familial 
hypercholesterolemia)
LDLR 1516 3321 2.2
221489_s_at sprouty homolog 4 (Drosophila) SPRY4 635 1380 2.2
201925_s_at decay accelerating factor for complement (CD55, 
Cromer blood group system)
DAF 831 1787 2.2
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Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 + Thrombin
Fold change
Control/LTD4 + Thrombin
204221_x_at GLI pathogenesis-related 1 (glioma) GLIPR1 155 330 2.1
202843_at DnaJ (Hsp40) homolog, subfamily B, member 9 DNAJB9 76 160 2.1
207029_at KIT ligand KITLG 157 332 2.1
212724_at Rho family GTPase 3 RND3 2029 4261 2.1
215990_s_at B-cell CLL/lymphoma 6 (zinc finger protein 51) BCL6 393 823 2.1
214038_at chemokine (C-C motif) ligand 8 CCL8 123 257 2.1
201236_s_at BTG family, member 2 BTG2 1022 2137 2.1
204093_at cyclin H CCNH 836 1746 2.1
202237_at nicotinamide N-methyltransferase NNMT 815 1696 2.1
201325_s_at Epithelial membrane protein 1 EMP1 1663 3443 2.1
203543_s_at Kruppel-like factor 9 KLF9 367 756 2.1
210762_s_at deleted in liver cancer 1 DLC1 1249 2556 2.0
218995_s_at endothelin 1 EDN1 1493 3038 2.0
201169_s_at basic helix-loop-helix domain containing, class B, 
2
BHLHB2 415 836 2.0
212420_at E74-like factor 1 (ets domain transcription factor) ELF1 639 1285 2.0
202499_s_at solute carrier family 2 (facilitated glucose 
transporter), member 3
SLC2A3 748 1504 2.0
216979_at nuclear receptor subfamily 4, group A, member 3 NR4A3 92 185 2.0
203542_s_at Kruppel-like factor 9 KLF9 609 1222 2.0
204596_s_at stanniocalcin 1 STC1 1199 2405 2.0
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B) Probe sets down-regulated >2-fold by LTD4 plus thrombin at 1 h
Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 + Thrombin
Fold change
─LTD4 + Thrombin/Control
208937_s_at inhibitor of DNA binding 1, dominant 
negative helix-loop-helix protein
ID1 3144 831 -3.8
201008_s_at thioredoxin interacting protein TXNIP 2213 632 -3.5
201009_s_at thioredoxin interacting protein TXNIP 2952 867 -3.4
201010_s_at thioredoxin interacting protein TXNIP 3726 1142 -3.3
203394_s_at hairy and enhancer of split 1, (Drosophila) HES1 1345 430 -3.1
202887_s_at DNA-damage-inducible transcript 4 DDIT4 1882 604 -3.1
203395_s_at hairy and enhancer of split 1, (Drosophila) HES1 1078 414 -2.6
204790_at SMAD, mothers against DPP homolog 7 
(Drosophila)
SMAD7 366 141 -2.6
222303_at n.a. 320 132 -2.4
201367_s_at zinc finger protein 36, C3H type-like 2 ZFP36L2 910 377 -2.4
201369_s_at zinc finger protein 36, C3H type-like 2 ZFP36L2 692 301 -2.3
207474_at SNF related kinase SNRK 203 91 -2.2
209905_at homeo box A9 HOXA9 438 198 -2.2
217164_at n.a. 234 107 -2.2
209602_s_at GATA binding protein 3 GATA3 211 96 -2.2
209604_s_at GATA binding protein 3 GATA3 2286 1092 -2.1
201939_at polo-like kinase 2 (Drosophila) PLK2 1515 724 -2.1
201368_at zinc finger protein 36, C3H type-like 2 ZFP36L2 4446 2165 -2.1
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Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 + Thrombin
Fold change
─LTD4 + Thrombin/Control
214295_at KIAA0485 protein KIAA0485 305 149 -2.0
205020_s_at ADP-ribosylation factor-like 4A ARL4A 1989 977 -2.0
205955_at n.a. 165 82 -2.0
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Table 15. Probe sets up-regulated by LTD4 plus thrombin and LTD4 or thrombin. Mean signals of three experiments are shown.
Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 Thrombin
LTD4 + 
Thrombin
38037_at heparin-binding EGF-like growth factor HBEGF 214 967 1498 1988
200632_s_at N-myc downstream regulated gene 1 NDRG1 1364 4032 3357 4367
200797_s_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 1950 6556 9611 10979
201041_s_at dual specificity phosphatase 1 DUSP1 1786 8797 8062 13187
201044_x_at dual specificity phosphatase 1 DUSP1 37 433 277 738
201289_at cysteine-rich, angiogenic inducer, 61 CYR61 920 7490 10516 12231
201531_at zinc finger protein 36, C3H type, homolog (mouse) ZFP36 287 3309 2367 4517
201694_s_at early growth response 1 EGR1 594 1868 2608 3607
202149_at neural precursor cell expressed, developmentally 
down-regulated 9
NEDD9 532 1995 2348 2520
202150_s_at neural precursor cell expressed, developmentally 
down-regulated 9
NEDD9 571 1965 2391 2985
202340_x_at nuclear receptor subfamily 4, group A, member 1 NR4A1 105 3363 2431 4233
202388_at Regulator of G-protein signalling 2, 24kDa RGS2 424 1994 1171 2099
202672_s_at activating transcription factor 3 ATF3 284 1223 2437 5091
202859_x_at interleukin 8 IL8 236 2080 3728 6053
203821_at heparin-binding EGF-like growth factor HBEGF 273 2598 3558 5355
204363_at coagulation factor III (thromboplastin, tissue factor) F3 26 400 177 592
204472_at GTP binding protein overexpressed in skeletal 
muscle
GEM 177 523 486 990
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Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 Thrombin
LTD4 + 
Thrombin
204621_s_at nuclear receptor subfamily 4, group A, member 2 NR4A2 28 2904 1771 3248
204622_x_at nuclear receptor subfamily 4, group A, member 2 NR4A2 93 4379 2855 5307
204748_at prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase)
PTGS2 344 5022 2602 7044
205027_s_at mitogen-activated protein kinase kinase kinase 8 MAP3K8 33 159 83 186
205249_at early growth response 2 (Krox-20 homolog, 
Drosophila)
EGR2 99 1012 739 1634
205290_s_at bone morphogenetic protein 2 BMP2 1299 4345 2382 4728
205960_at Pyruvate dehydrogenase kinase, isoenzyme 4 PDK4 441 1167 532 869
206115_at early growth response 3 EGR3 95 2344 1856 4178
206211_at selectin E (endothelial adhesion molecule 1) SELE 47 159 83 148
206765_at potassium inwardly-rectifying channel, subfamily J, 
member 2
KCNJ2 751 2638 1973 3077
207978_s_at nuclear receptor subfamily 4, group A, member 3 NR4A3 112 1077 981 1883
207980_s_at Cbp/p300-interacting transactivator, with Glu/Asp-
rich carboxy-terminal domain, 2
CITED2 345 807 1032 1100
208078_s_at SNF1-like kinase SNF1LK 377 2542 2659 3287
208370_s_at Down syndrome critical region gene 1 DSCR1 413 6414 3096 7837
209357_at Cbp/p300-interacting transactivator, with Glu/Asp-
rich carboxy-terminal domain, 2
CITED2 310 905 966 1239
209774_x_at chemokine (C-X-C motif) ligand 2 CXCL2 318 2116 698 3236
209959_at nuclear receptor subfamily 4, group A, member 3 NR4A3 38 878 815 1454
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Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 Thrombin
LTD4 + 
Thrombin
209967_s_at cAMP responsive element modulator CREM 300 1528 994 1426
210764_s_at cysteine-rich, angiogenic inducer, 61 CYR61 784 9244 14395 18409
211506_s_at interleukin 8 IL8 182 637 1191 1982
212614_at AT rich interactive domain 5B (MRF1-like) ARID5B 485 1918 1849 2508
214438_at H2-like homeo box 1 (Drosophila) HLX1 517 2322 1685 2207
214446_at elongation factor, RNA polymerase II, 2 ELL2 89 292 221 368
214508_x_at cAMP responsive element modulator CREM 546 1310 1022 1305
215253_s_at Down syndrome critical region gene 1 DSCR1 510 3551 1454 4158
216248_s_at nuclear receptor subfamily 4, group A, member 2 NR4A2 52 5338 3317 6241
218880_at FOS-like antigen 2 FOSL2 228 747 760 1111
219371_s_at Kruppel-like factor 2 (lung) KLF2 1141 3013 3264 3997
221031_s_at hypothetical protein DKFZp434F0318 DKFZP434F0
318
550 2653 2209 3766
221841_s_at Kruppel-like factor 4 (gut) KLF4 484 1954 3263 3853
222162_s_at a disintegrin-like and metalloprotease (reprolysin 
type) with thrombospondin type 1 motif, 1
ADAMTS1 594 5844 4240 6967
200796_s_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 375 1105 1667 2113
200798_x_at myeloid cell leukemia sequence 1 (BCL2-related) MCL1 1560 4435 6164 7289
201465_s_at v-jun sarcoma virus 17 oncogene homolog (avian) JUN 169 242 480 644
201466_s_at v-jun sarcoma virus 17 oncogene homolog (avian) JUN 307 341 1221 978
201739_at serum/glucocorticoid regulated kinase SGK 1173 2213 3521 4388
202269_x_at guanylate binding protein 1, interferon-inducible, 
67kDa
GBP1 211 212 614 635
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Affymetrix 
probe set ID
Gene title Gene symbol Control LTD4 Thrombin
LTD4 + 
Thrombin
202270_at guanylate binding protein 1, interferon-inducible, 
67kDa
GBP1 54 90 212 184
202768_at FBJ murine osteosarcoma viral oncogene homolog 
B
FOSB 27 710 4082 5352
204011_at sprouty homolog 2 (Drosophila) SPRY2 500 1292 1484 1846
204135_at downregulated in ovarian cancer 1 DOC1 539 1309 2469 2986
204222_s_at GLI pathogenesis-related 1 (glioma) GLIPR1 58 105 270 384
204470_at chemokine (C-X-C motif) ligand 1 (melanoma 
growth stimulating activity, alpha)
CXCL1 141 245 370 458
208119_s_at zinc finger protein 505 ZNF505 127 197 359 321
208960_s_at Kruppel-like factor 6 KLF6 811 1901 2914 3475
208961_s_at Kruppel-like factor 6 KLF6 1518 3089 5006 5769
209101_at connective tissue growth factor CTGF 5003 8668 16656 16777
214085_x_at GLI pathogenesis-related 1 (glioma) GLIPR1 335 375 856 1011
215198_s_at caldesmon 1 CALD1 147 264 557 616
215199_at caldesmon 1 CALD1 115 224 393 494
218541_s_at chromosome 8 open reading frame 4 C8orf4 129 402 660 1079
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